Clinical trial NCT03486392
Conditions: Obesity
Sponsor: Janssen Research & Development, LLC
Start date: 2018-03-26; Completion date: 2019-03-08
Enrollment: 474 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tolerability, in non-diabetic severely obese participants.

Detailed description:

Arms: arm 1: Participants will receive a JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 26-week treatment phase. arm 2: Participants will receive a JNJ-64565111 Dose Level 2 SC once-weekly for 26-week treatment phase. arm 3: Participants will receive a JNJ-64565111 Dose Level 3 SC once-weekly for 26-week treatment phase. arm 4: Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 26-week treatment phase. arm 5: Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
Interventions: intervention 1: JNJ-64565111 Dose Level 1 intervention 2: JNJ-64565111 Dose Level 2 intervention 3: JNJ-64565111 Dose Level 3 intervention 4: Liraglutide intervention 5: Placebo
Intervention descriptions: intervention 1: Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26. intervention 2: Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26. intervention 3: Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26. intervention 4: Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26. intervention 5: Participants will receive matching placebo SC once-weekly until Week 26.

Protocol documents:
Prot_000.pdf: 
1
Approved, Date: 23 August 2018
Janssen Research & Development *
Clinical Protocol
A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, 
Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of 
JNJ-64565111 in Non-diabetic Severely Obese Subjects 
Protocol 64565111OBE2001; Phase 2b
AMENDMENT 1
JNJ-64565111 (efinopegdutide)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen-Cilag International NV; Janssen, Inc; Janssen Infectious Diseases BVBA; Janssen 
Sciences Ireland UC; Janssen Vaccines BV; Janssen Pharmaceutica NV, or Janssen Research & 
Development, LLC. The term “sponsor” is used throughout the protocol to represent these various legal 
entities; the sponsor is identified on the Contact Information page that accompanies the protocol.
This compound is being investigated in Phase 2 clinical studies.
This study will be conducted under United States Food & Drug Administration IND regulations 
(21 CFR Part 312).
EudraCT NUMBER: 2017-003616-39
Status:
Approved
Date:
23 August 2018
Prepared by:
Janssen Research & Development, LLC
EDMS number:
EDMS-ERI-146124676, 3.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements.
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or 
confidential.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
2
Approved, Date: 23 August 2018
TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF ATTACHMENTS............................................................................................................................ 4
LIST OF IN-TEXT TABLES AND FIGURES................................................................................................ 5
PROTOCOL AMENDMENTS....................................................................................................................... 6
SYNOPSIS.................................................................................................................................................... 7
TIME AND EVENTS SCHEDULE .............................................................................................................. 18
TIME AND EVENTS SCHEDULE – PATIENT-REPORTED OUTCOMES................................................ 23
ABBREVIATIONS ...................................................................................................................................... 25
DEFINITIONS OF TERMS.......................................................................................................................... 27
1.
INTRODUCTION................................................................................................................................ 28
1.1.
Background on JNJ-64565111 ...................................................................................................... 30
1.1.1.
Nonclinical Studies ..................................................................................................................... 30
1.1.2.
Clinical Studies with JNJ-64565111 ........................................................................................... 32
1.1.3.
Ketogenesis with JNJ-64565111 ................................................................................................ 37
1.2.
Comparator Drug – Liraglutide (Saxenda®) ................................................................................... 38
1.3.
Overall Rationale of the Study ....................................................................................................... 39
2.
OBJECTIVES AND HYPOTHESES.................................................................................................. 39
2.1.
Objectives ...................................................................................................................................... 39
2.2.
Hypotheses .................................................................................................................................... 41
3.
STUDY DESIGN AND RATIONALE ................................................................................................. 41
3.1.
Overview of Study Design.............................................................................................................. 41
3.2.
Study Design Rationale.................................................................................................................. 44
4.
SUBJECT POPULATION.................................................................................................................. 48
4.1.
Inclusion Criteria ............................................................................................................................ 48
4.2.
Exclusion Criteria ........................................................................................................................... 49
4.3.
Prohibitions and Restrictions ......................................................................................................... 53
4.4.
Rescreening ................................................................................................................................... 53
5.
TREATMENT ALLOCATION AND BLINDING................................................................................. 54
6.
DOSAGE AND ADMINISTRATION .................................................................................................. 55
6.1.
Pre-Randomization Open-label Placebo........................................................................................ 55
6.2.
Post-Randomization Double-blind JNJ-64565111 or Matching Placebo and Open-label 
Liraglutide....................................................................................................................................... 55
7.
TREATMENT COMPLIANCE............................................................................................................ 59
8.
PRE-STUDY AND CONCOMITANT THERAPY ............................................................................... 59
9.
STUDY PROCEDURES AND EVALUATIONS................................................................................. 60
9.1.
General Procedures....................................................................................................................... 60
9.1.1.
Visit Schedule and Visit Windows .............................................................................................. 60
9.1.2.
Maximum Blood Volume Collected............................................................................................. 60
9.2.
Sub-study Procedures.................................................................................................................... 61
9.2.1.
24-hour Ambulatory Blood Pressure Monitoring [Sub-study] ..................................................... 61
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
3
Approved, Date: 23 August 2018
9.3.
Pre-treatment Phase Procedures and Evaluations........................................................................ 62
9.3.1.
Screening Visit (Week -3)........................................................................................................... 62
9.3.2.
Run-in Phase (Week -2 to Day -1) ............................................................................................. 63
9.3.2.1.
Training on Subcutaneous Drug Administration...................................................................... 63
9.3.2.2.
Study Drug Diaries .................................................................................................................. 64
9.3.2.3.
Pre-day 1 Visit (ABPM Sub-study Subjects Only)................................................................... 64
9.4.
Treatment Phase Procedures and Evaluations ............................................................................. 64
9.4.1.
Day 1/ Day of Randomization..................................................................................................... 65
9.4.2.
Weeks 1, 3, 4, and 24 Contact ................................................................................................... 66
9.4.3.
Weeks 2, 5, 10, 15, 20 Visits ...................................................................................................... 66
9.4.4.
Pre-Week 26 Visit (ABPM Sub-study Subjects Only)................................................................. 66
9.4.5.
End-of-Treatment/Early Study Drug Discontinuation ................................................................. 66
9.4.6.
Management of Hyperglycemia.................................................................................................. 67
9.5.
Post-treatment (Follow-up) Procedures and Evaluations .............................................................. 67
9.6.
Internal Data Monitoring Committee (DMC)................................................................................... 68
9.7.
Efficacy Evaluations....................................................................................................................... 69
9.7.1.
Primary Efficacy Endpoint........................................................................................................... 69
9.7.2.
Secondary and Exploratory Efficacy Endpoints ......................................................................... 69
9.7.3.
Patient-reported Outcomes ........................................................................................................ 69
9.7.4.
Interviews.................................................................................................................................... 72
9.8.
Pharmacokinetics and Immunogenicity ......................................................................................... 72
9.8.1.
Pharmacokinetic Evaluations ..................................................................................................... 72
9.8.1.1.
Sample Collection and Handling ............................................................................................. 72
9.8.1.2.
Analytical Procedures.............................................................................................................. 73
9.8.1.3.
Pharmacokinetic Parameters .................................................................................................. 73
9.8.2.
Immunogenicity Assessments (Anti-JNJ-64565111 Antibodies)................................................ 73
9.9.
Archive Samples for Exploratory Research ................................................................................... 74
9.10.
Safety Evaluations ......................................................................................................................... 74
9.11.
Survey on Experience with Self-injection of Study Drug................................................................ 77
10.
SUBJECT COMPLETION/DISCONTINUATION OF STUDY TREATMENT/ 
DISCONTINUATION FROM THE STUDY ........................................................................................ 77
10.1.
Completion ..................................................................................................................................... 77
10.2.
Discontinuation of Study Treatment/ Discontinuation from the Study ........................................... 78
11.
STATISTICAL METHODS................................................................................................................. 81
11.1.
Analysis Sets.................................................................................................................................. 81
11.2.
Sample Size Determination ........................................................................................................... 81
11.3.
Efficacy Analyses ........................................................................................................................... 82
11.4.
Pharmacokinetic Analyses............................................................................................................. 84
11.5.
Immunogenicity Analyses .............................................................................................................. 85
11.6.
Safety Analyses ............................................................................................................................. 85
11.7.
Interim Analysis.............................................................................................................................. 86
12.
ADVERSE EVENT REPORTING ...................................................................................................... 86
12.1.
Definitions ...................................................................................................................................... 87
12.1.1.
Adverse Event Definitions and Classifications ........................................................................... 87
12.1.2.
Attribution Definitions.................................................................................................................. 88
12.1.3.
Severity Criteria .......................................................................................................................... 89
12.2.
Special Reporting Situations.......................................................................................................... 89
12.3.
Procedures..................................................................................................................................... 89
12.3.1.
All Adverse Events...................................................................................................................... 89
12.3.2.
Serious Adverse Events ............................................................................................................. 90
12.3.3.
Pregnancy................................................................................................................................... 91
12.4.
Contacting Sponsor Regarding Safety........................................................................................... 91
13.
PRODUCT QUALITY COMPLAINT HANDLING.............................................................................. 91
13.1.
Procedures..................................................................................................................................... 92
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
4
Approved, Date: 23 August 2018
13.2.
Contacting Sponsor Regarding Product Quality ............................................................................ 92
14.
STUDY DRUG INFORMATION......................................................................................................... 92
14.1.
Physical Description of Study Drugs.............................................................................................. 92
14.2.
Packaging ...................................................................................................................................... 93
14.3.
Labeling.......................................................................................................................................... 93
14.4.
Preparation, Handling, and Storage............................................................................................... 93
14.5.
Drug Accountability ........................................................................................................................ 93
15.
STUDY-SPECIFIC MATERIALS....................................................................................................... 94
16.
ETHICAL ASPECTS ......................................................................................................................... 95
16.1.
Study-Specific Design Considerations........................................................................................... 95
16.2.
Regulatory Ethics Compliance....................................................................................................... 97
16.2.1.
Investigator Responsibilities ....................................................................................................... 97
16.2.2.
Independent Ethics Committee or Institutional Review Board ................................................... 98
16.2.3.
Informed Consent ....................................................................................................................... 99
16.2.4.
Privacy of Personal Data .......................................................................................................... 100
16.2.5.
Long-Term Retention of Samples for Additional Future Research .......................................... 100
16.2.6.
Country Selection ..................................................................................................................... 101
17.
ADMINISTRATIVE REQUIREMENTS ............................................................................................ 101
17.1.
Protocol Amendments.................................................................................................................. 101
17.2.
Regulatory Documentation .......................................................................................................... 101
17.2.1.
Regulatory Approval/Notification .............................................................................................. 101
17.2.2.
Required Pre-study Documentation ......................................................................................... 101
17.3.
Subject Identification, Enrollment, and Screening Logs .............................................................. 102
17.4.
Source Documentation................................................................................................................. 103
17.5.
Case Report Form Completion .................................................................................................... 103
17.6.
Data Quality Assurance/Quality Control ...................................................................................... 104
17.7.
Record Retention ......................................................................................................................... 104
17.8.
Monitoring .................................................................................................................................... 105
17.9.
Study Completion/Termination..................................................................................................... 105
17.9.1.
Study Completion/End of Study................................................................................................ 105
17.9.2.
Study Termination..................................................................................................................... 105
17.10.
On-Site Audits .............................................................................................................................. 106
17.11.
Use of Information and Publication.............................................................................................. 106
REFERENCES.......................................................................................................................................... 108
INVESTIGATOR AGREEMENT ............................................................................................................... 121
LIST OF ATTACHMENTS
Attachment 1:
New York Heart Association Classification of Cardiac Disease............................... 110
Attachment 2:
Method of Blood Pressure and Pulse Rate Measurement....................................... 111
Attachment 3:
Anthropometric Measurements ................................................................................ 112
Attachment 4:
Standardized Nonpharmacologic Weight Reduction Therapy ................................. 113
Attachment 5:
Clinical Laboratory Tests.......................................................................................... 114
Attachment 6:
Algorithm for Monitoring Abnormal Liver Function Tests ......................................... 116
Attachment 7:
Pancreatitis Monitoring and Withdrawal Criteria ...................................................... 117
Attachment 8: 
Guidelines for Calcitonin Monitoring......................................................................... 118
Attachment 9:
Instructions for the Completion of PRO Assessments ............................................. 119
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
5
Approved, Date: 23 August 2018
LIST OF IN-TEXT TABLES AND FIGURES
TABLES
Table 1: 
Comparison of JNJ-64565111 Doses Used in Phase 1 Studies .............................................. 33
Table 2: 
Mean (Range) Cmax and AUC of JNJ-64565111 on Weeks 1 and 4 (Study 
645651111EDI1002)................................................................................................................. 35
Table 3:
Maximum Volume of Blood to be Collected from Each Subject ............................................... 61
FIGURES
Figure 1:
Mean (SD) Serum Concentration-time Profiles Following Multiple SC Administration of 
JNJ-64565111 Weekly for 4 Doses in T2DM Subjects............................................................. 34
Figure 2:
Schematic Overview of the Study............................................................................................. 44
Figure 3:
Liraglutide Titration Schedule ................................................................................................... 56
Figure 4:
Injection-training Procedures .................................................................................................... 64
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
6
Approved, Date: 23 August 2018
PROTOCOL AMENDMENTS
Protocol Version
Date
Original Protocol
08 February 2018
Amendment 1
23 August 2018
Amendments below are listed beginning with the most recent amendment.
Amendment 1 (23 August 2018)
The overall reason for the amendment: The overall reasons for the amendment are to provide further instructions 
on the safety monitoring of subjects with adverse events of moderate and severe vomiting that may lead to 
dehydration, and to add a discontinuation criterion for subjects who experience severe vomiting.
Applicable Section(s)
Description of Change(s)
Rationale: To provide further instructions on the management of subjects with adverse events of moderate and 
severe vomiting that may lead to dehydration.
9.10, Safety Evaluations
Added:

Instructions on the monitoring, evaluation, and follow-up of subjects with 
moderate and severe vomiting 

Instruction on how to manage study drug in subjects with moderate or severe 
vomiting

Clarification on the use of anti-emetics to treat subjects with moderate and 
severe vomiting.
Rationale: To add a discontinuation criterion about vomiting.
10.2, Discontinuation of 
Study 
Treatment/Discontinuation 
from the Study
Added discontinuation criterion “Subject experiences an episode of vomiting assessed 
as “severe” lasting more than 24 hours and considered to be at least possibly related to 
study drug without any other potential cause (eg, viral gastroenteritis, food-borne 
illness).”
Rationale: To fix minor errors.
10.2, Discontinuation of 
Study 
Treatment/Discontinuation 
from the Study
Added discontinuation criterion that the investigator can formally unblind the 
subject’s treatment allocation.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
7
Approved, Date: 23 August 2018
SYNOPSIS
A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, 
Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-
diabetic Severely Obese Subjects 
JNJ-64565111 
(efinopegdutide,
formerly
designated 
as 
HM12525A, 
developed 
by 
Hanmi 
Pharmaceuticals) is a synthetic, modified oxyntomodulin (OXM) peptide conjugated to a constant region 
of a human immunoglobulin G4 fragment to prolong the plasma half-life of the peptide.
Oxyntomodulin is an endogenous peptide secreted by cells in the gut in response to nutrient ingestion. 
Oxyntomodulin is a dual agonist, acting at both the glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) 
and the glucagon receptor (GCGR). These combined actions at the GLP-1R (enhanced glucose-stimulated 
insulin secretion and suppression of food intake) and the GCGR (suppression of food intake, increased 
energy expenditure, and improved lipid metabolism) suggest that OXM-based therapeutics could provide 
several benefits to obese patients and might provide superior weight loss as compared to currently 
available weight-management medications.
In animal models of obesity, JNJ-64565111 improves lipid profiles and causes significant weight loss.  
The goal of this dose-range-finding study is to assess the efficacy, safety, tolerability, and 
pharmacokinetics (PK) over a range of JNJ-64565111 doses that yield therapeutic benefit in subjects with 
severe obesity (body mass index [BMI] 35 to 50 kg/m2) to provide information for selecting
JNJ-64565111 dose(s) to be assessed in Phase 3 studies.
OBJECTIVES AND HYPOTHESES
Objectives
Primary Objectives
In non-diabetic severely obese subjects, to assess the effects of JNJ-64565111 compared with placebo 
after 26 weeks of treatment on:

the percentage change in body weight from baseline

safety and tolerability
Secondary Objectives
In non-diabetic severely obese subjects, to assess the effects of JNJ-64565111 compared with placebo 
after 26 weeks of treatment on:

the proportion of subjects with 5% weight loss from baseline

the proportion of subjects with 10% weight loss from baseline

the absolute change in body weight from baseline
Exploratory Objectives
In non-diabetic severely obese subjects, to assess the effects of JNJ-64565111 compared with placebo 
after 26 weeks of treatment on:

the change in BMI from baseline

the change in waist circumference from baseline 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
8
Approved, Date: 23 August 2018

the change in fasting lipids (total cholesterol, low-density lipoprotein cholesterol [LDL-C], 
high-density lipoprotein cholesterol [HDL-C], and triglycerides) from baseline

the change in fasting plasma glucose (FPG) from baseline

the change in fasting insulin from baseline 

the change in fasting C-peptide from baseline

the changes in Homeostasis Model Assessment for B cell function (HOMA-B) and HOMA-insulin 
resistance (IR) from baseline

the change in systolic blood pressure (SBP) from baseline

the change in diastolic blood pressure (DBP) from baseline

the change in pulse rate from baseline

the change in pulse-pressure product from baseline

in a subset of subjects participating in the 24-hour ambulatory blood pressure monitoring (ABPM)
assessment, the changes from baseline in 24-hour SBP, DBP, pulse rate, and pulse-pressure product 

Pharmacokinetic (PK) exposure

the change from baseline in scores on the Impact of Weight on Quality of Life-Lite (IWQOL-Lite),
single item Ease of Weight Management, and the Patient Activation Measure (PAM)

in English-speaking subjects in selected countries only, the change from baseline in scores on the 
eating-related concept question (ERCQ) and the Patient-Reported Outcomes Measurement 
Information System (PROMIS) physical function short form 8b (PROMIS SF 8b) (Note:  the Patient 
Global Impression Status [PGIS] and Patient Global Impression of Change [PGIC] will be used to 
calculate responder definitions for these new instruments only and are not exploratory objectives.)

in English-speaking subjects in selected countries only, describe pre-trial goals and expectations as 
well as post-trial experiences qualitatively using the Anticipations of Clinical Trial Treatment 
(ACTT) pre-trial interviews and a modified Safety, Tolerability, and Efficacy Preview (STEP) exit 
interview 
In non-diabetic severely obese subjects, to assess the effects of JNJ-64565111 compared with liraglutide 
after 26 weeks of treatment on:

the absolute change and percentage change in body weight from baseline

the proportion of subjects with 5% weight loss from baseline

the proportion of subjects with 10% weight loss from baseline 
Hypotheses
In non-diabetic severely obese subjects, treatment for 26 weeks with JNJ-64565111 compared with 
placebo leads to a greater:
Primary: 

percentage reduction in body weight
Secondary: 

proportion of subjects with 5% weight loss from baseline

proportion of subjects with 10% weight loss from baseline
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
9
Approved, Date: 23 August 2018

absolute reduction in body weight from baseline
OVERVIEW OF STUDY DESIGN
This is a randomized, double-blind, placebo-controlled and open-label active-controlled, parallel-group, 
5-arm, multicenter study. Non-diabetic, severely obese subjects who are 18 and 70 years of age and 
have a BMI 35 to 50 kg/m2 will be assessed.
Subjects meeting all eligibility criteria will enter a 2-week run-in phase, which is to occur approximately 
1 week after the screening visit and is designed to train the subject on subcutaneous (SC) self-injection 
and to establish the subject’s ability to comply with the protocol-specified requirements. On Day 1, 
approximately 440 subjects who continue to meet eligibility criteria will be randomly assigned in a 
1:1:2:2:2 ratio to blinded treatment with placebo, JNJ-64565111 (5.0, 7.4, or 10.0 mg) or open-label 
liraglutide 3.0 mg, stratified by ABPM sub-study participation (yes or no), and then will enter a 26-week 
treatment phase. To maintain blinding, subjects randomly assigned to placebo will be subsequently 
randomly assigned in a 1:2:2 ratio to a placebo that matches the volume of the 5.0, 7.4, and 10.0 mg 
JNJ-64565111 doses (ie, approximately 11, 22, and 22 subjects, respectively). Post-randomization visits 
will be conducted at Weeks 2, 5, 10, 15, 20, 26/end-of-treatment (EOT) visit and 4-week serious adverse 
event (SAE) follow-up visit. The subset of subjects in the ABPM sub-study will have 2 additional visits 
(ie, Pre-Day 1 and Pre-Week 26). A subset of subjects will have 1 additional visit (Day 4 1 day 
sampling window) to collect a non-trough PK sample. In addition, subjects in the open-label liraglutide 
treatment group will also be contacted preferably by telephone at Weeks 1, 3, and 4 to remind about the 
dosing titration (ie, to increase their dose of liraglutide by an 0.6 mg dose increment weekly).
The efficacy evaluation will include the percentage change in body weight from baseline as the primary 
efficacy endpoint.
Safety evaluations will include the monitoring of adverse events (AEs) (including protocol-specified AEs
of interest), vital sign measurements, clinical laboratory tests (including calcitonin, lipase, amylase, 
alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin, sodium), urinalysis, review 
of concomitant medications, and serum pregnancy testing.
Subjects who prematurely discontinue study drug will require an immediate EOT assessment (either on 
the day of study drug discontinuation or as soon as possible following study drug discontinuation) and the 
4-week SAE follow-up. Subjects that discontinue study drug early will continue in the study and be 
assessed with the off-treatment procedures at the subsequent visit(s) per the Time and Events visit 
schedule, starting at the next scheduled visit from when study drug was permanently discontinued up to 
the final Week 26 visit. These off-treatment visits will include assessment and collection of SAEs, 
specific AEs of interest (ie, major adverse cardiovascular event [MACE] events, acute pancreatitis, and 
possible cases of thyroid neoplasm), vital signs (including body weight), and concomitant medications. 
Subjects who discontinued prior to Week 26 and have the 4-week SAE follow-up visit do not need to 
return for a second 4-week SAE follow-up visit. All subjects, except those who died, were lost to 
follow-up, or have a withdrawn consent, will have a follow-up visit approximately 5 weeks after the last 
dose of study drug for JNJ-64565111-treated or placebo-treated subjects and 4 weeks after the last dose of 
study drug for liraglutide-treated subjects to collect any SAEs. For subjects randomly assigned to 
JNJ-64565111 or placebo, blood samples for immunogenicity anti-drug antibody and PK assessments will 
also be obtained at the SAE follow-up visit.
A non-trough PK visit will occur at selected sites and will involve approximately 180 subjects 
(approximately 45 subjects each in the placebo, JNJ-64565111 5 mg, JNJ-64565111 7.4 mg, and 
JNJ-64565111 10 mg groups). A 24-hour ABPM assessment will be performed at selected sites and will 
involve approximately 120 subjects (approximately 15 subjects each in the placebo and JNJ-64565111 
5 mg groups, and 30 subjects each in the JNJ-64565111 7.4 mg, JNJ-64565111 10 mg, and liraglutide 
groups). During the run-in phase, these subjects will wear the ABPM device for at least 24 hours 1 or 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
10
Approved, Date: 23 August 2018
2 days prior to the Day1/Randomization visit. The ABPM readings will be masked. When subjects return 
for the Day 1 visit, ABPM readings will be assessed for subject eligibility into the ABPM sub-study 
based on the ABPM requirements. After randomization, subjects participating in the ABPM sub-study
will be required to repeat a 24-hour ABPM assessment 1 or 2 days prior to the Week 26/ EOT in subjects 
who have not withdrawn consent, died or were lost to follow-up. For subjects treated with JNJ-64565111 
or matching placebo, every effort should be made to have the procedure performed within 7 days from the 
previous dose of study drug.
The IWQOL-Lite, Ease of Weight Management, and PAM will be administered at all sites to all subjects. 
The PROMIS SF 8b and ERCQ along with both the PGIS and PGIC will be administered at selected sites 
and will involve approximately 120 English-speaking subjects. These instruments are intended to measure 
eating-related concepts such as hunger, appetite, cravings, and satiety, and physical function.
Subjects who withdraw from the study will not be replaced.
The overall study duration is approximately 33 weeks and comprises of 3 phases:
Pre-treatment phase

Screening phase: 1 week

Run-in (injection-training) phase: 2 weeks
Treatment phase (double-blind and open-label arms)

Placebo- and active-controlled treatment phase: 26 weeks
Post-treatment phase (SAE follow-up visit): 4 weeks
Approximately 440 subjects will be randomly assigned in a 1:1:2:2:2 ratio to one of the following once 
SC treatments:

55 subjects to double-blind placebo matching JNJ-64565111,

55 subjects to double-blind JNJ-64565111 5.0 mg,

110 subjects to double-blind JNJ-64565111 7.4 mg,

110 subjects to double-blind JNJ-64565111 10.0 mg, and

110 subjects to open-label liraglutide 3.0 mg.
SUBJECT POPULATION
Non-diabetic, severely obese subjects who are 18 and 70 years of age and have a BMI 35 to 
50 kg/m2 will be assessed.
DOSAGE AND ADMINISTRATION
Pre-Randomization Open-label Placebo 
At the Week -2 visit, subjects will be instructed on the use of pre-filled safety injectors to perform SC 
self-injections, and will be asked to perform a self-injection in the presence of the study-site staff. Only 
subjects who express willingness and demonstrate the ability to administer daily SC injections are eligible 
to participate in the study. To assess compliance with the dosing regimen, eligible subjects will be 
dispensed pre-filled safety injectors containing 0.5 mL open-label placebo and instructed to perform 
once-weekly self-injections at home during the 2-week run-in phase, as well as keep a study drug diary of 
their injection schedule.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
11
Approved, Date: 23 August 2018
Post-randomization Double-blind JNJ-64565111 or Matching Placebo and Open-label Liraglutide
Double-blind JNJ-64565111 or Matching Placebo
Double-blind JNJ-64565111 or matching placebo supplies should be stored in the refrigerator at 36 to 
46°F (2 to 8°C) and kept in their carton until ready for use and protected from direct heat and light. 
Blinded study drug can be left out at room temperature up to 8 hours. Avoid shaking blinded study drug.
JNJ-64565111 will be supplied as a solution for injection at a concentration of 20.0 mg/mL. Blinded 
study drug will be provided in pre-filled safety injectors with attached SC needle, pre-filled with nominal 
volumes of 0.25, 0.37, or 0.50 mL of JNJ-64565111 (5.0, 7.4, or 10.0 mg, respectively) or 1 of 
3 matching volumes of placebo.
On Day 1, subjects randomly assigned to the double-blind treatment arms will receive a supply of their 
study drug (or matching placebo), and will be reminded of the once-weekly dosing regimen and to record 
the date and time of each administered dose in the study drug diary. Subjects will self-administer the first 
dose of JNJ-64565111 or matching placebo at the site under the supervision of study staff. 
Subjects will be reminded that if the day of their once-weekly injection coincides with the day of a clinic 
visit, subjects are not to inject JNJ-64565111 or matching placebo before arriving at the clinic; once all 
study visit procedures have been completed, subjects may self-administer blinded study drug (or matching
placebo) either at the study site or once they have returned home that day.
JNJ-64565111 or matching placebo will not be titrated. Subjects will remain on their assigned dosages 
throughout the treatment phase (ie, until Week 26 or early discontinuation of study drug).
Open-label Liraglutide (Saxenda®)
Commercially available supplies of liraglutide will be dispensed to subjects randomly assigned to the 
open-label liraglutide arm of the study. Liraglutide is supplied as a pre-filled, multi-dose pen that delivers 
once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg (6.0 mg/mL, 3.0 mL).
On Day 1, subjects randomly assigned to open-label liraglutide will receive instruction on the use of the 
pre-filled multi-dose pen. Subjects will self-administer the first dose of study drug at the site under the 
supervision of study staff. 
The dosage of liraglutide to be used in this study is consistent with the approved labeling for its use as an 
adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult 
patients. The starting dosage of liraglutide on Day 1 will be 0.6 mg/day. At the beginning of Weeks 1, 2, 
3, and 4, subjects will be contacted preferably by telephone and instructed to up-titrate their daily dose to 
1.2, 1.8, 2.4, and 3.0 mg in 0.6 mg weekly increment. At Week 5, subjects will return to the clinic and 
should already be up-titrated to their daily dose of 3.0 mg. Subjects should remain on this dose for the 
remainder of the treatment phase.
For subjects who experience significant gastrointestinal intolerance within the weeks prior to the Week 5 
visit, up-titration of liraglutide may be delayed by 1 week. The reason for delaying up-titration will be 
documented on the study drug diary and electronic case report form (eCRF). If a subject cannot tolerate 
the 3.0 mg dose of liraglutide by Week 6, they should be discontinued from study treatment, as the 
efficacy of liraglutide for weight management has not been established at lower doses.
Drug Administration
Injections of JNJ-64565111 (or matching placebo) and liraglutide can be done at any time of day 
irrespective of meals. However, it is preferable that the general time of day (ie, morning, evening, just 
prior to bed, etc.) for injecting study drug be kept consistent, to the extent possible.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
12
Approved, Date: 23 August 2018
Double-blind JNJ-64565111 or Matching Placebo
Subjects randomly assigned to double-blind JNJ-64565111 (or matching placebo) will be instructed to 
administer study drug SC once-weekly for the entire duration of the 26-week treatment phase or until 
early discontinuation. Subjects will be instructed to inject to the 4 quadrants of the anterior abdominal 
wall. For consistency, and to avoid dosing in the same abdominal area, subjects should be instructed to 
begin in one quadrant and on subsequent dosing weeks proceed in the next quadrant in a 
counterclockwise manner.
JNJ-64565111 (or matching placebo) should be taken on the same day of the week throughout the study 
(ie, the regularly scheduled study drug day). If the day of the once-weekly injection coincides with the 
day of a clinic visit, subjects are NOT to inject JNJ-64565111 (or matching placebo) before arriving at the 
clinic. Instead, AFTER all study visit procedures have been completed, subjects may self-administer 
blinded study drug either at the study site or once they have returned home.
Subjects are to record the date and time of study drug administration on the study drug diary. Subjects 
should mark a calendar to remind them of when to take the next weekly dose.
Subjects in the JNJ-64565111 (or matching placebo) groups should be instructed not to take 2 doses 
within 3 days (72 hours) of each other. If a subject misses taking the next dose of JNJ-64565111 (or 
matching placebo) on their regularly scheduled study drug day, the missed dose should be taken as soon 
as possible, if there are at least 3 days (72 hours) until their next regularly scheduled study drug day. If 
there are less than 3 days remaining, the subject should skip the missed dose and take the next dose on 
their regularly scheduled study drug day.
Open-label Liraglutide (Saxenda®)
Subjects randomly assigned to open-label liraglutide will be instructed to administer study drug SC once 
daily for the entire duration of the 26-week treatment phase or until early drug discontinuation.
Liraglutide solution should be inspected prior to each injection, and the solution should be used only if it 
is clear, colorless, and contains no particles.
Subjects may administer liraglutide SC either in the abdomen, thigh, or upper arm. The injection site may 
be changed at any time. If the same injection area is being used, subjects will be instructed to choose 
different injection sites in that area (eg, rotating through different abdominal quadrants).
On the days of scheduled clinic visits, subjects in the open-label liraglutide group should be instructed 
NOT to inject liraglutide before arriving at the clinic. Instead, AFTER all study visit procedures have 
been completed, subjects may self-administer liraglutide either at the study site or once they have returned
home.
If a dose of liraglutide is missed, the once-daily regimen should be resumed with the next scheduled dose. 
An extra dose should not be taken to make up for the missed dose. 

After an interruption of more than 6 days, the subject who had already reached the 3.0 mg dose 
level should re-initiate liraglutide with a starting dose of 1.8 mg and re-up-titrate to 3.0 mg. 

For an interruption of 4 to 6 days in duration, it will be up to investigator’s judgment to assess 
whether the subject should re-start at 3.0 mg daily dose, or re-start at 1.8 mg or 2.4 mg. 
If, after an interruption of at least 4 days, the subject re-starts at a dose of 1.8 mg or 2.4 mg, the dose 
should be up-titrated in 0.6 mg increment every 7 days until the full dosage of 3.0 mg is reached.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
13
Approved, Date: 23 August 2018
Drug Storage
Study-site personnel will instruct subjects on how to store study drug for at-home use as indicated for this 
protocol.
Double-blind JNJ-64565111 or Matching Placebo
Double-blind JNJ-64565111 or matching placebo supplies should be stored in the refrigerator at 36 to 
46°F (2 to 8°C) and kept in their carton until ready for use and protected from direct heat and light. 
Blinded study drug or matching placebo can be left out at room temperature up to 8 hours. Avoid shaking 
blinded study drug.
Open-label Liraglutide (Saxenda®)
Prior to first use, liraglutide pens should be stored in the refrigerator at 36 to 46°F (2 to 8°C) and 
protected from direct heat and light. Do not store in the freezer or directly adjacent to the refrigerator 
cooling element. Liraglutide pens should not be frozen; if the pen is frozen, it should be thrown away.
After initial use of the liraglutide pen, it is preferably to be stored in a refrigerator (36 to 46°F; 2 to 8°C). 
Alternatively, it may be stored at controlled room temperature (59 to 86°F; 15 to 30°C) for up to 30 days 
only. The pen cap should be kept on when not in use.
To reduce the potential for contamination, infection, and leakage while also ensuring dosing accuracy, 
subjects should be instructed to always remove and safely discard the needle after each injection and store 
the liraglutide pen without an injection needle attached.
EFFICACY EVALUATIONS
Primary Efficacy Endpoint
The primary efficacy endpoint will be the percentage change in body weight from baseline to Week 26 
between JNJ-64565111 compared to placebo.
Secondary and Exploratory Efficacy Endpoints
The secondary measures of efficacy at Week 26 include proportion of subjects with 5% and 10% 
weight loss from baseline, and absolute change in body weight from baseline. Exploratory efficacy 
endpoints at Week 26 include change from baseline in BMI, waist circumference, fasting lipids (total 
cholesterol, LDL-C, HDL-C, and triglycerides), FPG, fasting insulin, fasting C-peptide, SBP, DBP, pulse 
rate, pulse-pressure product, PK exposure, and patient-reported outcomes (PROs) (ie, changes in 
IWQOL-Lite, single item Ease of Weight Management, and PAM).
Additional exploratory endpoints assessed in English-speaking subjects in selected countries only at 
Week 26 include PROs (ie, changes in ERCQ and PROMIS SF 8b), changes in qualitative assessments of 
pre-trial expectations and post-trial experiences using the ACTT pre-trial interviews, and a modified 
STEP exit interview.
The effects of JNJ-64565111 compared with liraglutide on the percentage change and absolute change in 
body weight from baseline and the proportion of subjects with ≥5% and ≥10% weight loss from baseline 
will also be assessed at Week 26.
PHARMACOKINETIC AND IMMUNOGENICITY EVALUATIONS
In subjects randomly assigned to JNJ-64565111 or matching placebo (but not in subjects randomly 
assigned to open-label liraglutide), venous blood samples will be collected according to the Time and 
Events Schedule for determination of serum trough concentrations of JNJ-64565111 and attainment of 
steady-state concentrations, as well as for detection and characterization of anti-JNJ-64565111 antibodies. 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
14
Approved, Date: 23 August 2018
On the days of the clinic visits at which PK samples are to be obtained, subjects are not to inject the study 
drug before arriving at the clinic. The exact dates and times of the study drug previous injection and blood 
sampling must be recorded in the eCRF or laboratory requisition form.
In a subset of subjects, non-trough PK samples will be collected 4 days (1 day) after the first dose of 
JNJ-64565111 or matching placebo.
SAFETY EVALUATIONS
Safety evaluations will include the monitoring of AEs (including protocol-specified AEs of interest), vital 
sign measurements, clinical laboratory tests (including serum chemistry, CBC, calcitonin, lipase, and 
amylase), and serum pregnancy testing. Adverse events of interest include MACE (ie, cardiovascular 
death, nonfatal myocardial infarction, and nonfatal stroke), hypotension-related AEs, acute pancreatic 
events (ie, AEs of pancreatitis, AEs of serious or severe abdominal pain leading to suspicion of 
pancreatitis, and confirmed lipase or amylase elevations 3× upper limit of normal), calcitonin elevation, 
and thyroid neoplasm.
STATISTICAL METHODS
Analysis Sets
The intent-to-treat (ITT) analysis set will include all subjects who are randomly assigned to a treatment 
group and have a baseline measurement of body weight. The modified intent-to-treat (mITT) population 
includes all ITT subjects who had at least 1 post-baseline measurement of body weight within 7 days 
following a dose of study drug. The completers’ analysis set will consist of all mITT subjects who have 
completed 26 weeks of double-blind treatment (ie, documented in the eCRF by the investigators that the 
subject has completed participation in the study through the Week 26 visit). The safety analysis set will 
include all randomized subjects who have received at least one dose of study drug.
The primary efficacy analysis, to demonstrate the superiority of JNJ-64565111 compared to placebo on 
percentage reduction in body weight from baseline to Week 26, as well as all secondary efficacy analyses, 
will be based on the mITT analysis set and will include only those measurements taken up to and 
including the last dose of study drug plus 7 days. A secondary analysis of the primary and secondary 
efficacy endpoints will be based on the ITT population. This analysis will include all measurements. 
Sensitivity analyses based on the completers’ analysis set will also be performed for the primary endpoint. 
Efficacy data will be analyzed according to the initial randomization assignment, regardless of the actual 
treatment received. Safety data will be analyzed according to the predominant treatment received, in the 
event that a subject receives a treatment other than that to which he/she is randomly assigned.
Sample Size Determination
A total of approximately 440 subjects will be randomized into this study with approximately 55 subjects 
per group allocated to placebo and JNJ-64565111 5.0 mg group, and approximately 110 subjects per 
group allocated to each of the other 3 groups: JNJ-64565111 7.4 mg, JNJ-64565111 10.0 mg, and open-
label liraglutide 3.0 mg. Sample size was determined based on assessing the primary hypothesis that the 
treatment with JNJ-64565111 for 26 weeks leads to greater percentage reduction in body weight 
compared with placebo as well as the exploratory hypothesis that the treatment with JNJ-64565111 leads 
to greater percentage reduction in body weight compared with open-label liraglutide. 
Assuming a common standard deviation of 7% with respect to percent change in body weight at Week 26 
and a 2-sided Type 1 error rate of 0.05, it is estimated that a sample size of 55 randomized subjects per 
group will have approximately 90% power to detect a treatment difference of 4.4%, 110 randomized 
subjects per group will have approximately 90% power to detect a treatment differences of 3.1%.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
15
Approved, Date: 23 August 2018
Safety Analyses
The evaluation of safety will be based on the incidence of AEs and changes in clinical laboratory test 
results and vital sign results (SBP, DBP, and pulse rate). Summaries of AEs, clinical laboratory test 
results, and vital sign results will be provided by treatment group. 
Efficacy Analyses
All hypotheses will be tested 2-sided at a 5% significance level unless otherwise specified.
Primary Efficacy Endpoint
The primary efficacy endpoint will be the percentage change in body weight between JNJ-64565111 and 
placebo from baseline to Week 26.
The primary efficacy endpoint will be analyzed based on the mITT analysis set using a mixed model for 
repeated measures (MMRM). The analysis will use the observed data through Week 26 while on 
treatment (up to the last dose of study drug plus 7 days) and will include the fixed, categorical effects of 
treatment, visit, and treatment-by-visit interaction, as well as the fixed, continuous, covariates of baseline 
body weight and baseline-by-visit interaction. An unstructured covariance will be used to model the 
within-patient errors. The treatment comparisons will be made between each of the JNJ-64565111 
treatment groups and placebo at Week 26 based on this model.
A secondary analysis of the primary endpoint will be based on the ITT population and will employ 
pattern mixture models using multiple imputation methods. Responses for subjects who discontinued 
from the study earlier than Week 26 will be imputed based on subjects who discontinued treatment 
prematurely but subsequently provided off-treatment measurements. The imputation will be done within 
groups defined by randomized treatment. Data will be analyzed using the same model as in the primary 
analysis. The treatment comparisons between each of the JNJ-64565111 treatment groups and placebo 
will be made at Week 26. Details of this approach will be provided in the Statistical Analysis Plan (SAP).
Finally, the primary efficacy endpoint will be analyzed based on the completers’ analysis set. Additional 
analysis using a MCP-Mod (Multiple Comparison Procedure – Modeling) approach will be performed to 
explore the dose-response relationship.
Secondary Efficacy Endpoints
Secondary efficacy analyses at Week 26 will include proportion of subjects with 5% and 10% weight 
loss and the absolute change in body weight from baseline.
The continuous secondary endpoints (ie, absolute change in body weight from baseline) at Week 26 will 
be analyzed with an MMRM model similar to the primary efficacy endpoint in the mITT analysis set.
The categorical secondary efficacy endpoint (ie, the proportion of subjects with 5% weight loss and the 
proportion of subjects with 10% weight loss at Week 26) will be analyzed longitudinally using a 
generalized linear mixed model. The model will include the fixed, categorical effects of treatment, visit, 
and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline body weight, and 
baseline-by-visit interactions. An unstructured covariance will be used to model the within-patient errors. 
The odds ratio and associated p-value for the treatment comparison between each of the JNJ-64565111 
treatment groups versus placebo at Week 26 based on this model will be provided.
A secondary analysis of the secondary endpoints will be based on the ITT population and will employ 
pattern mixture models using multiple imputation methods based on subjects who discontinued treatment 
prematurely but subsequently provided off-treatment measurements. For the categorical endpoints, 
response status will be determined from the imputed continuous response based on subjects who 
discontinued treatment prematurely but subsequently provided off-treatment measurements.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
16
Approved, Date: 23 August 2018
Multiplicity Adjustment
The type I error will be strongly controlled at α=5% for each of primary endpoint and secondary 
endpoints. The Dunnett’s method will be used to adjust the multiplicity of the comparisons of each of the 
JNJ-64565111 doses versus placebo for the primary efficacy endpoint of the percentage change in body 
weight and the secondary endpoint of the absolute change in body weight. The Bonferroni correction will 
be used to adjust the multiplicity of the comparisons for the secondary endpoints of the proportion of 
subjects with weight loss 5% and 10%.  
Exploratory Endpoints
The exploratory analysis of the assessments between the JNJ-64565111 treatment groups and placebo 
include the following to Week 26:

the change in BMI from baseline

the change in waist circumference from baseline 

the change in fasting lipids (total cholesterol, LDL-C, HDL-C, and triglycerides) from baseline

the change in FPG from baseline

the change in fasting insulin from baseline 

the change in fasting C-peptide from baseline

the changes in HOMA-B and HOMA-IR from baseline

the change in SBP from baseline

the change in DBP from baseline

the change in pulse rate from baseline

the change in pulse-pressure product from baseline

in a subset of subjects participating in the 24-hour ABPM assessment, the changes in 24-hour SBP, 
DBP, pulse rate, and pulse-pressure product
Change from baseline in total cholesterol, LDL-C, HDL-C, and triglycerides, change from baseline in 
fasting insulin, change from baseline in SBP, change from baseline in DBP, and change from baseline in 
pulse-pressure rate will be analyzed using a MMRM model similar to that used to analyze the primary 
efficacy endpoint.
The exploratory PRO endpoints will be summarized descriptively at baseline and over time. These 
endpoints include:

IWQOL-Lite total and physical function, self-esteem, sexual life, public distress, and work domain 
scores

Ease of Weight Management total scores

PAM total scores

ERCQ domain scores and PROMIS SF 8b total scores (in English-speaking subjects in selected
countries only)

Describe pre-trial goals and expectations as well as post-trial experiences qualitatively using the 
ACTT Pre-trial interviews and a modified STEP exit interview (in English-speaking subjects in 
selected countries only)  
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
17
Approved, Date: 23 August 2018
The exploratory analysis of the assessments between the JNJ-64565111 treatment groups (7.4 mg and 
10 mg) and liraglutide on the percentage change in body weight will also be performed. The same 
analysis model used for the comparisons with placebo on the primary efficacy endpoint will be used for 
these assessments.
The exploratory analysis of the assessments between the JNJ-64565111 treatment groups (7.4 mg and 
10 mg) and liraglutide on 5% weight-loss responders and 10% weight-loss responders and the absolute 
change in body weight at Week 26 will also be performed. The same analysis models used for the 
comparisons with placebo will be used for these assessments.
Interim Analysis
An interim analysis will be performed when approximately 90% of subjects have either completed or 
discontinued prior to approximately 10 weeks of study drug treatment. The objective of this interim 
analysis is to identify active treatment groups, if any, associated with safety or tolerability issues and to 
facilitate planning of the Phase 3 program. The dissemination of the interim analysis results will be 
limited to an internal data monitoring committee (DMC), and will not be shared with investigators, 
subjects, or the sponsor staff who will continue to be involved in the conduct of the study before the final 
database lock. The operational details of the interim analysis will be provided in the DMC SAP.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
18
Approved, Date: 23 August 2018
TIME AND EVENTS SCHEDULE
Protocol Activity
Pre-treatment
Treatment
Post-
treatment 
Screening
Run-In
Wk -3
Wk -2
Pre-Day 1 
(ABPM 
Only)a
Day 1 
(Random-
ization)
Day 4
Wk 1
(RC)
Wk 2
Wk 3
(RC)
Wk 4
(RC)
Wk 5b Wk 10b Wk 15b Wk 20b
Pre-Wk 
26 
(ABPM 
Only)a
Wk 26/
EOTc
4-Week 
SAE F/Ud
Screening/Administrative
Informed consent e
X
Inclusion/exclusion criteria
X
X
X
Medical history & 
demographics
X
Prior therapy reporting and 
review f
X
X
X
IWRS log-in/tracking
X
X
X
X
X
X
X
X
Randomization
X
Study Drug Administration
Show and/or describe 
injection device of 
JNJ-64565111/matching 
placebo
X
X
Show and/or describe 
injection device of liraglutide
X
X
Dispense open-label placebo 
X
Dispense open-label 
liraglutide or double-blind 
JNJ-64565111/ matching 
placebo 
X
X
X
X
X
Drug titration (liraglutide 
arm only)g
X
X
X
X
Injection at study siteh
X
X
Dispense study drug diary 
X
X
X
X
X
X
Review study drug diary
X
X
X
X
X
X
Run-in compliance 
assessment
X
Drug accountability
X
X
X
X
X
X
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
19
Approved, Date: 23 August 2018
Protocol Activity
Pre-treatment
Treatment
Post-
treatment 
Screening
Run-In
Wk -3
Wk -2
Pre-Day 1 
(ABPM 
Only)a
Day 1 
(Random-
ization)
Day 4
Wk 1
(RC)
Wk 2
Wk 3
(RC)
Wk 4
(RC)
Wk 5b Wk 10b Wk 15b Wk 20b
Pre-Wk 
26 
(ABPM 
Only)a
Wk 26/
EOTc
4-Week 
SAE F/Ud
Survey on self-
administration of study drugi
X
Clinical Procedures
Physical examination
X
X
Vital signs (pulse rate and 
BP, in triplicate)j
X
X
X
X
X
X
X
Weightj
X
X
X
X
X
X
X
Heightj
X
Waist circumference k
X
X
X
12-lead ECG (local)
X
24-hour ABPM sub-study a
Set up ABPM device and 
dispense ABPM diary
X
X
Return ABPM device, 
transfer ABPM data, 
generate and review ABPM 
report
X
X
Review ABPM diary 
X
X
Laboratory Assessments l
Fasting lipid profile m
X
X
X
X
Serum chemistry
X
X
X
X
X
X
X
X
FPG
X
X
X
X
X
X
X
Xn
HbA1c
X
X
X
Fasting insulin
X
X
Fasting C-peptide
X
X
Hematology
X
X
X
Calcitonin
X
X
X
X
Serum ß-hydroxybutyrate
X
X
X
X
X
X
Urine dipstick/ urinalysis
X
X
Serum pregnancy test o
X
X
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
20
Approved, Date: 23 August 2018
Protocol Activity
Pre-treatment
Treatment
Post-
treatment 
Screening
Run-In
Wk -3
Wk -2
Pre-Day 1 
(ABPM 
Only)a
Day 1 
(Random-
ization)
Day 4
Wk 1
(RC)
Wk 2
Wk 3
(RC)
Wk 4
(RC)
Wk 5b Wk 10b Wk 15b Wk 20b
Pre-Wk 
26 
(ABPM 
Only)a
Wk 26/
EOTc
4-Week 
SAE F/Ud
Follicle-stimulating 
hormone p
X
Trough pharmacokinetic and 
Immunogenicity ADA
samples
(For subjects in JNJ-
64565111 or matching 
placebo groups only) q
X
X
X
X
X
X
X
Non-trough pharmacokinetic
sample (For subjects in 
JNJ-64565111 or matching 
placebo groups only) r
X
Fasting plasma, serum, and 
urine archive samples for 
exploratory research m
X
X
Interviews  
ACTT interview (subset of 
subjects)s
X
STEP interview (subset of 
subjects)s
X
Subject Counseling and 
Ongoing 
Review/Assessments
Assessment of subjects’ 
status and reinforcement of 
study procedures
X
Diet and exercise 
counseling t
X
X
X
X
X
Adverse Event reporting and 
review
X
X
X
X
X
X
X
X
X
Record concomitant therapyf
X
X
X
X
X
X
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
21
Approved, Date: 23 August 2018
ABPM = Ambulatory blood pressure monitoring; ACCT = Anticipations of Clinical Trial Treatment; ADA = anti-drug antibodies; BP = blood pressure; ECG = Electrocardiogram; 
EOT = End-of-treatment; FPG = fasting plasma glucose; FSH = Follicle-stimulating hormone; F/U = follow-up; HbA1c = Hemoglobin A1c; IWRS = interactive web response system;
PK = Pharmacokinetics; RC = remote contact (preferably by telephone); SAE = serious adverse event; STEP = Safety, Tolerability, and Efficacy Preview; Wk = week.
a)
A 24-hour ABPM will be obtained in a subset of subjects at selected sites. At the Week -2 visit, subjects participating in the ABPM sub-study will be asked to return to the study 
site 1 or 2 days prior to the Day 1 and Week 26/ EOT visits to be fitted with an ABPM device. Subjects will return the device at the Day 1 and Week 26/EOT visits. Instructions 
for collecting ABPM measurements can be found in the procedural manual.
b)
At some time between Weeks 2, 5, 10, 15, 20, and 26 visits, study-site staff is encouraged to contact subjects preferably by telephone to reinforce the adherence to diet and 
exercise, study drug dosing reminder, assessment of subjects’ status, and compliance with the protocol procedures (eg, diary completion reminder). 
c)
Subjects who prematurely discontinue study drug will require an immediate EOT assessment (either on the day of study drug discontinuation or as soon as possible following 
study drug discontinuation). Subjects that discontinue study drug early will continue in the study and be assessed with the off-treatment procedures at the subsequent visit(s) per 
the Time and Events visit schedule, starting at the next scheduled visit from when study drug was permanently discontinued up to the final Week 26 visit. These off-treatment 
procedures will include assessment and collection of SAEs, specific AEs of interest (ie, MACE events, acute pancreatitis, and possible cases of thyroid neoplasm), vital signs
(including body weight) and concomitant medications.
d)
The SAE follow-up visit will be conducted for all subjects approximately 5 weeks after the last dose of study drug for JNJ64565111/placebo-treated subjects and 4 weeks after the 
last dose of study drug for liraglutide-treated subjects to collect SAEs unless the subject has died, has been lost to follow-up, or has withdrawn consent. For subjects randomly 
assigned to double-blind JNJ-64565111 or placebo, blood samples will also be collected for PK and immunogenicity anti-drug antibody (ADA) measurement. Subjects who
prematurely discontinue study drug for any reason prior to Week 26 and have not withdrawn consent, will continue (off-treatment) in the study following the EOT visit and 
undergo the off-treatment procedures based on the predefined study visit schedule.
e)
Informed Consent must be signed at the screening visit before any study procedures are performed.
f)
Record any medications taken from up to 30 days before screening until the first dose of double-blind study drug on Day 1 (baseline) as pre-study therapy in the corresponding 
eCRF. Concomitant therapy includes all medications since the first dose of study drug on Day 1.
g)
The starting dosage of liraglutide on Day 1 will be 0.6 mg once daily. Subjects will be contacted preferably by telephone weekly during the first 4 weeks of the study and 
instructed to increase their dose of liraglutide by an 0.6 mg dose increment every 7 days, until they have reached the full dosage of 3.0 mg once daily by Week 5. Subjects will 
then continue on the 3.0 mg once-daily dosage for the remainder of the study. For subjects who experience significant gastrointestinal intolerance prior to the Week 5 visit, up-
titration of liraglutide may be delayed by 1 week. If a subject cannot tolerate the 3.0 mg dose of liraglutide by Week 6 they should be discontinued from study treatment.
h)
Subjects will be asked to perform a self-injection of open-label JNJ-64565111-matching placebo (Week -2) or their randomly assigned study drug (Day 1) at the study site in the 
presence of the study-site staff. After Day 1, injections may be performed by the subject at home.
i)
A survey will be given to English-speaking subjects in selected countries to assess subject satisfaction with the experience of self-administering JNJ-64565111 or matching 
placebo or liraglutide. The PI should use their discretion to determine whether the subject is sufficiently fluent in English to take the survey.
j)
Blood pressure and pulse rate: 3 seated readings will be recorded in the source and eCRF. See Attachment 2, Method of Blood Pressure and Pulse Rate Measurement.
k)
Body weight will be measured using a calibrated scale; subjects should be weighed wearing underwear and a gown. Note: if disrobing for weighing is logistically impossible, the 
subject must be dressed as lightly as possible, with consistency from visit to visit; subjects will be instructed to take off their shoes and to empty their bladders before being 
weighed. Anthropometric measurements, for height, body weight and waist circumference measurement procedures, are described in Attachment 3.
l)
Specific details about specimen collection, storage, packaging, and shipping will be provided in an operations manual from the central laboratory.
m)
Subjects must fast for at least 8 hours before blood sample collection. If not fasting at the time of the screening visit, the subject should return to the site soon after the screening 
visit (and before the start of the run-in phase) to have a fasting sample collected.
n)
FPG will be assessed in subjects who initiated metformin during the 26-week treatment period.
o)
Serum (-human chorionic gonadotropin [-hCG]) pregnancy testing will be performed for all women of childbearing potential (ie, unless they are permanently sterilized or 
unless there is a documented history of their postmenopausal status, as defined in Section 4.1, Inclusion Criteria) at the screening and Week 26/EOT visits. Additional serum or 
urine pregnancy tests may be conducted throughout the study in sufficient number, as determined by the investigator or required by local regulations, to establish the absence of 
pregnancy during the study. 
p)
FSH will be measured in women >45 years of age with amenorrhea for at least 6 months and <18 months prior to screening.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
22
Approved, Date: 23 August 2018
q)
For PK sampling, subjects will be instructed to refrain from taking the study drug in the morning before the clinic visit. The subject must report the time that the study drug was 
taken on the day preceding the clinic visit.
r)
A subset of subjects will have 1 additional visit (Day 4 ± 1 day sampling window) to collect a non-trough PK sample.
s)
Study entry (ACTT) and exit (STEP) interviews will be given to a subset of English-speaking subjects in selected countries. The PI should use their discretion to determine 
whether the subject is sufficiently fluent in English to take these surveys. 
t)
Counseling should be done by dietitians/nutritionists on Day 1/Day of Randomization to provide assessment and recommendation on a reduced-calorie diet and exercise regimen 
(see Attachment 4). At subsequent visits (Week 5, Week 10, Week 15 and Week 20), counseling and reinforcement of the recommended diet and exercise regimen will be 
conducted by a trained counselor. 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
23
Approved, Date: 23 August 2018
TIME AND EVENTS SCHEDULE – PATIENT-REPORTED OUTCOMES 
Protocol Activity
Pre-treatment
Treatment
Screening
Run-In
Week -3
Week -2
Week -1 
Day 1 
(Random-
ization)
Week 15
Week 16
Week 20
Week 24
Week 25
Week 26/
EOTa
Patient-Reported Outcomes b  
IWQOL-Lite
X
X
X
Single item Ease of Weight 
Management
X
X
X
Patient Activation Measure (PAM)
X
X
X
Dispense diary containing Eating-
related Concepts Questionnaire 
(ERCQ) (subset of subjects)
X
X
X
Remote Site Contact to remind 
Completion of ERCQ diary (subset 
of subjects)
X
Completion of ERCQ (subset of 
subjects) 
X------------------Xc
X----------------Xc
X----------------Xc
PROMIS Physical function short 
form (PROMIS SF 8b) (subset of 
subjects)
X
X
X
X
Patient Global Impression Status 
(PGIS) (subset of subjects)
Xd
Xd
Xd
Patient Global Impression of 
Change (PGIC) (subset of subjects)
Xd
Xd
EOT = End-of-treatment; ERCQ = Eating-related Concepts Questionnaire; IWQOL-Lite = Impact Of Weight On Quality Of Life-Lite; PAM = Patient Activation Measure; 
PGIC = Patient Global Impression of Change; PGIS = Patient Global Impression Status; PROMIS = Patient-reported Outcomes Measurement Information System; 
PROMIS SF 8b = PROMIS Short Form 8b.
a)
Subjects who prematurely discontinue study drug will require an immediate EOT assessment (either on the day of study drug discontinuation or as soon as possible following 
study drug discontinuation). Subjects that discontinue study drug early will continue in the study and be assessed with the off-treatment procedures at the subsequent visit(s) per 
the Time and Events visit schedule, starting at the next scheduled visit from when study drug was permanently discontinued up to the final Week 26 visit. These off-treatment 
procedures will include assessment and collection of SAEs, specific AEs of interest (ie, MACE events, acute pancreatitis, and possible cases of thyroid neoplasm), vital signs 
(including body weight) and concomitant medications.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
24
Approved, Date: 23 August 2018
b)
All patient-reported outcome (PRO) assessments should be completed at the beginning of the clinic visit (whenever possible) for site visit-based assessments and completed at the 
same time each day in the same setting each day for home-based assessments as specified in the Time and Events Schedule, or at the time the subject discontinues the study drug 
or withdraws from the study, before all other evaluations, as specified in the Time and Events Schedule. Assessments (whenever possible) should be completed before any tests, 
procedures, or discussion of AEs or the subject’s medical condition.
c)
ERCQ diary should be completed at home for 7 consecutive days at these time points: (1) starting Week -1 to day before Day 1 for 7 consecutive days, (2) the next 1 or 2 days 
after Week 15 for 7 consecutive days, and (3) starting Week 25 up to the day before Week 26. For subjects who discontinue early from study drug, no ERCQ diary completion is 
required at the EOT visit.
d)
PGIS and PGIC are needed to calculate responder definitions for new PRO instruments ERCQ and PROMIS SF 8b. These are not exploratory efficacy endpoints.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
25
Approved, Date: 23 August 2018
ABBREVIATIONS
5-HT2C
5-hydroxytryptamine type 2C receptor
-hCG
serum -human chorionic gonadotropin
ABPM
ambulatory blood pressure monitoring
ACTT
anticipations of Clinical Trial Treatment
ADA
anti-drug antibodies
AE(s)
adverse event(s)
ALT
alanine aminotransferase
ANCOVA
analysis of covariance
ANOVA
analysis of variance
AST
aspartate aminotransferase
AUC
area under the curve
AUC168hr
area under the curve in the interval 0–168 hours
AUC(0-inf)
area under the curve from time zero (pre-dose) to extrapolated infinite time
AUC(0-last)
area under the curve from time zero (pre-dose) to last measurable concentration
AUC(Tau)
area under the curve from time zero (pre-dose) to the end of dosing period
BMI
body mass index
bpm
beats per minute
CI
confidence interval
Cmax
maximum concentration
Cmin
minimum observed plasma concentration
CKD-Epi
Chronic Kidney Disease Epidemiology Collaboration
CPK
creatinine phosphokinase
CT
computed tomography
CV
cardiovascular
DBP
diastolic blood pressure
DIO
diet-induced obese
DKA
diabetic ketoacidosis
DMC
data monitoring committee
DPP-IV
dipeptidyl peptidase-IV
ECG
electrocardiogram
eCRF(s)
electronic case report form(s) 
eDC
electronic data capture
eGFR
estimated glomerular filtration rate
EMA
European Medicines Agency
EOT
end-of-treatment
ERCQ
Eating-related Concept Questionnaire
EU
European Union
FDA
US Food and Drug Administration
FPG
fasting plasma glucose
FSH
follicle-stimulating hormone
GABA
gamma-aminobutyric acid
GCGR
glucagon receptor
GCP
Good Clinical Practice
geo CV%
geometric coefficient variation
GI
gastrointestinal
GLP
Good Laboratory Practices
GLP-1
glucagon-like peptide-1
GLP-1R
GLP-1 receptor
HAART
highly Active Anti-retroviral therapy
HbA1c
Hemoglobin A1c
HCV
hepatitis C virus
HDL-C
high-density lipoprotein cholesterol
hERG
human ether-a-go-go-related gene
HMC001
human immunoglobulin G4 fragment
HMOXM25
GLP 1/Glucagon dual receptor agonist
HOMA-B
Homeostasis Model Assessment for B cell function
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
26
Approved, Date: 23 August 2018
HOMA-IR
Homeostasis Model Assessment of Insulin Resistance
ICF
informed consent form
ICH
International Conference on Harmonisation
IEC
Independent Ethics Committee
IRB
Institutional Review Board
ITT
intent-to-treat
IUD
intrauterine device
IUS
intrauterine hormone-releasing system
IWQOL-Lite
Impact of Weight on Quality of Life-Lite
IWRS
interactive web response system
LDL-C
low-density lipoprotein cholesterol
LOCF
last observation carried forward
LS
Least-square
MACE
major adverse cardiovascular events
MAD
multiple ascending dose
MedDRA
Medical Dictionary for Regulatory Activities
MEN 2
multiple endocrine neoplasia syndrome type 2
MI
myocardial infarction
mITT
modified intent-to-treat
mmHg
millimeters mercury
MMRM
mixed model for repeated measures
MRI
magnetic resonance imaging
MTC
medullary thyroid carcinoma
NOAEL
No Observed Adverse Effect Level
NYHA
New York Heart Association
OXM
oxyntomodulin
PAM
Patient Activation Measure
PD
pharmacodynamics
PEG
polyethylene glycol
PG
plasma glucose
PGIC
Patient Global Impression of Change
PGIS
Patient Global Impression Status
PI
Principal Investigator
PK
pharmacokinetics
PPG
postprandial plasma glucose
PPI
proton pump inhibitor
PQC
product quality complaint
PRO
patient-reported outcome(s) (paper or electronic as appropriate for this study)
PROMIS SF 8b
PROMIS physical function Short Form 8b
QTcR
Rautaharju corrected QT interval
REML
restricted maximum likelihood
SAD
single ascending dose
SAE(s)
serious adverse event(s)
SAP
statistical analysis plan
SBP
systolic blood pressure
SC
subcutaneous, subcutaneously
SD
standard deviation
SGLT2
sodium-glucose cotransporter 2
STEP
Safety, Tolerability, and Efficacy Preview
SUSAR(s)
suspected unexpected serious adverse reaction(s)
T2DM
type 2 diabetes mellitus
TEAE(s)
treatment-emergent adverse event(s)
t½
terminal half-life
Tmax
time to maximum concentration
ULN
upper limit of normal
US
United States
WHO
World Health Organization
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
27
Approved, Date: 23 August 2018
DEFINITIONS OF TERMS
Electronic source 
system (eSource)
Contains data traditionally maintained in a hospital or clinic record to document medical 
care or data recorded in a eCRF as determined by the protocol. Data in this system may be 
considered source documentation
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
28
Approved, Date: 23 August 2018
1.
INTRODUCTION
The prevalence of obesity is increasing worldwide. The World Health Organization (WHO)
estimated that worldwide obesity has nearly tripled since 1975, affecting more than 650 million 
adults (WHO 2017). In the United States (US) in 2015-2016, 39.8% of adults and 18.5% of 
children and adolescents were obese, representing a significantly increasing trend compared to 
the prevalence of 30.5% and 13.9%, respectively, reported in the 1999-2000 period (Hales 2017). 
The US Centers for Disease Control and Prevention predict that obesity-related deaths could 
soon overtake smoking-related illnesses as the leading cause of mortality in the US. Indeed,
obesity represents a major risk factor for cardiovascular (CV) diseases (eg, hypertension, 
atherosclerotic diseases, stroke), metabolic diseases (eg, type 2 diabetes mellitus [T2DM], 
dyslipidemia, non-alcoholic fatty liver disease [NAFLD]/ steatohepatitis [NASH]), conditions of 
the genito-urinary system (polycystic ovary syndrome, sexual dysfunction, stress urinary 
incontinence), musculoskeletal apparatus (eg, degenerative arthritis, pain). In addition, obesity is 
associated with impaired quality of life, an increased risk of depression, and several types of 
cancers, predominantly of the digestive tract and female reproductive system (Kyrgiou 2017;
Wolfe 2017). The increased obesity-related morbidity was recently demonstrated in the Patient 
Outcome Research to Advance Learning study of more than 12 million individuals in the US 
who were overweight or had obesity and assessed for the prevalence of cardiometabolic risk 
factors: elevated blood pressure, elevated triglycerides, low high-density lipoprotein–cholesterol
(HDL-C), and prediabetes. Compared with being overweight, obesity classes I (body mass index 
[BMI] 30.0-34.9 kg/m2), II (BMI 35.0–39.9 kg/m2), and III (BMI 40 kg/m2) were associated 
with a nearly 2-fold, 3-fold, and 4-fold, respectively, greater probability of having at least 
1 cardiometabolic risk factor
(Nichols 2017).
Hence, subjects with severe obesity 
(BMI >35 kg/m2) are consequently more affected by the disease, have a poor quality of life, and 
thus have the greatest need for weight-loss therapy. Indeed, these comorbid conditions are 
expected to improve or go into remission in the presence of effective and sustained weight loss.
Current treatments for severe obesity include dietary and behavioral interventions, 
pharmacologic therapies, and eventually bariatric surgery. While combination strategies using 
diet, exercise, and behavior therapy have been shown to be more effective in the short term than 
diet and exercise alone (NIH 2000), these treatments are usually ineffective in subjects who are 
severely obese. Although weight reduction by as little as 5% of body weight has been shown to 
improve many obesity comorbidities, this modest weight reduction is insufficient to result in 
significant improvement in this population. Additionally, weight regain is common in severely 
obese patients, even when approaches are used that combine dietary therapy with exercise and 
behavior modification.
Pharmacotherapy is the second-line therapy recommended when lifestyle changes are ineffective 
in yielding significant weight loss. Currently available drug therapies include gastrointestinal
(GI) lipase inhibitors such as orlistat (Xenical® [Xenical USPI], Roche Laboratories, Inc. or 
Alli®, GlaxoSmithKline Inc.), selective 5-HT2C-receptor agonists such as lorcaserin (Belviq®
[Belviq USPI], Arena Pharmaceuticals Inc.), glucagon-like peptide-1 (GLP-1) receptor agonists 
such as liraglutide (Saxenda® [Saxenda USPI], Novo Nordisk Inc.), the combination of 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
29
Approved, Date: 23 August 2018
naltrexone, an opioid antagonist, and bupropion, a dopamine and norepinephrine-reuptake-
inhibitor (Contrave®, Mysimba®, Orexigen Therapeutics Ireland Ltd.), and the combination of 
phentermine, a sympathomimetic amine, and topiramate, an anti-epileptic drug (Qsymia®
[Qsymia USPI] in the US, Vivus Inc.). In addition, phentermine (Adipex-P USPI), as well as 
some other anorectic agents (including diethylpropion, benzphetamine, and phendimetrazine), 
are registered in the US for short-term use (a few weeks, according to the label). 
Pharmacological compounds have variable efficacy and their use can be limited by side effects 
including diarrhea, abdominal cramps, and reduced absorption of fat-soluble vitamins with 
orlistat (Xenical USPI);
serotonin-associated adverse reactions; cognitive impairment, 
psychiatric disorders, and possible valvular heart disease with lorcaserin (Belviq USPI); nausea, 
vomiting, elevation in pulse rate, and acute pancreatitis with liraglutide (Saxenda USPI); GI side 
effects, psychiatric, neurocognitive and sleep disorders with the combination of naltrexone and 
bupropion (Contrave USPI); and cognitive impairment, psychiatric disorders, and elevation in 
pulse rate with the combination of phentermine and topiramate (Qsymia USPI); and adverse 
events (AEs) related to the central nervous system or the cardiovascular system with 
phentermine (Adipex-P USPI). 
Although bariatric surgery represents the most effective treatment option for severe obesity as it 
provides significant and sustained weight loss, and is more effective than lifestyle or 
pharmacological management in achieving glycemic control and reductions in morbidity and 
mortality, it can be associated with peri-operative (eg, venous thromboembolism, anastomotic 
leaks, wound infections, bleeding, and hernias) and post-operative (eg, nausea, vomiting, 
dumping syndrome, fat-soluble vitamin malabsorption) complications.
Given the above, there is a need for more effective and well-tolerated weight-management 
therapies that may also positively affect obesity-related comorbidities such as hypertension, 
dyslipidemia and T2DM (Padwal 2003).
While patients who undergo gastric banding and gastric bypass surgery have a reduction in 
caloric intake, there are also changes in several gut hormones that may play a role in reducing 
appetite and enhancing glucose control (le Roux 2007). Among the changes that have been 
consistently observed following bariatric surgery are increased postprandial levels of glucagon, 
GLP-1, and oxyntomodulin (OXM) (Chandarana 2012; le Roux 2007). Therefore, administration 
of metabolically stable endogenous gut peptides represents a potential therapeutic approach to 
modulating the pathophysiology of obesity and T2DM.
Oxyntomodulin is an endogenous 37-amino acid peptide secreted from enteroendocrine L-cells 
in the gut in response to and in proportion to nutrient ingestion. Oxyntomodulin is a dual agonist, 
acting at both the GLP-1R and the glucagon receptor (GCGR). These combined actions at the 
GLP-1R (enhanced glucose-stimulated insulin secretion and suppression of food intake) and the 
GCGR (suppression of food intake, increased energy expenditure, and improved lipid 
metabolism) suggest that OXM-based therapeutics could provide several benefits to obese 
patients and might produce superior weight loss as compared to currently available weight-
management medications. Rodent and human studies support this hypothesis. Oxyntomodulin-
based agonists cause marked weight loss in obese mice, and that effect is reduced in mice 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
30
Approved, Date: 23 August 2018
lacking either GLP-1R or GCGR (Day 2009). Oxyntomodulin treatment in humans reduced food 
intake acutely by 14 to 20% (Cohen 2003; Field 2010) and resulted in a 2% body weight 
reduction after 4 weeks relative to subjects who received placebo (Wynne 2005).
JNJ-64565111 (efinopegdutide, formerly designated as HM12525A, developed by Hanmi 
Pharmaceuticals) is a synthetic, modified OXM peptide; it is the site-specific form of 
HMGLP/GCG25 (a GLP-1/glucagon dual agonist peptide), that is conjugated to constant region 
of human immunoglobulin G4 fragment (HMC001) via a 10 kDa polyethylene glycol (PEG) 
linker. The constant region of human immunoglobulin G4 fragment was chosen as the stabilizing 
agent, because it is a highly prevalent blood protein and has an in vivo half-life of several weeks, 
and lacks immune effector functions, such as complement-dependent cytotoxicity or antibody-
dependent cell-mediated cytotoxicity.
In vitro, JNJ-64565111 stimulates both GLP-1 and GCGR with comparable potency. Moreover, 
JNJ-64565111 lowers body weight and plasma glucose in animal models of obesity and T2DM. 
The mechanisms mediating body weight loss by JNJ-64565111 are thought to be via synergistic 
effects on caloric (food) intake and energy expenditure. In addition, the theoretical potential for 
blood glucose elevation with JNJ-64565111 due to GCGR agonism, appears to be efficiently 
offset by its GLP-1 receptor activity, as demonstrated by reduced blood glucose levels in mice 
and in humans with T2DM, as summarized in Section 1.1.1, Nonclinical Studies and 1.1.2, 
Clinical Studies with JNJ-64565111. JNJ-64565111 lowers cholesterol, low-density lipoprotein 
(LDL), and triglycerides in animal models of dyslipidemia.
For the most comprehensive nonclinical and clinical information regarding JNJ-64565111, refer 
to the latest version of the Investigator's Brochure for JNJ-64565111 (JNJ-64565111 IB).
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
1.1.
Background on JNJ-64565111
1.1.1.
Nonclinical Studies
Pharmacologic Profile
JNJ-64565111, formerly designated as HM12525A, is a site-specific conjugate of HMOXM25 
(GLP 1/glucagon dual receptor agonist; also abbreviated to HMGLP/GCG25) and the HMC001 
linked via 10 kDa polyethylene glycol (PEG) linker.
Simultaneous activation of GLP-1R and GCGR were shown to have beneficial effects in body 
weight loss by synergistic regulation mechanisms in energy intake and expenditure. Using a 
high-fat, diet-induced obese (DIO) animal model (ie, DIO mice), studies showed potent body 
weight loss by food intake inhibition as well as increased energy expenditure following treatment 
with JNJ-64565111. The body weight loss was mainly derived from the fat mass reduction, and 
accompanied with improvements in serum lipid profile. In addition, the simultaneous activity of 
JNJ-64565111 on GLP-1R and GCGR resulted in glucose-lowering in other animal models. 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
31
Approved, Date: 23 August 2018
JNJ-64565111 normalized the glycemic excursion following an intraperitoneal glucose tolerance 
test in DIO mice and improved glycemic control in an animal model of T2DM (ie, db/db mice).
Safety Pharmacology
In safety pharmacology studies, JNJ-64565111 was evaluated in neurobehavioral, pulmonary,
and cardiovascular pharmacology studies. In a neurobehavioral safety pharmacology study in 
rats up to 100 nmol/kg, JNJ-64565111 induced some changes (hunched posture, abnormal gait, 
reduce body temperature, tremor, etc.) but the changes were considered to be secondary to the 
large body weight
losses recorded, which was an expected pharmacological effect. 
JNJ-64565111 produced no significant effects on any of the respiratory parameters (respiratory 
rate, tidal volume, and minute volume) measured in rats up to a dose of 100 nmol/kg. In 
cardiovascular safety pharmacology studies, JNJ-64565111 did not inhibit human ether-a-go-go-
related gene (hERG) channel current in vitro even in 100-fold higher concentration (half 
maximal inhibitory concentration, IC50 >9.39 M) than a pharmacological active concentration. 
In conscious telemetered cynomolgus monkeys, the pulse rate, Rautaharju corrected QT interval 
(QTcR) and body temperature generally remained within vehicle range except for the night 
periods where increases compared with vehicle control were observed at 15, 40, and 
100 nmol/kg, but these changes remained within the high value limits of historical background 
data. Blood pressure values were generally lower than vehicle in the whole study period and may 
be consistent with the vasodilatory effects of GLP-agonists. In a subsequent cardiovascular 
safety pharmacology study in conscious telemetered cynomolgus monkeys given lower doses of 
1 and 5 nmol/kg, there was no effect on body temperature, electrocardiogram (ECG) intervals 
(PR, QRS, QT, and QTcR), or blood pressure at either dose, and a slight non-adverse decrease in 
pulse rate during the nocturnal periods for the 1 nmol/kg dose was not evident at 5 nmol/kg.
Overall, JNJ-64565111 was well tolerated across the battery of safety pharmacology studies.
Toxicology 
The safety of JNJ-64565111 was addressed in several studies, including single- and repeat-dose 
studies of up to 24 weeks in rats and 16 weeks in monkeys. All safety studies, pivotal repeat-
dose toxicity studies in rats and cynomolgus monkeys and genotoxicity studies were conducted 
in compliance with Good Laboratory Practices (GLP). 
In general, JNJ-64565111 exposure increased with dose with no substantive sex differences in rat 
and monkey. Anti-drug antibodies (ADA) were produced in monkey but not in rats. The ADA 
decreased the exposure of JNJ-64565111 in the 16-week monkey toxicity study. There were no 
toxicological findings that resulted from antigen-antibody complex. No test-item related 
injection site lesion was observed in either the rat or monkey studies.
In all studies, reduced body weight and food consumption were dose-limiting in rats and 
monkeys, with the most common clinical signs in rats being hunched position, abnormal gait,
and decreased activity.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
32
Approved, Date: 23 August 2018
Anemia characterized by decreased red blood cell count, hemoglobin, and hematocrit occurred in 
rats and monkeys, and these changes in red blood cell parameters were due to bone marrow 
damage consistent with malnutrition.
All organs changes observed in the rat 4-week toxicity study (0, 10, 30, and 60 nmol/kg/week) 
were attributed to effects caused by decreased food consumption, body weight loss and 
associated metabolic stress, not by a direct effect of JNJ-64565111. These included effects on 
liver, pancreas, intestine, bone and bone marrow, reproductive organs, and immune organs 
(thymus, etc.), and generally consisted of decreases in functional activity and organ size. The No 
Observed Adverse Effect Level (NOAEL) was 30 nmol/kg. At the NOAEL, Week 4 exposure in 
male and female rats corresponded to a maximum concentration (Cmax) of 274 and 321 nmol/L, 
and an area under the curve in the interval 0–168 hours (AUC168hr) of 34,558 and 
39,971 h.nmol/L, respectively.
JNJ-64565111 was generally well tolerated in monkeys during the 4-week toxicity study (0, 15, 
40, and 100 nmol/kg/week) with the predominant treatment-related effects (reduced food intake, 
body weight loss, and/or poor body weight gain) attributable to the pharmacological action of the 
test substance resulting in a number of secondary findings on the erythrocytic and clinical 
chemistry parameters, liver and pancreas. Increases in pulse rate and QTcR were considered to 
be within the historical background range for monkeys. Based on non-adverse but 
pharmacology-related changes up to high dose, the NOAEL in a 4-week toxicity study in 
monkeys was 100 nmol/kg. At the NOAEL, Week 4 exposure in male and female monkeys 
corresponded to a Cmax of 1,099 and 742 nmol/L, and AUC168hr of 100,151 and 64,142 h.nmol/L, 
respectively.
The findings attributed to secondary effects of decreased food consumption and body weight loss 
were more severe in rats than monkeys. The findings generally showed partial or complete 
recovery after a 2-week treatment-free period in both rats and monkeys. Monkeys presented only 
liver (increased or decreased glycogen content) and pancreatic changes (degranulation of acinar 
cells related to fasting effects, and increased cellularity). Increased pancreas cellularity has been 
observed for other GLP-1 agonists (eg, exenatide) and is considered a pharmacological effect.
No mutagenic effects were detected with JNJ-64565111 during in vitro and in vivo genotoxicity 
studies.
In conclusion, the majority of findings recorded in the toxicity studies in rat and monkey are 
considered to be secondary to decreased food consumption and the large body weight losses 
recorded, an expected pharmacological effect, and JNJ-64565111 was considered well tolerated.
1.1.2.
Clinical Studies with JNJ-64565111
Clinical experience with JNJ-64565111 includes a first in human study (ie, HM-OXM-101) and 
two 4-week multiple
ascending dose (MAD) studies (ie, 64565111EDI1001 and 
64565111EDI1002). 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
33
Approved, Date: 23 August 2018
The first in human study had a single ascending dose (SAD) part in healthy subjects (dose levels: 
0.25, 0.5, 1.0, 2.0, and 4.0 nmol/kg) and a MAD part in subjects with T2DM (dose levels: 0.5, 
1.0, 1.5, and 2.0 nmol/kg, administered once-weekly for 4 weeks).
The second MAD study, 64565111EDI1001, was conducted in subjects with T2DM and 
explored higher doses of JNJ-64565111 (2.5 and 3.0 nmol/kg). Results from this study showed 
non-dose-proportional PK data after repeated doses compared to data observed in the SAD 
portion of Study HM-OXM-101. Hence, an additional 4-week MAD study (64565111EDI1002) 
is being conducted to evaluate the full-dose range and PK profile. In this study, 4 groups of 
subjects with T2DM and treated with metformin have been dosed with 5.0, 10.0, 12.4, and 
15.0 mg of JNJ-64565111, (approximately equivalent to the body weight-based doses of 1.0, 2.0, 
2.5, and 3.0 nmol/kg, respectively, for a 90 kg individual, see Table 1) once-weekly for 4 weeks. 
Each group is to be composed of 8 subjects randomly assigned to JNJ-64565111 and 2 subjects 
randomly assigned to placebo. As of 01 February 2018, all subjects have completed treatment 
with study drug, but subjects in the 15 mg group are still in the post-treatment follow-up period. 
Since the study is still ongoing, the individual subjects’ level safety data remain blinded and the 
group level efficacy results from this study described below are to be considered preliminary.
Table 1:
Comparison of JNJ-64565111 Doses Used in Phase 1 Studies
Weight-based dose of 6456511 (nmol/kg)
0.5 
1.0
1.5
2.0
2.5
3.0
Fixed dose of 64565111 (mg)
2.5
5.0
7.4
10.0
12.4
15.0
Pharmacokinetics
In the first 2 Phase 1 studies, JNJ-64565111 was administered using weight-adjusted doses. PK 
analyses from these studies showed that following single subcutaneous (SC) administration, 
JNJ-64565111 is slowly absorbed with time to maximum concentration (Tmax) at approximately 
4 to 6 days post-administration. The terminal half-life (t1/2) of JNJ-64565111 is 7 to 8 days with 
an accumulation ratio of approximately 3 to 4 fold after repeated dosing. 
PK parameters in the ongoing Study 64565111EDI1002, where the full range of JNJ-64565111 
was studied using a fixed dose rather than weight-based dose showed that following the first 
dose of JNJ-64565111 of 5 to 15 mg, the mean (SD) JNJ-64565111 Cmax ranged from 
0.259 (0.072) to 0.744 (0.22) g/mL and the range for Tmax was 2 to 7 days post-dose.  
Following the last of the 4 weekly doses of JNJ-64565111 of 5 to 15 mg, the mean (±SD) 
JNJ-64565111 Cmax ranged from 0.565 (0.20) µg/mL to 2.14 (0.66) µg/mL and the range of Tmax 
was 0 to 6 days post-dose. 
The mean accumulation ratio calculated as the ratio of Week 4 AUCτ versus Week 1 AUC168h
was 2.33 to 4.01 for the 5 to 15 mg dose range, indicating moderate accumulation of 
JNJ-64565111 exposure upon multiple dosing that was commensurate with the dosing interval 
and t½ of JNJ-64565111 (t½ = 6 to 7 days in Study 64565111EDI1002). The mean 
JNJ-64565111 trough serum concentrations on Days 8, 15, 22, and 29 (Figure 1) indicate that 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
34
Approved, Date: 23 August 2018
JNJ-64565111 had not attained steady-state following 4 weekly doses. This is also 
commensurate with the observed t½ but >90% of steady-state was achieved by Week 4.
Figure 1:
Mean (SD) Serum Concentration-time Profiles Following Multiple SC Administration of 
JNJ-64565111 Weekly for 4 Doses in T2DM Subjects
a. Linear-Linear
b. Log-Linear
Legend
5.0 mg JNJ-64565111
10.0 mg JNJ-64565111
12.4 mg JNJ-64565111
15.0 mg JNJ-64565111
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
35
Approved, Date: 23 August 2018
Mean Week 1 and Week 4 Cmax and AUC of JNJ-64565111, shown in Table 2, after the first and 
fourth dose increased for 5, 10, and 15 mg doses. However, the exposure from the 12.4 mg dose 
showed deviation from this behavior. The reason for the complex PK characteristics after 
administration of 12.4 mg dose in Study 64565111EDI1002 is currently not understood. 
Table 2:
Mean (Range) Cmax and AUC of JNJ-64565111 on Weeks 1 and 4 (Study 645651111EDI1002) 
Mean (Range)
Cohort 1 (5 mg)
Cohort 2 (10 mg)
Cohort 3 (12.4 mg)
Cohort 4 (15 mg)
Cmax (µg/mL)
Week 1
0.259
(0.155 – 0.373)
0.613
(0.367 – 0.920)
0.363
(0.233 – 0.579)
0.744
(0.321 – 1.01)
Week 4
0.565
(0.387 – 0.869)
1.23
(0.774 – 2.38)
1.09
(0.794 – 1.39)
2.14
(1.22 – 2.76)
AUC (µg·h/mL)
Week 1
34.4
(19.0 – 48.6)
81.8
(49.2 – 121)
46.7
(25.4 – 77.7)
93.6
(36.4 – 136)
Week 4
79.2
(48.0 – 121)
182
(112 – 352)
160
(128 – 192)
307
(174 – 388)
AUC= area under the curve; Cmax= maximum concentration.
Safety and Tolerability
Based on the completed and ongoing Phase 1 studies, treatment with JNJ-64565111 appears to 
be generally well tolerated. As with other GLP-1R agonists, the majority of the AEs were related 
to the GI system, with nausea, vomiting, abdominal distension, dyspepsia, and diarrhea being 
reported as the most common AEs. Of the non-GI AEs, the most common were decreased 
appetite and fatigue. No documented event of hypoglycemia has been reported. While there 
appeared to be a trend in dose-dependent increase in the incidence of AEs, most were mild in 
intensity. In general, no treatment-related or clinically relevant trends were observed for the 
hematology, coagulation, and biochemistry parameters, as well as for serum calcitonin, amylase 
and lipase values, and for the urinalysis parameters across dose groups. There were no clinically 
relevant changes in ECG parameters. None of the subjects in the completed Phase 1 studies that 
were treated with JNJ-64565111 experienced a SAE or discontinued due to AEs. 
In the ongoing Study 64565111EDI1002, 2 SAEs occurred in the 10 mg/placebo group. 
Specifically, 1 subject who had low plasma sodium levels at baseline (132 mmol/L 
[132 mEq/L]), had a SAE of hyponatremia, (sodium levels of 114 mmol/L [114 mEq/L]), 
associated with mild hypokalemia and dehydration following protracted nausea, vomiting, and 
diarrhea, and which was treated with saline. The SAE occurred 4 days after the last dose of study 
drug and was considered to be related to study drug by the investigator. Laboratory and imaging 
workup for inappropriate antidiuretic hormone secretion (including brain on magnetic resonance 
imaging [MRI] and chest computed tomography [CT] scan to evaluate for central nervous 
system or pulmonary etiologies, respectively) were negative. The second SAE was influenza 
pneumonia that occurred 49 days after the last dose of study drug and was considered not related 
to study drug by the investigator. In addition, 3 subjects were withdrawn from the study due to 
AEs: 2 from Group 3 (12.4 mg/placebo) and 1 from Group 4 (15 mg/placebo). One subject in the 
12.4 mg/placebo group had an AE of chest pain and ECG changes suggestive of ischemia on 
Day 8, after the first study drug dose. This event was considered not related to study drug by the 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
36
Approved, Date: 23 August 2018
reporting investigator. Another subject in the 12.4 mg/placebo group withdrew consent on 
Day 22 (after receiving 3 doses of study drug) due to an AE of nausea. This event was 
considered related to study drug by the reporting investigator. There was no clinical, laboratory,
or imaging evidence for pancreatitis or hepatobiliary pathology. In the 15 mg/placebo group, 
1 subject discontinued on Day 22 (after receiving 3 doses) due to elevation in FPG (up to 
24.42 mmol/L [440 mg/dL]) and hyponatremia and mild hypokalemia. The subject was treated 
with the addition of a sulfonylurea that rapidly improved FPG levels, with subsequent 
improvement in serum sodium. Both AEs were considered to be drug related by the 
investigators. 
Pulse rate and blood pressure were assessed in all studies by use of ambulatory blood pressure 
monitoring (ABPM). In general, there was a consistent trend of increase in pulse rate and 
decrease in SBP and DBP across studies. In Study HM-OXM-101, following repeated doses, 
there was an increase in pulse rate after the 1.5 and 2 nmol/kg doses (LS means differences 
relative to placebo of 5.6 beats per minute [bpm] and 7.7 bpm, respectively). At the dose of 
2 nmol/kg, SBP decreased by -7.8 mmHg (LS means differences relative to placebo). There was 
no consistent trend in changes in DBP. 
In Study 64565111EDI1001, mean increases in pulse rate of 6.6 and 15.3 bpm were observed in 
the 2.5 and 3 nmol/kg groups, respectively, compared to a 1.3 bpm increase on placebo. Both 
SBP and DBP decreased by a mean of 11.8 and 4.2 mmHg, respectively, in the 2.5 nmol/kg 
group but remained unchanged in the 3 nmol/kg group and increased by 7.3 and 4.7 mmHg on 
placebo. A similar trend has been observed in the ongoing Study 64565111EDI1002 but 
individual treatment assignment is still blinded. 
Efficacy
Body weight change
After 4 weeks of treatment in Study HM-OXM-101, a reduction in mean body weight was 
observed in all JNJ-64565111 groups while no changes in body weight were seen in subjects in 
the placebo group. Percentages of body weight loss were -1.3, -3.0, -4.1, and -3.9% in the 0.5, 
1.0, 1.5, and 2.0 nmol/kg, respectively. In Study 64565111EDI1001, the 2.5 nmol/kg and 
3.0 nmol/kg groups showed a mean body weight loss of -6.2% and -5.3%, respectively, relative 
to baseline compared to a mean weight loss of -1.4% in the placebo group. Weight loss was also 
observed in Study 64565111EDI1002, with decrease of approximately -4% in the 5, 10, and 
12.4 mg group and approximately -6% in the 15 mg group compared to a decrease of 
approximately 1% in the placebo group.
Glycemic parameters 
In Study HM-OXM-101, after 4 weeks of treatment, change in mean FPG from baseline 
of -1.62 mmol/L (-29.2 mg/dL), -0.64 mmol/L (-11.5 mg/dL), -2.21 mmol/L (-39.8 mg/dL),
and -0.29 mmol/L (-5.2 mg/dL) were observed in the 0.5, 1.0, 1.5 nmol/kg, and placebo groups,
respectively, 
compared 
to 
virtually 
no 
change 
in 
the 
2.0 
nmol/kg 
group. 
In 
Study 64565111EDI1001, the mean changes from baseline in FPG were 0.30 (5.4 mg/dL) 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
37
Approved, Date: 23 August 2018
and -0.48 mmol/L (-8.7 mg/dL) in the 2.5 and 3.0 nmol/kg group, respectively, and -0.71 
(-12.8 mg/dL) in placebo. In the ongoing Study 64565111EDI1002, in which the mean baseline 
HbA1c was higher compared to the previous Phase 1 studies, hence resulting in a greater glucose 
variability, the mean changes in FPG were approximately -0.83 mmol/L (-15 mg/dL), 
1.05 mmol/L (19 mg/dL), -0.67 mmol/L (-12 mg/dL), and 0.28 mmol/L (5 mg/dL) in the 5, 10, 
12.4, and 15 mg groups, respectively, and -1.83 mmol/L (-33 mg/dL) in the placebo group. The 
median changes in FPG were approximately -1.22 mmol/L (-22 mg/dL), 0.56 mmol/L 
(10 mg/dL), -0.39 mmol/L (-7 mg/dL), -0.78 mmol/L (-14 mg/dL), and -2.0 mmol/L (-36 mg/dL)
in the 5, 10, 12.4, 15 mg, and placebo groups, respectively.
After 4 weeks of treatment, mean HbA1c values decreased from baseline in all groups in Study
HM-OXM-101. Mean HbA1c decreases from baseline were -0.19, -0.28, -0.73, -0.22,
and -0.06 for the 0.5, 1.0, 1.5, and 2.0 nmol/kg groups and placebo, respectively. In 
Study 64565111EDI1001, mean HbA1c decreases from baseline were -0.1% and -0.23% in the 
2.5 nmol/kg and 3.0 nmol/kg groups, respectively, compared to an increase of 0.01% in the 
placebo group. In the ongoing Study 64565111EDI1002, HbA1c reduction ranging from 
approximately -0.3 to -0.5% were observed in the 5 mg, 10 mg, 12.4 mg, and placebo group 
compared to an increase of approximately 0.3% in the 15 mg group.
Changes in fasting lipids
Across studies, 4 weeks of treatment with JNJ-64565111 was associated with decreases in mean 
values for total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides. The 
decreasing trend in these parameters was generally not observed in the placebo subjects. 
Compared to Study HM-OXM-101 where small decreases in high-density lipoprotein cholesterol 
(HDL-C) were observed in subject treated with JNJ-64565111, in Study 64565111EDI1001 and 
Study 64565111EDI1002, small decreases were observed with no apparent dose-dependency, 
ranging from -0.03 to -0.35 mmol/L (-1.2 to -13.7 mg/dL).
1.1.3.
Ketogenesis with JNJ-64565111
An increase in ketones is a normal physiologic response to fasting, prolonged exercise, and 
certain dietary weight-loss regimens (eg, low carbohydrate-high fat diets) in which fatty acids are 
transformed in the liver into the ketones, aceto-acetate, and β-hydroxybutyrate. Physiologically, 
these ketones are used by the brain and muscles, including the heart, as an alternative fuel source
when glucose is not readily available (Laffel 1999). The production of free fatty acids and their 
conversion to ketone bodies is stimulated by glucagon and inhibited by insulin. In the presence 
of near-normal or normal insulin function, such as in subjects without diabetes enrolled in this 
study, the rate of hepatic ketone formation is balanced by the rate of the body’s ketones 
utilization and, to a certain degree, ketones loss into the urine. Importantly, in obese non-diabetic 
subjects who follow ketogenic diets, ketonemia without acidemia is commonly observed
(Gomez-Arbelaez 2107).
As noted in Section 1.1.2, Clinical Studies with JNJ-64565111, treatment with JNJ-64565111 is 
associated with a percent reduction in body weight of up to approximately 6% from baseline (in 
part, related to reduced caloric intake) and mechanistically is an agonist for both GLP-1 and 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
38
Approved, Date: 23 August 2018
GCGR. Therefore, as anticipated, a 2- to 3-fold increase in the serum levels of the ketone,
β-hydroxybutyrate, relative to placebo was seen in the Phase 1 Studies 64565111EDI1001 and 
64565111EDI1002 in which 50 subjects with T2DM (on either diet/exercise alone or on 
metformin monotherapy) were treated for 4 weeks with the addition of JNJ-64565111. 
Importantly, in these 2 studies conducted in subjects with T2DM, no AEs of ketoacidosis or 
metabolic acidosis were reported. In the current study of subjects without T2DM, serum 
-hydroxybutyrate will be assessed as a marker of target engagement. To avoid the potential 
unblinding of subject to treatment assignment, both serum β-hydroxybutyrate and urinary 
ketones will remain masked to investigators and sponsor.
1.2.
Comparator Drug – Liraglutide (Saxenda®)
Liraglutide is an acylated GLP-1 analogue that shares 97% amino acid sequence homology to 
human endogenous GLP-1 (7–37) (Saxenda USPI). The single amino acid substitution of lysine 
with arginine at position 34 and the attachment of a C16 fatty acid chain to lysine at position 26 
enables liraglutide to self-associate and form a heptameric structure, which delays absorption 
from the SC injection site and provides protection against degradation by dipeptidyl peptidase 
(DPP)-IV enzyme and neutral endopeptidases. As a consequence, liraglutide has a much longer 
half-life than endogenous GLP-1 (~13 hr versus 1.5 to 2 min). Liraglutide binds to and activates 
the GLP-1R, in pancreatic beta cells (but not in pancreatic alpha cells) and is the target for 
endogenous GLP-1. This results in dose-dependent insulin release in patients with elevated 
glucose levels. At the same time, liraglutide acts in a glucose-dependent manner to decrease 
inappropriately high glucagon secretion, thereby blocking the effects of glucagon on hepatic 
glucose output. In addition to these glucoregulatory mechanisms of action in patients with 
T2DM, liraglutide slightly delays gastric emptying, and reduces body weight and body fat mass 
by reducing hunger and lowering energy intake.
The efficacy of once-daily SC liraglutide (titrated to 3.0 mg daily during a 4-week period), in 
conjunction with reduced caloric intake and increased physical activity in obese 
(BMI 30.0 kg/m2) or overweight (BMI 27 to 29.9 kg/m2 and at least 1 weight-related comorbid 
condition such as treated or untreated dyslipidemia or hypertension) patients is well established, 
based on 3 large, multicenter, Phase 3 trials. Subcutaneous liraglutide (Saxenda®) 3.0 mg is 
approved in the US, Canada, European Union (EU), and other countries. It is indicated as an 
adjunct to a reduced-calorie diet and increased physical activity for chronic weight management 
in adult patients with an initial BMI of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater 
(overweight) in the presence of at least 1 weight-related comorbid condition (eg, hypertension, 
T2DM, or dyslipidemia) (Saxenda USPI).
Liraglutide is administered SC once daily at any time of the day, without regard to the timing of 
meals. The initial starting dosage is 0.6 mg/day for 1 week; this low initial dosage is intended to 
reduce the risk of GI AEs. After 1 week, the dosage of liraglutide should be increased by 0.6 mg 
weekly until 3.0 mg/day dose is reached.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
39
Approved, Date: 23 August 2018
Liraglutide is generally well tolerated in non-diabetic obese and overweight subjects. In clinical 
trials, the most common adverse reactions, reported in 10% of obese and overweight patients 
treated with liraglutide 3.0 mg and more commonly than in patients treated with placebo, are: 
headache, nausea, diarrhea, constipation, vomiting, headache, decreased appetite, and dyspepsia.
Liraglutide is contraindicated in patients with a personal or family history of medullary thyroid 
carcinoma (MTC) and in patients with in patients with Multiple Endocrine Neoplasia syndrome 
type 2 (MEN 2). Liraglutide is also contraindicated in patients with a history of a serious 
hypersensitivity reaction to liraglutide, such as anaphylaxis or angioedema, and in pregnancy. 
Local labels for liraglutide vary with regard to restrictions/contraindications, and therefore 
subjects with contraindications to the use of liraglutide based upon the local label of the 
investigational site will not be eligible to participate in the study.
For further information regarding liraglutide refer to the locally approved label (Saxenda USPI).
1.3.
Overall Rationale of the Study
JNJ-64565111 has been studied in SAD and MAD studies in subjects with and without T2DM 
for up to a 4-week period. JNJ-64565111 was generally well tolerated and no safety signals 
precluding further development were seen. This Phase 2b dose-ranging study is being conducted 
to assess the safety and efficacy of JNJ-64565111 over a 26-week treatment phase in non-
diabetic severely obese subjects and to provide information to select JNJ-64565111 dose(s) to be 
assessed in Phase 3 studies.
2.
OBJECTIVES AND HYPOTHESES
2.1.
Objectives
Primary Objectives
In non-diabetic severely obese subjects, to assess the effects of JNJ-64565111 compared with 
placebo after 26 weeks of treatment on:

the percentage change in body weight from baseline

safety and tolerability
Secondary Objectives
In non-diabetic severely obese subjects, to assess the effects of JNJ-64565111 compared with 
placebo after 26 weeks of treatment on:

the proportion of subjects with 5% weight loss from baseline

the proportion of subjects with 10% weight loss from baseline

the absolute change in body weight from baseline
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
40
Approved, Date: 23 August 2018
Exploratory Objectives
In non-diabetic severely obese subjects, to assess the effects of JNJ-64565111 compared with 
placebo after 26 weeks of treatment on:

the change in BMI from baseline

the change in waist circumference from baseline 

the change in fasting lipids (total cholesterol, LDL-C, HDL-C, and triglycerides) from 
baseline

the change in FPG from baseline

the change in fasting insulin from baseline 

the change in fasting C-peptide from baseline

the changes in Homeostasis Model Assessment for B cell function (HOMA-B) and HOMA-
insulin resistance (IR) from baseline

the change in SBP from baseline

the change in DBP from baseline

the change in pulse rate from baseline

the change in pulse-pressure product from baseline

in a subset of subjects participating in the 24-hour ABPM assessment, the changes from 
baseline in 24-hour SBP, DBP, pulse rate, and pulse-pressure product 

PK exposure

the change from baseline in scores on the Impact of Weight on Quality of Life-Lite
(IWQOL-Lite) (Kolotkin 2001; Kolotkin 2002), single item Ease of Weight Management, 
and Patient Activation Measure (PAM) (Hibbard 2005)

in English-speaking subjects in selected countries only, the change from baseline in scores 
on the eating-related concept question (ERCQ) and the PROMIS physical function short 
form 8b (PROMIS SF 8b) (Note: the Patient Global Impression Status [PGIS] and Patient
Global Impression of Change [PGIC] will be used to calculate responder definitions for the 
new instruments only and are not exploratory objectives.)

in English-speaking subjects in selected countries only, describe pre-trial goals and 
expectations as well as post-trial experiences qualitatively using the Anticipations of 
Clinical Trial Treatment (ACTT) Pre-trial interviews and a modified Safety, Tolerability, 
and Efficacy Preview (STEP) exit interview  
In non-diabetic severely obese subjects, to assess the effects of JNJ-64565111 compared with 
liraglutide after 26 weeks of treatment on:

the absolute change and percentage change in body weight from baseline

the proportion of subjects with 5% weight loss from baseline

the proportion of subjects with 10% weight loss from baseline 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
41
Approved, Date: 23 August 2018
2.2.
Hypotheses
In non-diabetic severely obese subjects, treatment for 26 weeks with JNJ-64565111 compared 
with placebo leads to a greater:
Primary: 

percentage reduction in body weight from baseline
Secondary: 

proportion of subjects with 5% weight loss from baseline

proportion of subjects with 10% weight loss from baseline

absolute reduction in body weight from baseline
3.
STUDY DESIGN AND RATIONALE
3.1.
Overview of Study Design
This is a randomized, double-blind, placebo-controlled and open-label active-controlled, 
parallel-group, 5-arm, multicenter study. Non-diabetic, severely obese subjects who are 18 and 
70 years of age and have a BMI 35 to 50 kg/m2 will be assessed.
Subjects meeting all eligibility criteria will enter a 2-week run-in phase, which is to occur 
approximately 1 week after the screening visit and is designed to train the subject on SC 
self-injection and to establish the subject’s ability to comply with the protocol-specified 
requirements. On Day 1, approximately 440 subjects who continue to meet eligibility criteria 
will be randomly assigned in a 1:1:2:2:2 ratio to blinded treatment with placebo, JNJ-64565111 
(5.0, 7.4, or 10.0 mg) or open-label liraglutide, stratified by ABPM sub-study participation (yes 
or no), and then will enter a 26-week treatment phase. To maintain blinding, subjects randomly 
assigned to placebo will be subsequently randomly assigned in a 1:2:2 ratio to a placebo that 
matches the injection volume of the 5.0, 7.4, and 10.0 mg JNJ-64565111 doses (ie, 11, 22, and 
22 subjects, respectively). Post-randomization visits will be conducted at Weeks 5, 10, 15, 20, 
26/end-of-treatment (EOT) visit and 4-week SAE follow-up after Week 26/EOT visit. A subset
of subjects in the ABPM sub-study will have 2 additional visits (ie, Pre-Day 1 and Pre-Week 26). 
A subset of subjects will have 1 additional visit (Day 4 1 day sampling window) to collect a
non-trough PK sample. All subjects will be contacted preferably by telephone to reinforce the 
adherence to diet and exercise, study drug dosing reminder, assessment of subjects’ status, and 
compliance with the protocol procedures (eg, diary completion reminder) at Week 2. Study-site 
staff is encouraged to contact subjects (preferably by telephone) to do the same at some time in 
between Week 5, 10, 15, 20, and 26 visits. Subjects in the open-label liraglutide treatment group 
will also be contacted preferably by telephone at Weeks 1, 3, and 4 to remind about the dosing 
titration (ie, to increase their dose of liraglutide by an 0.6 mg dose increment weekly).
During the pre-treatment/run-in and treatment phases, subjects will undergo efficacy and safety 
assessments including physical examination, ECG, laboratory testing,
and vital signs 
measurement. A serum pregnancy test will be performed at screening and Week 26/EOT in 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
42
Approved, Date: 23 August 2018
women of childbearing potential. In a subset of subjects, a 24-hour ABPM (approximately 
120 subjects total) will be performed.
Counseling should be done by dietitians/nutritionists on Day 1/Day of Randomization to provide 
assessment and recommendation on a reduced-calorie diet and exercise regimen (see 
Attachment 4). At subsequent visits (Week 5, Week 10, Week 15, and Week 20), counseling and 
reinforcement of the recommended diet and exercise regimen will be conducted by a trained 
counselor. At each treatment visit, the investigator or qualified, assigned designee will review the 
subject’s diaries, concomitant medications, and the AEs that started or changed since the last 
visit.
The efficacy evaluation will include the percentage change in body weight from baseline as the 
primary efficacy endpoint.
Safety evaluations will include the monitoring of AEs (including protocol-specified AEs of 
interest), vital sign measurements, clinical laboratory tests (including calcitonin, lipase, amylase,
alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin), urinalysis, 
review of concomitant medications, and serum pregnancy testing. Refer to Section 9.10, Safety 
Evaluations, for further details.
Subjects who prematurely discontinue study drug will require an immediate EOT assessment 
(either on the day of study drug discontinuation or as soon as possible following study drug 
discontinuation) and the 4-week SAE follow-up. Subjects that discontinue study drug early will 
continue in the study and be assessed with the off-treatment procedures at the subsequent visit(s) 
per the Time and Events visit schedule, starting at the next scheduled visit from when study drug 
was permanently discontinued up to the final Week 26 visit. These off-treatment visits will 
include collection of SAEs, specific AEs of interest (ie, major adverse cardiovascular events 
[MACE] events, acute pancreatitis, and possible cases of thyroid neoplasm), vital signs
(including body weight), and concomitant medications (see Section 9.4.5, End-of-
Treatment/Early Study Drug Discontinuation). Subjects who discontinued prior to Week 26 and 
have the 4-week SAE follow-up visit after last study drug dose, do not need to return for a 
second 4-week SAE follow-up visit. All subjects (except those who died, were lost to follow-up, 
or have a withdrawn consent) will have a follow-up visit approximately 5 weeks after the last 
dose of study drug for JNJ-64565111-treated or placebo-treated subjects and 4 weeks after the 
last dose of study drug for liraglutide-treated subjects to collect any SAEs. For subjects randomly 
assigned to JNJ-64565111 or placebo, blood samples for immunogenicity ADA and PK 
assessments will also be obtained at this SAE follow-up visit.
A 24-hour ABPM assessment will be performed at selected sites and will involve approximately 
120 subjects (approximately 15 subjects each in the placebo and JNJ-64565111 5 mg groups, and 
30 subjects each in the JNJ-64565111 7.4 mg, JNJ-64565111 10 mg, and liraglutide groups). 
During the run-in phase, these subjects will wear the ABPM device for at least 22 hours 1 or 
2 days prior to the Day1/Randomization visit. The ABPM readings will be masked. When 
subjects return for the Day 1 visit, ABPM readings will be assessed for subjects’ eligibility into
the ABPM sub-study based on the ABPM requirements (see Section 4.1, Inclusion Criteria, for 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
43
Approved, Date: 23 August 2018
further details). After randomization, subjects participating in the ABPM assessment will be 
required to repeat a 24-hour ABPM assessment 1 or 2 days prior to the Week 26/ EOT in 
subjects who have not withdrawn consent or died. For subjects treated with JNJ-64565111 or 
matching placebo, every effort should be made to have the procedure performed within 7 days 
from the previous dose of study drug.
The IWQOL-Lite, Ease of Weight Management, and PAM will be administered at all sites to all 
subjects. The PROMIS SF 8b and ERCQ along with both the PGIS and PGIC will be 
administered at selected sites and will involve approximately 120 English-speaking subjects. 
These instruments are intended to measure eating-related concepts such as hunger, appetite, 
cravings, and satiety, and physical function.
Subjects who withdraw from the study will not be replaced.
An interim analysis will be performed when approximately 90% of subjects have either
completed or discontinued prior to approximately 10 weeks of study drug treatment. The 
objective of this interim analysis is to identify active treatment groups, if any, associated with 
safety or tolerability issues and to facilitate planning of the Phase 3 program. The dissemination 
of the interim analysis results will be limited to an internal data monitoring committee (DMC), 
and will not be shared with investigators, subjects, or the sponsor staff who will continue to be 
involved in the conduct of the study before the final database lock. The operational details of the 
interim analysis will be provided in the DMC Statistical Analysis Plan (SAP) (see Section 11.7, 
Interim Analysis).
The overall study duration is approximately 33 weeks and comprises of 3 phases:

Pre-treatment phase

Screening phase: 1 week

Run-in (injection-training) phase: 2 weeks

Treatment phase (double-blind and open-label arms)

Placebo- and active-controlled treatment phase: 26 weeks

Post-treatment phase (SAE follow-up visit): 4 weeks
Approximately 440 subjects will be randomly assigned in a 1:1:2:2:2 ratio to one of the 
following once-weekly SC treatments:

55 subjects to double-blind placebo matching JNJ-64565111

55 subjects to double-blind JNJ-64565111 5.0 mg

110 subjects to double-blind JNJ-64565111 7.4 mg

110 subjects to double-blind JNJ-64565111 10.0 mg

110 subjects to open-label liraglutide 3.0 mg
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
44
Approved, Date: 23 August 2018
A diagram of the study design is provided in Figure 2.
Figure 2:
Schematic Overview of the Study
3.2.
Study Design Rationale
The study was designed in general accordance with the US Food and Drug Administration 
(FDA) and European Medicines Agency (EMA) guidance on the development of medications 
and clinical investigations for the treatment of obesity (FDA 2009; Guidance for Industry 
Developing Products for Weight Management 2007; Guideline on Clinical Investigation of 
Medicinal Products Used in Weight Management 2016).
Blinding, Study Phases, Treatment Groups
Randomization will be used to minimize bias in the assignment of subjects to treatment groups, 
to increase the likelihood that known and unknown subject attributes (eg, demographic and 
baseline characteristics) are evenly balanced across treatment groups, and to enhance the validity 
of statistical comparisons across treatment groups. Blinded treatment will be used in the 
JNJ-64565111 and placebo treatment arms to reduce potential bias during data collection and 
evaluation of clinical endpoints. Due to the use of commercially available liraglutide, which is 
provided as pre-filled auto-injector pens and must be injected daily, it is not practical to 
double-blind the liraglutide treatment arm.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
45
Approved, Date: 23 August 2018
The 1-week screening phase will allow time prior to the beginning of the injection-training phase 
to obtain laboratory results that are needed to determine the subject’s eligibility for the study. 
Subjects enrolled in this study will likely have no prior experience with self-injection of 
medication. Therefore, a 2-week SC injection-training phase will include training of subjects by 
the study staff on the use of the pre-filled safety injectors for self-injection. Study staff will also 
evaluate the subject’s ability and willingness to self-inject prior to being randomized. The 
duration of the treatment phase in this study is 26 weeks, which should be sufficient to capture 
the maximal or near-maximal weight loss effects of the active doses. The 4-week SAE follow-up 
visit is designed to assess safety by collecting data on SAEs or resolution of ongoing SAEs that 
occurred since the last study visit.
Study Population
The randomized study population consists of non-diabetic severely obese subjects, ages 18 to 
70 years, inclusive, at screening who have a BMI 35 kg/m2 to 50 kg/m2. Men and women will 
be enrolled in this study. In this study the definition of “severe” obesity, which is commonly 
used within the surgical community to refer to subjects who are eligible for bariatric surgery, is 
inclusive of the WHO definition of Obese Class II (35-39 kg/m2) and III (40 kg/m2)
(WHO 2017).
Dose Selection and Dose Interval of JNJ-64565111
The t ½ of 6 to 8 days allows for a weekly dosing frequency for JNJ-64565111. While in earlier 
Phase 1 studies, JNJ-64565111 was administered using weight-based doses, fixed doses of 
JNJ-64565111 were tested in Study 64565111EDI1002. As such, the dosing regimen is more 
practical and is likely to be associated with greater adherence. Fixed weekly doses of 5 and 
10 mg of JNJ-64565111 in the Phase 1 Study 64565111EDI1002 showed similar exposures 
compared with doses of 1.0 and 2.0 nmol/kg/week observed in the previous Phase 1 MAD study. 
Moreover, fixed dosing resulted in overall similar variability in exposure compared with body 
weight-based dosing for equivalent doses of 5 and 10 mg of JNJ-64565111. In 4-week studies in 
overweight and obese subjects with T2DM, doses of JNJ-64565111 in this dose range resulted in 
approximately 2 to 4% reduction in body weight. As this duration of treatment is too short to
observe the full weight-loss potential of any pharmacological intervention, this study is being 
conducted with the doses specified for 26 weeks of treatment. Twenty-six weeks is generally 
sufficient to capture the maximal or near-maximal weight loss in a Phase 2 trial. The lower dose 
of 5 mg was chosen since it is expected to be a minimally efficacious dose. The upper end of the 
dose range was selected because drug exposures are highly variable beyond doses of 10 mg 
weekly (Study 64565111EDI1002) and because doses above 10 mg, while leading to greater 
weight loss, also appeared to be less tolerated as indicated by a dose-dependent increase in the 
incidence in GI AEs as well as increase in mean pulse rate. As the assessment of more than 
2 active doses is desirable to evaluate a dose-response relationship for JNJ-64565111 an 
intermediate dose of 7.4 mg was incorporated into the current study.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
46
Approved, Date: 23 August 2018
Choice of Efficacy Measures
The primary efficacy endpoint will be a comparison of percentage change in body weight
between the JNJ-64565111-treated and placebo-treated groups. This is an accepted endpoint for 
clinical trials of weight-management products (FDA 2009). Secondary endpoints will include the 
proportion of subjects in each treatment group who lose 5% and 10% of baseline body weight
and the mean absolute change in body weight, both of which are also accepted endpoints in 
weight-management studies.
Change from baseline in SBP, DBP, pulse rate, pulse-pressure product, and fasting lipid levels 
will be evaluated to assess the effects of JNJ-64565111 on the common weight-related 
comorbidities of hypertension and dyslipidemia. Additional exploratory measures of efficacy 
(ie, change from baseline in BMI; waist circumference; FPG, fasting insulin, and fasting 
C-peptide; serum β-hydroxybutyrate; IWQOL-Lite, single item Generic Rating of Health, single 
item Ease of Weight Management, PAM, and in English-speaking subjects in selected countries 
only, ERCQ, PROMIS SF 8b, a ACTT pre-trial interview, and a modified STEP exit interview) 
will be evaluated to identify additional treatment effects of JNJ-64565111.
Rationale for Use of Placebo Control
A placebo control will be used to establish the frequency and magnitude of changes in clinical 
endpoints that may occur in the absence of active treatment, improving the precision of the 
assessments of both efficacy and safety. A study without a placebo arm cannot properly 
determine the weight-reducing efficacy of a weight-management product, given the impact of 
co-interventions (eg, diet and exercise counseling). Similarly, given background occurrence of 
AEs in this population in which comorbidities are common, without a placebo treatment group, it 
is not possible to precisely define the safety and tolerability profile of a new weight-management 
product.
Rationale for Open-label Reference Arm
Liraglutide is a GLP-1 receptor agonist indicated as an adjunct to a reduced-calorie diet and 
increased physical activity for chronic weight management in adult patients with an initial BMI 
of 30 kg/m2 or 27 kg/m2 in the presence of at least one weight-related comorbid condition 
(eg, hypertension, T2DM, or dyslipidemia), as indicated in the product labeling. In a Phase 3 
clinical study of 56 weeks duration with 3.0 mg liraglutide conducted in obese and overweight 
subjects the mean change in body weight was -4.5% (95% confidence interval [CI]: -3.8 
to -5.2%) relative to placebo control. Given the partially common mechanism of action, a direct 
comparison between liraglutide and JNJ-64565111 will facilitate the interpretation of efficacy 
findings and of possible differences in efficacy measures observed between the 2 drugs. 
Importantly, the use of liraglutide will provide an essential reference arm for the assessment of 
the safety and tolerability profile of JNJ-64565111, as it is expected that both agents are 
associated with an increased incidence of GI AEs. Further, the same administration route SC
reduces the possible confounding effect of treatment compliance that would exist if the 
comparator was an oral agent.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
47
Approved, Date: 23 August 2018
Choice of Patient-reported Outcome (PRO) Measures and Subject Interviews 
Evaluation of health status and treatment experience from the subject’s perspective is 
increasingly important in the evaluation of new treatments. Several PRO instruments have been 
selected to measure these concepts of importance (ie, IWQOL-Lite, Ease of Weight 
Management, PAM). In English-speaking subjects in selected countries only, PRO instruments 
will also be administered to measure eating-related concepts of hunger, appetite, cravings, 
satiety, and physical function (ie, PROMIS SF 8b, ERCQ, PGIS, and PGIC). Also, in a subset of 
subjects, interviews will be conducted to describe qualitatively pre-trial goals and expectations as 
well as post-trial experiences. The ACTT pre-trial interview and a modified STEP exit interview 
will be used (see Section 9.7.3, Patient-reported Outcomes for a full description of the objectives 
of the PRO measures). The exploratory endpoints from this subset of subjects may be used to 
support outcomes/benefits from a subject’s perspective.
Interim Analysis
An interim analysis will be performed when approximately 90% of subjects have either 
completed or discontinued prior to 10 weeks of study drug treatment. The objective of this 
interim analysis is to identify active treatment groups, if any, associated with safety or 
tolerability issues and to facilitate planning of the Phase 3 program. The dissemination of the 
interim analysis results will be limited to an internal DMC, and will not be shared with 
investigators, subjects, or the sponsor staff who are involved in the conduct of the study before 
the final database lock. The operational details of the interim analysis will be provided in the 
charter of the interim analysis committee.
Collection of Additional Information for Selected Adverse Events
For selected AEs of interest, investigators will be asked to provide additional information which 
may include the use of subjects’ source documentation or supplementary electronic case report 
forms (eCRFs) to support more detailed analyses. These events include hypotension-related AEs, 
calcitonin elevation, acute pancreatitis, and thyroid neoplasm. 
Pharmacokinetic Samples
Pharmacokinetics will be evaluated to explore exposure-response relationships, and to develop a 
population PK model. All PK data from subjects in this study will be combined with data from 
other clinical studies of JNJ-64565111 for a pooled population PK analysis to develop a 
structural PK model of JNJ-64565111, and to evaluate the dependence of the PK of 
JNJ-64565111 on population covariates.
Archive Samples for Exploratory Research
Numerous bio-markers have been studied as potentially important surrogate measures of 
cardiovascular and overall health of subjects (Ridker 2004). Plasma, serum, and urine archive 
samples will be collected (where local regulations permit) to allow for the analysis of important 
bio-markers (not prespecified) that could help to further explain and examine the efficacy and 
safety findings in this study.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
48
Approved, Date: 23 August 2018
4.
SUBJECT POPULATION
The inclusion and exclusion criteria for enrolling subjects in this study are described in the 
following 2 subsections. If there is a question about the inclusion or exclusion criteria below, the 
investigator must consult with the appropriate sponsor representative and resolve any issues 
before enrolling a subject in the study. Protocol inclusion/exclusion waivers are not permitted.
4.1.
Inclusion Criteria
Each potential subject must satisfy all of the following criteria to be enrolled in the study:
1.
Subjects must have signed an informed consent form (ICF) indicating that they understand 
the purpose of and procedures required for the study and are willing to participate in the 
study.
2.
Male or female, 18 to 70 years of age, inclusive
3.
BMI 35 to 50 kg/m2 at the screening visit
4.
Stable weight (ie, change of 5% within 12 weeks before screening based on medical 
history)
5.
Subjects are, in the investigator’s opinion, well-motivated, capable, and willing to learn 
how to self-inject treatment, as required for this study
6.
On Day 1, subjects must have 100% compliance with the open-label placebo run-in 
medication based on 1 of the following: 
returned empty study drug cartons
injections recorded in study drug diary
7.
Women must be either:

postmenopausal, defined as:

>45 years of age with amenorrhea for at least 18 months, or

>45 years of age with amenorrhea for at least 6 months and <18 months and a 
serum follicle-stimulating hormone (FSH) level >40 mIU/mL (>40 IU/L), or

permanently sterilized (eg, bilateral tubal occlusion [which includes tubal ligation 
procedures as consistent with local regulations], hysterectomy, bilateral salpingectomy, 
bilateral oophorectomy); or otherwise be incapable of pregnancy, or

heterosexually active and practicing a highly effective method of birth control (failure 
rate of <1% per year when used consistently and correctly), including combined 
(estrogen-
and progestogen-containing) hormonal contraception associated with 
inhibition of ovulation: oral, intravaginal, and transdermal; progestogen-only hormone 
contraception associated with inhibition of ovulation: oral, injectable, or implantable; 
intrauterine device (IUD); intrauterine hormone-releasing system (IUS); vasectomized 
partner (provided that the partner is the sole sexual partner of the woman of 
childbearing potential and the absence of sperm has been confirmed; if not, additional 
highly effective method of contraception should be used), and agrees to remain on a 
highly effective method of contraception throughout the study and for at least 4 weeks 
after the last dose of study drug
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
49
Approved, Date: 23 August 2018
Note: Typical use failure rates may differ from those when used consistently and 
correctly. Use should be consistent with local regulations regarding the use of 
contraceptive methods for subjects participating in clinical studies.

not heterosexually active
Note: Women who are not heterosexually active at screening must agree to utilize a 
highly effective method of birth control if they become heterosexually active during 
their participation in the study and for at least 4 weeks after the last dose of study drug
8.
Woman of childbearing potential (ie, those subjects who do not meet the postmenopausal 
definition in the Inclusion Criterion above, regardless of age) must have a negative highly 
sensitive serum -human chorionic gonadotropin (-hCG) pregnancy test at screening
9.
Willing and able to adhere to the prohibitions and restrictions specified in this protocol
For Subjects Participating in the 24-hour ABPM Sub-study:
10. Subject understands instructions on the use of the ABPM device and is willing to undergo 
the 24-hour ABPM procedure
11. An average of 3 seated blood pressure readings of SBP >90 to <140 mmHg 
12. Has completed a successful ABPM reading, defined as at least 22 hours of recording with 
70% of valid scheduled readings, and no continuous interruption of >2 hours of recording
Note: If the subject does not have a valid baseline ABPM reading according to the 
definition above or the subject has unexpected illness or other circumstance during the 
day(s) of the 24-hour ABPM recording that could confound the assessment of the endpoint, 
at the discretion of the investigator the subject may repeat the procedure within one week 
prior to randomizing subject to first study dose. If the invalid reading was due to subject 
noncompliance with the procedure, it is up to the investigator’s discretion to decide whether 
the subject should attempt a second 24-hour ABPM procedure. If the 24-hour repeat 
recording is successful, this repeat recording will be used as the subject’s baseline 24-hour 
ABPM. If no valid ABPM reading is obtained following the second attempt, the subject 
should be excluded from the ABPM sub-study, but may be randomized into the main study 
if they continue to meet other eligibility criteria.
4.2.
Exclusion Criteria
Any potential subject who meets any of the following criteria will be excluded from participating 
in the study:
Metabolic/Endocrine
1.
History of obesity with a known secondary cause (eg, Cushing’s disease/syndrome)
2.
History of Type 1 diabetes mellitus, T2DM, diabetic ketoacidosis (DKA), pancreas or -cell 
transplantation, or diabetes secondary to pancreatitis or pancreatectomy
3.
Has an HbA1c of 6.5% or FPG 126 mg/dL (7.0 mmol/L) at screening
Note: a one-time repeat measurement is allowed, at the discretion of the investigator, if the 
value of HbA1c and/or FPG is not consistent with prior values
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
50
Approved, Date: 23 August 2018
4.
Ongoing, inadequately controlled thyroid disorder as assessed by the investigator’s review 
of the subject’s medical history. Subjects taking thyroid hormone replacement therapy must 
be on stable doses for at least 6 weeks before the screening visit
5.
History of glucagonoma
6.
Screening calcitonin of 50 pg/mL (50 ng/L), personal history or family history of 
medullary thyroid cancer, or of MEN 2, regardless of time prior to screening
Note: Investigators are recommended to refer subjects with screening calcitonin value of 
50 pg/mL (50 ng/L) to an endocrinologist for follow-up.
Cardiovascular
7.
A myocardial infarction (MI), unstable angina, revascularization procedure (eg, stent or 
bypass graft surgery), or cerebrovascular accident within 12 weeks before screening, or a 
revascularization procedure is planned during the trial
8.
Heart failure of New York Heart Association (NYHA) Class II-IV cardiac disease (The 
Criteria Committee of the NYHA) (refer to Attachment 1, NYHA Classification of Cardiac 
Disease)
9.
Findings on 12-lead electrocardiogram (ECG) at the screening visit that would require 
urgent diagnostic evaluation or intervention
10. An average of 3 seated blood pressure readings of SBP 160 mm Hg and/or DBP 
100 mm Hg at the screening visit (refer to Attachment 2, Method of Blood Pressure and 
Pulse Rate Measurement)
11. History of tachyarrhythmia (eg, atrial flutter, atrial fibrillation, ventricular tachycardia) 
within 6 months before screening
12. An average of 3 seated pulse rate readings of <50 or >100 bpm
Gastrointestinal
13. Known significant liver disease (eg, acute hepatitis, chronic active hepatitis, cirrhosis)
14. History of acute or chronic pancreatitis
15. History of bariatric surgical procedure or a known clinically significant gastric emptying 
abnormality (eg, severe gastroparesis or gastric outlet obstruction)
Psychiatric-Related
16. History of a clinically significant eating disorder (eg, anorexia nervosa, bulimia, or 
binge-eating) 
17. Any history of major depressive disorder within the last 2 years. 
18. Any history of other severe psychiatric disorders (eg, schizophrenia, bipolar disorder, etc.).
19. Any lifetime history of suicide attempt.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
51
Approved, Date: 23 August 2018
Laboratory
20. Estimated glomerular filtration rate (eGFR) <55 mL/min/1.73 m2 using the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-Epi) formula at screening (Levey 2009), refer to 
Attachment 5, Clinical Laboratory Tests
Note: A one-time repeat measurement is allowed at the discretion of the investigator, if the 
value for eGFR is not consistent with recent values
21. Alanine aminotransferase level is >2.0 times the ULN or total bilirubin is >1.5X the ULN 
(unless consistent with history of Gilbert's disease) at screening
Note: A one-time repeat of ALT is allowed at the discretion of the investigator, if the 
screening value is not consistent with recent values.
22. Fasting triglycerides 600 mg/dL (6.77 mmol/L) at screening (or subsequent visit prior to 
randomization, if not fasting at screening).
Note: A one-time repeat of the serum triglycerides is allowed, at the discretion of the 
investigator, if the screening value is not consistent with recent values.
23. Serum sodium < 130 mEq/L (<130 mmol/L)
Other Conditions
24. History of malignancy within 5 years before screening (eg, any evidence of active disease 
within 5 years, or diagnosis of malignancy within this period)
Note: Subjects with squamous or basal cell carcinomas of the skin, carcinomas in situ of the 
cervix, or a malignancy that in the opinion of the investigator, with concurrence with the 
sponsor’s medical monitor, are considered cured with minimal risk of recurrence, may 
participate.
25. Previous (ie, within 12 weeks from screening visit) or current use of a Highly Active Anti-
retroviral therapy (HAART)
26. Major surgery (eg, requiring general anesthesia) within 12 weeks before screening, or has 
not fully recovered from surgery, or planned major surgery during the participation of the 
current study.
Note: Subjects with planned surgical procedures to be conducted under local anesthesia may 
participate.
27. Clinically important hematologic disorder (eg, symptomatic anemia, proliferative bone 
marrow disorder, thrombocytopenia) or a disorder of hemoglobin (ie, a hemoglobinopathy) 
Medications/Therapies
28. Previous or current participation in a JNJ-64565111 study
29. Known allergies, hypersensitivity, contraindication, or intolerance to the excipients of 
JNJ-64565111 or liraglutide
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
52
Approved, Date: 23 August 2018
30. Known or potential history of intolerance to prior use of any GLP-1 receptor agonist 
(eg, AEs, lack of efficacy) which, in the opinion of the investigator, makes participation not 
in the best interest of the subject
31. Currently treated with antihypertensive or antihyperlipidemic therapy that is not on stable 
dose for at least 4 weeks prior to screening
Note:
If during the screening phase adjustments to the antihypertensive or 
antihyperlipidemic medication regimen are considered to be clinically necessary, the subject 
should be excluded from continuing in the study. The subject may be rescreened after 
adjustments in the antihypertensive or antihyperlipidemic medication regimen have been 
made and the dose has been stable for at least 4 weeks.
32. Prescription weight-management
medication (including but not limited to orlistat, 
topiramate and/or phentermine, lorcaserin, naltrexone and/or bupropion, or over-the-counter 
weight-loss medications or therapies within 12 weeks before the screening visit or is 
planning to initiate non-study-related weight-loss treatment during the study
33. Current or previous use of liraglutide within 12 weeks prior to the screening visit
34. Use of systemic corticosteroid medication within 12 weeks before the screening visit or 
likely to require treatment with systemic corticosteroid medication during study treatment 
phase (for longer than 2 consecutive weeks in duration)
Note: Subjects using inhaled, intranasal, intra-articular, or topical corticosteroids or 
corticosteroids in therapeutic replacement doses may participate
35. Use of the following medications within the 12 weeks before screening or likely to require 
treatment with the following medications during study treatment phase:

Antihyperglycemic agents 

Antipsychotic drugs

Anticonvulsants, 
including barbiturates, gamma-aminobutyric acid (GABA)
analogues, hydantoins, phenyltriazines, succinimides, valproic acid and its 
derivatives, carbamazepine, zonisamide, and felbamate

Tricyclic antidepressants, lithium, levodopa, and dopamine receptor agonists
36. Use of selective serotonin reuptake inhibitors (including but not limited to fluoxetine, 
sertraline, paroxetine, escitalopram, citalopram, dapoxetine, seproxetine, zimelidine, 
mesembrine, reboxetine) and serotonin-norepinephrine reuptake inhibitors (including but 
not limited to venlafaxine, duloxetine, desvenlafaxine, milnacipran, fluvoxamine) that have
not been stable for at least 12 weeks prior to the screening visit
37. Received an investigational drug (including vaccines) other than a placebo agent, or used an 
investigational medical device within 12 weeks prior to screening
General
38. Significant change in smoking habits within 12 weeks before the screening visit
39. Female subject is pregnant or breastfeeding, planning to become pregnant during the study
or follow-up phase, or planning to donate eggs (ova, oocytes) for the purposes of assisted 
reproduction during the study or for a period of 4 weeks after the last dose of study drug
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
53
Approved, Date: 23 August 2018
40. An employee of the investigator or study site, with direct involvement in the proposed study 
or other studies under the direction of that investigator or study site, or is a family members 
of an employee or the investigator
41. Any condition that, in the opinion of the investigator or sponsor’s medical monitor, would 
make participation not in the best interest of the subject, or could prevent, limit, or confound 
the protocol-specified assessments
For Subjects Participating in the 24-hour ABPM Sub-study
42. Currently treated with beta-blockers drugs or calcium-channel blockers
43. Currently has a pacemaker or automated implantable cardioverter defibrillator
44. Currently employed at a job that requires rotating or permanent night shifts
Investigators should ensure that all study eligibility criteria have been met at screening. If a 
subject's clinical status changes (including any available laboratory results or receipt of 
additional medical records) after screening but before the first dose of study drug is given such 
that he or she no longer meets all eligibility criteria, then the subject should be excluded from 
participation in the study. Section 17.4, Source Documentation, describes the required 
documentation to support meeting the eligibility criteria.
4.3.
Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the study to be eligible for participation:
1.
Women of childbearing potential who are heterosexually active, must remain on a highly 
effective method of birth control (failure rate of <1% per year when used consistently and 
correctly; refer to Section 4.1, Inclusion Criteria) throughout the study and for at least 
4 weeks after the last dose of study drug.
2.
Women must agree not to donate eggs (ova, oocytes) for the purposes of assisted 
reproduction during the study and for a period of 4 weeks after the last dose of study drug
3.
Prohibited medications as detailed in Section 8, Pre-study and Concomitant Therapy.
4.4.
Rescreening
Subjects who do not meet all inclusion criteria or who meet an exclusion criterion may, at the 
discretion of the investigator, be rescreened 1 time if the reason for non-eligibility relates to 
duration of stable thyroid hormone replacement, antihypertensive, or antihyperlipidemic therapy,
or time from a MI, unstable angina, revascularization procedure or cerebrovascular accident.
Subjects who are to be rescreened must sign a new informed consent before rescreening.
Subjects rescreened within 4 weeks may use the initial screening laboratory results to determine 
eligibility (with the exception of serum chemistry which must meet inclusion criteria range at 
Week -1 or within 3 weeks before Week -1). Rescreening for an abnormal laboratory value is 
only allowed as indicated for the specific laboratory exclusion (see Section 4.2, Exclusion 
Criteria).
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
54
Approved, Date: 23 August 2018
5.
TREATMENT ALLOCATION AND BLINDING
Randomization and Blinding Procedures
On Day 1, subjects will be randomly assigned to 1 of 5 treatment groups based on a 
computer-generated randomization schedule prepared before the study by or under the 
supervision of the sponsor. The randomization will use randomly permuted blocks. In addition, 
to assure maintenance of the randomization ratio in the ABPM sub-study, subjects will be 
stratified in the interactive web response system (IWRS) by participation in the 24-hour ABPM 
sub-study (yes or no). Subject enrollment into the ABPM sub-study at selected study sites will be 
tracked and capped as necessary. If the overall study target enrollment has been achieved, subject 
recruitment may be closed even if the target enrollment numbers for the ABPM sub-study have 
not been reached.
At baseline (Day 1), the treatment code, which is linked to the randomization schedule, will be 
assigned after logging on to the IWRS designated by the sponsor. The requestor must use his or 
her own user identification and personal identification number when contacting the IWRS, and 
will then give the relevant subject details to uniquely identify the subject. Based on this 
information, the IWRS will assign a unique treatment code, which will dictate the treatment 
assignment and matching study drug kit for the subject. As subjects are randomly assigned to 
treatment, the IWRS will assign a study drug kit to be dispensed at that visit. New study drug kits 
will be assigned each time the IWRS is accessed for dispensing additional study drug.
Blinding
Liraglutide will be administered in an open-label fashion in this study.
JNJ-64565111 and placebo will be given in a double-blind fashion, as described below. To 
maintain blinding, subjects randomly assigned to placebo will be subsequently randomized to 
receive the corresponding volumes of placebo matching the 5.0, 7.4, and 10.0 mg JNJ-64565111 
doses.
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality to allow the investigator to break the blind for an 
individual subject.
Data that may potentially unblind the JNJ-64565111 treatment assignment (eg, serum 
β-hydroxybutyrate, urine ketones, and ABPM measurement) will be handled with special care to 
ensure that the integrity of the blind is maintained and the potential for bias is minimized. This 
can include making special provisions, such as segregating the data in question from view by the 
investigators, clinical team, or others as appropriate until the time of database lock and 
unblinding.
Under normal circumstances, the blind should not be broken until all subjects have completed 
the study and the database is finalized. Otherwise, the blind should be broken only if specific 
emergency treatment/course of action would be dictated by knowing the treatment status of the 
subject. In such cases, the investigator may in an emergency determine the identity of the 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
55
Approved, Date: 23 August 2018
treatment by accessing the IWRS. It is recommended that the investigator contact the sponsor or 
its designee if possible to discuss the particular situation, before breaking the blind. Telephone 
contact with the sponsor or its designee will be available 24 hours per day, 7 days per week. In 
the event the blind is broken, the sponsor must be informed as soon as possible. The date and 
reason for the unblinding must be documented in the appropriate section of the eCRF and in the 
source document. The documentation received from the IWRS indicating the code break must be 
retained with the subject's source documents in a secure manner (eg, sealed envelope) so as not 
to unblind the treatment assignment to the study site or sponsor personnel. The investigator is 
also advised not to reveal the study treatment assignment to the study site (except as necessary 
for the clinical management of the subject) or sponsor personnel.
In general, treatment codes will be disclosed fully only after the study is completed and the 
clinical database is closed. However, for the specified interim analysis, the randomization codes 
and, if required, the translation of randomization codes into treatment and control groups will be 
disclosed to those authorized and only for those subjects included in the interim analysis.
6.
DOSAGE AND ADMINISTRATION
6.1.
Pre-Randomization Open-label Placebo
At the Week -2 visit, subjects will be instructed on the use of pre-filled safety injectors to 
perform SC self-injections, and will be asked to perform a self-injection in the presence of the 
study-site staff. Only subjects who express willingness and demonstrate the ability to administer 
SC injections are eligible to participate in the study (see Section 4.1, Inclusion Criteria, No. 5). 
To assess compliance with the dosing regimen, eligible subjects will be dispensed pre-filled
safety injectors containing 0.5 mL open-label placebo and instructed to perform once-weekly
self-injections at home during the 2-week run-in phase, as well as keep a study drug diary of 
their injection schedule (see Section 9.3.2.1, Training on Subcutaneous Drug Administration for 
details on training instructions).
6.2.
Post-Randomization Double-blind JNJ-64565111 or Matching Placebo and 
Open-label Liraglutide
Double-blind JNJ-64565111 or Matching Placebo
JNJ-64565111 will be supplied as a solution for injection at a concentration of 20.0 mg/mL. 
Blinded study drug will be provided in pre-filled safety injectors with attached SC needle, 
pre-filled with nominal volumes of 0.25, 0.37, or 0.50 mL of JNJ-64565111 (5.0, 7.4, and 
10.0 mg, respectively) or 1 of 3 matching volumes of placebo.
On Day 1, subjects randomly assigned to the double-blind treatment arms will receive a supply 
of their randomly assigned study drug (or matching placebo), and will be reminded of the 
once-weekly dosing regimen and to record the date and time of each administered dose in the 
study drug diary. Subjects will self-administer the first dose of JNJ-64565111 or matching 
placebo at the site under the supervision of study staff.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
56
Approved, Date: 23 August 2018
Subjects will be reminded that if the day of their once-weekly injection coincides with the day of 
a clinic visit, subjects are not to inject JNJ-64565111 or matching placebo before arriving at the 
clinic; once all study visit procedures have been completed, subjects may self-administer blinded 
study drug (or matching placebo) either at the study site or once they have returned home that 
day.
JNJ-64565111 or matching placebo will not be titrated. Subjects will remain on their assigned 
dosages throughout the treatment phase (ie, until Week 26 or early discontinuation of study 
drug). 
Open-label Liraglutide (Saxenda®)
Commercially available supplies of liraglutide will be dispensed to subjects randomly assigned
to the open-label liraglutide arm of the study. Liraglutide is supplied as a pre-filled, multi-dose 
pen that delivers once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg (6.0 mg/mL, 3.0 mL)
(Saxenda USPI).
On Day 1, subjects randomly assigned to open-label liraglutide will receive instruction on the 
use of the pre-filled multi-dose pen. Subjects will receive the first dose of study drug at the site 
under the supervision of study staff.
The dosage of liraglutide to be used in this study is consistent with the approved labeling for its 
use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight 
management in adult patients. The starting dosage of liraglutide on Day 1 will be 0.6 mg/day. At 
the beginning of Weeks 1, 2, 3, and 4, subjects will be contacted preferably by telephone and 
instructed to up-titrate their daily dose to 1.2, 1.8, 2.4, and 3.0 mg in 0.6 mg weekly increment. 
At Week 5, subjects will return to the clinic and should already be up-titrated to their daily dose 
of 3.0 mg and remain on this dose for the remainder of the treatment phase. A diagram of the 
titration schedule is shown in Figure 3.
Figure 3:
Liraglutide Titration Schedule
For subjects who experience significant GI intolerance within the weeks prior to the Week 5
visit, up-titration of liraglutide may be delayed by 1 week; the reason for delaying up-titration 
will be documented on the study drug diary and eCRF. If a subject cannot tolerate the 3.0 mg 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
57
Approved, Date: 23 August 2018
dose of liraglutide by Week 6, they should be discontinued from study treatment, as the efficacy 
of liraglutide for weight management has not been established at lower doses (Saxenda USPI).
No dose down-titration is allowed.
Drug Administration
Injections of JNJ-64565111 (or matching placebo) and liraglutide can be done at any time of day 
irrespective of meals. However, it is preferable that the general time of day (ie, morning, 
evening, just prior to bed, etc) for injecting study drug be kept consistent, to the extent possible.
General instructions for dosing procedures and storage of study drug (or matching placebo) are 
provided below. Detailed instructions for dosing procedures and storage conditions of 
JNJ-64565111, matching placebo, and liraglutide will be provided to the study site in an 
additional guidance document that is provided separately.
Double-blind JNJ-64565111 or Matching Placebo
Subjects randomly assigned to double-blind JNJ-64565111 (or matching placebo) will be 
instructed to administer study drug SC once-weekly for the entire duration of the 26-week 
treatment phase or until early discontinuation. Subjects will be instructed to inject to the 
4 quadrants of the anterior abdominal wall. For consistency, and to avoid dosing in the same 
abdominal area, subjects should be instructed to begin in one quadrant and on subsequent dosing 
weeks proceed in the next quadrant in a counterclockwise manner.
JNJ-64565111 (or matching placebo) should be taken on the same day of the week throughout 
the study (ie, the regularly scheduled study drug day). If the day of the once-weekly injection 
coincides with the day of a clinic visit, subjects are NOT to inject JNJ-64565111 (or matching 
placebo) before arriving at the clinic. Instead, AFTER all study visit procedures have been 
completed, subjects may self-administer blinded study drug either at the study site or once they 
have returned home.
Subjects are to record the date and time of study drug administration on the study drug diary. 
Subjects should mark a calendar to remind them of when to take the next weekly dose.
Subjects in the JNJ-64565111 (or matching placebo) groups should be instructed not to take 
2 doses within 3 days (72 hours) of each other. If a subject misses taking the next dose of 
JNJ-64565111 (or matching placebo) on their regularly scheduled study drug day, the missed 
dose should be taken as soon as possible, if there are at least 3 days (72 hours) until their next 
regularly scheduled study drug day. If there are less than 3 days remaining, the subject should 
skip the missed dose and take the next dose on their regularly scheduled study drug day.
Open-label Liraglutide (Saxenda®)
Subjects randomly assigned to open-label liraglutide will be instructed to administer study drug 
SC once daily for the entire duration of the 26-week treatment phase or until early drug 
discontinuation.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
58
Approved, Date: 23 August 2018
Liraglutide solution should be inspected prior to each injection, and the solution should be used 
only if it is clear, colorless, and contains no particles.
Subjects may administer liraglutide SC either in the abdomen, thigh, or upper arm. The injection 
site may be changed at any time. If the same injection area is being used, subjects will be 
instructed to choose different injection sites in that area (eg, rotating through different abdominal 
quadrants).
On the days of scheduled clinic visits, subjects in the open-label liraglutide group should be 
instructed NOT to inject liraglutide before arriving at the clinic. Instead, AFTER all study visit 
procedures have been completed, subjects may self-administer liraglutide either at the study site 
or once they have returned home.
If a dose of liraglutide is missed, the once-daily regimen should be resumed with the next 
scheduled dose. An extra dose should not be taken to make up for the missed dose.

After an interruption of more than 6 days, the subject who had already reached the 3.0 mg 
dose level should re-initiate liraglutide with a starting dose of 1.8 mg and re-up-titrate to 
3.0 mg. 

For an interruption of 4 to 6 days in duration, it will be up to investigator’s judgment to 
assess whether the subject should re-start at 3.0 mg daily dose, or re-start at 1.8 mg or 
2.4 mg. 
If, after an interruption of at least 4 days, the subject re-starts at a dose of 1.8 mg or 2.4 mg. The 
dose should be up-titrated in 0.6 mg increment every 7 days until the full dosage of 3.0 mg is 
reached.
Drug Storage
Study-site personnel will instruct subjects on how to store study drug for at-home use as 
indicated for this protocol.
Double-blind JNJ-64565111 or Matching Placebo
Double-blind JNJ-64565111 or matching placebo supplies should be stored in the refrigerator at 
36 to 46°F (2 to 8°C) and kept in their carton until ready for use and protected from direct heat 
and light. Blinded study drug or matching placebo can be left out at room temperature up to 
8 hours. Avoid shaking blinded study drug.
Open-label Liraglutide (Saxenda®)
Prior to first use, liraglutide pens should be stored in the refrigerator at 36 to 46°F (2 to 8°C) and 
protected from direct heat and light. Do not store in the freezer or directly adjacent to the 
refrigerator cooling element. Liraglutide pens should not be frozen; if the pen is frozen, it should 
be thrown away.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
59
Approved, Date: 23 August 2018
After initial use of the liraglutide pen, it is preferably to be stored in a refrigerator (36 to 46°F; 
2 to 8°C). Alternatively, it may be stored at controlled room temperature (59 to 86°F; 15 to 
30°C) for up to 30 days only. The pen cap should be kept on when not in use.
To reduce the potential for contamination, infection, and leakage while also ensuring dosing 
accuracy, subjects should be instructed to always remove and safely discard the needle after each 
injection and store the liraglutide pen without an injection needle attached.
7.
TREATMENT COMPLIANCE
The investigator or designated study-site personnel will maintain a log of all drug dispensed and 
returned. Drug supplies for each subject will be inventoried and accounted for throughout the 
study. Subjects who are poorly compliant with blinded (based on unused safety injector(s), 
empty study drug carton(s), and/or study drug diary) and open-label study drug (based on unused
pen, partially or fully used pen(s), empty study drug carton(s), and/or study drug diary) should 
receive counseling on the importance of dosing compliance.
Subjects will receive clear instructions on compliance with study procedures at the screening 
visit. During the course of the study, the investigator or designated study-site personnel will be 
responsible for providing additional instructions to reeducate any subject who is not compliant 
with taking the study drug or following study procedures.
8.
PRE-STUDY AND CONCOMITANT THERAPY
Pre-study therapy includes any therapy used before the first dose of treatment phase study drug. 
Concomitant therapy is any therapy used after the first dose of treatment phase study drug that is 
administered on Day 1.
Pre-study therapies administered up to 30 days before first dose of treatment phase study drug 
must be recorded.
All therapies (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; non-pharmacologic therapies such as electrical stimulation, acupuncture, different 
from the study drug must be recorded as pre-study therapy (before the first dose of treatment 
phase study drug) or concomitant therapy (after first dose of treatment phase study drug) on the 
eCRF.
Prohibited Therapies
1.
Prescription weight-management drugs (including but not limited to orlistat, topiramate 
and/or phentermine, lorcaserin, naltrexone and/or bupropion, or over-the-counter weight-
loss medications or therapies
2.
Oral, intravenous, or intramuscular corticosteroids for longer than 2 consecutive weeks in 
duration
Note: Inhaled, intranasal, intra-articular, or topical corticosteroids, or corticosteroids in 
therapeutic replacement doses are allowed
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
60
Approved, Date: 23 August 2018
3.
Previous (ie, within 12 weeks from screening visit) or current use of HAART
4.
Antihyperglycemic agents (including sulfonylureas, metformin, DPP-IV inhibitors, 
meglitinides, acarbose, thiazolidinediones, exenatide, GLP-1 or GLP-1 analogues, 
pramlintide, sodium-glucose cotransporter 2 (SGLT2) inhibitors, insulin, colesevelam, or 
bromocriptine). 
Note: Metformin is allowed in subjects who develop hyperglycemia during the double-blind 
treatment period
5.
Antipsychotic drugs
6.
Anticonvulsants, including barbiturates, GABA analogues, hydantoins, phenyltriazines, 
succinimides, valproic acid and its derivatives, carbamazepine, zonisamide, and felbamate
7.
Tricyclic antidepressants, lithium, levodopa, and dopamine receptor agonists
8.
In the subset of subjects participating in the 24-hour ABPM sub-study, beta-blockers and 
calcium-channel blockers
9.
Any other investigational agents during the study
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
9.
STUDY PROCEDURES AND EVALUATIONS
The Time and Events Schedule summarizes the frequency and timing of scheduled visits, and the 
timing of efficacy, safety, PK, PRO, and other measurements applicable to this study.
9.1.
General Procedures
9.1.1.
Visit Schedule and Visit Windows
Screening and run-in scheduled study visits should generally occur within a 3-day window 
(ie, 4 days) and after randomization (from Day 1) scheduled study visits should generally occur 
within a 7-day window (ie, 7 days) around the protocol-specified visit schedule (as provided in 
the Time and Events Schedule). For study visits that cannot be held within the recommended 
visit window, the visit should be conducted as closely as possible to the study visit schedule. All 
subsequent visits should be scheduled relative to the date of randomization (Day 1), and not the 
date of the rescheduled visit.
9.1.2.
Maximum Blood Volume Collected
The maximum blood volume (for blood collections shown in the Time and Events Schedule) that 
would be collected if a subject were to complete the 4-week follow-up visit after the 
Week 26/EOT visit would be approximately 176.0 mL for subjects randomly assigned to the 
blinded JNJ-64565111 or placebo treatment arms and approximately 137.5 mL for subjects 
randomly assigned to the open-label liraglutide treatment arm. See Table 3 below for details.
Blood collections for PK assessments should be kept as close to the specified time as possible. 
Other measurements may be done earlier than specified timepoints if needed. Actual dates and 
times of assessments will be recorded in the source documentation and/or eCRF.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
61
Approved, Date: 23 August 2018
Table 3:
Maximum Volume of Blood to be Collected from Each Subject
Type of Sample
Volume per 
Sample (mL)
No. of Samples per 
subject randomized 
to JNJ-64565111
or matching 
placebo
Total Volume 
of Blood 
(mL)a
No. of Samples per 
subject randomized 
to liraglutide
Total 
Volume of 
Blood (mL)a
Hematology
2.0
3
6.0
3
6.0
HbA1c
2.0
3
6.0
3
6.0
Serum chemistry
2.5
8
20.0
8
20.0
Calcitonin
2.5
4
10.0
4
10.0
Serum ß-hydroxybutyrate
2.5
6
15.0
6
15.0
Fasting insulin
2.0
2
4.0
2
4.0
Fasting C-peptide
2.0
2
4.0
2
4.0
FPG
2.0
7
14.0
7
14.0
Fasting lipid panel
3.5
4
14.0
4
14.0
Serum -hCG pregnancy 
tests
2.5
2
5.0
2
5.0
FSH
2.5
1
2.5
1
2.5
Pharmacokinetic (PK) -
trough and immunogenicity 
samplesb
5.0
7
35.0
0
0
PK non-trough
3.5
1
3.5
0
0
Plasma, serum archive 
samples
18.5
2
37.0
2
37.0
Approximate Total,
176.0
137.5
HbA1c = hemoglobin A1c; hCG = human chorionic gonadotropin; FPG = fasting plasma glucose; FSH = follicle-stimulating 
hormone
a
Calculated as number of samples multiplied by amount of blood per sample.
b
Blood samples for PK and anti-JNJ-64565111 antibodies will only be collected from subjects randomly assigned to the 
double-blind JNJ-64565111 or placebo arms; these samples will not be collected from subjects randomly assigned to open-
label liraglutide.
9.2.
Sub-study Procedures
9.2.1.
24-hour Ambulatory Blood Pressure Monitoring [Sub-study]
The 24-hour ABPM sub-study will be performed at selected sites and in a subset of 
approximately 120 subjects (approximately 15 subjects each in the placebo and JNJ-64565111 
5 mg groups, and 30 subjects each in the JNJ-64565111 7.4 mg, JNJ-64565111 10 mg, and 
liraglutide groups) who meet the specific criteria for subjects participating in the 24-hour ABPM 
sub-study (described in Section 4.1, Inclusion Criteria and Section 4.2, Exclusion Criteria). 
Subjects who do not meet these specific criteria (eg, due to concomitant use of beta-blocker or 
calcium-channel blockers) but who meet all other eligibility criteria may be enrolled in the main 
study and will not be required to undergo the ABPM procedure.
Eligible subjects will return to the study site prior to the Day 1 visit (on Day -2 or Day -1) and 
will be dispensed an ABPM device in an appropriate size. The device will be set up by study 
staff and placed on the non-dominant arm to obtain the 24-hour ABPM baseline measurement; 
the ABPM readings will be masked. Study staff will turn on the device and instruct the subjects 
on how to wear the device. Subjects will be given the ABPM diary and instructed to record 
events such as chest pain, chest discomfort, palpitations, tachycardia dizziness, lightheadedness, 
hypotension, orthostatic hypotension, near syncope, syncope, etc. Subjects will be instructed to 
record time and date of such events, concomitant activities (eg, physical exercise), and if 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
62
Approved, Date: 23 August 2018
possible obtain an additional reading of blood pressure using the ABPM device. This diary will 
be reviewed by study-site personnel at each scheduled visit. Subject-reported events considered 
by the investigator to be AEs will also be recorded on the AE eCRF.
After 24 hours, subjects will return to the study site and the device will be removed from the 
subject, the data will be transferred, and an assessment will be made of whether or not the 
readings are valid using the definition of ‘valid’ in the ABPM inclusion criterion (ie, at least 
22 hours of recording with 70% of valid scheduled readings, and no continuous interruption of 
>2 hours of recording).
Subjects who have valid baseline ABPM readings and who meet all other enrollment criteria 
may be randomized on Day 1. If the subject does not have a valid baseline ABPM reading due to 
technical issues (eg, breakage of device components) or the subject has unexpected illness or 
other circumstance during the day(s) of the 24-hour ABPM recording that could confound the 
assessment of the endpoint, at the discretion of the investigator, the subject may repeat the 
procedure within 1 week prior to randomizing subject to first study dose. If the 24-hour repeat 
recording is successful, this repeat recording will be used as the subject’s baseline 24-hour 
ABPM. If no valid ABPM reading is obtained following the second attempt, the subject should 
be excluded from the ABPM sub-study, but may be randomized into the main study if they 
continue to meet other eligibility criteria. In this case, the subject should not undergo the ABPM 
procedure at the Week 26/EOT visit.
Subjects will repeat the procedure 1 or 2 days prior to the Week 26/EOT visit in subjects who 
have not withdrawn consent from the study, died, or were lost to follow-up. For subjects treated 
with JNJ-64565111 or matching placebo, every effort should be made to have the procedure 
performed within 7 days from the previous dose of study drug. Subjects treated with open-label 
liraglutide should continue to their daily dosing schedule. If the subject does not have a valid 
Pre-Week 26 ABPM reading due to technical issues (eg, breakage of device components) or the 
subject has unexpected illness or other circumstance during the day(s) of the 24-hour ABPM 
recording, at the discretion of the investigator, the site may delay subject’s Week 26/EOT visit 
up to another week, and the subject will be asked to repeat the procedure within 1 week prior to 
coming to Week 26/EOT visit. If needed, additional study drug may be dispensed to allow 
dosing 7 days prior to the repeat ABPM procedure. If the 24-hour repeat recording is successful,
this repeat recording will be used as the subject’s Week 26/EOT ABPM.
9.3.
Pre-treatment Phase Procedures and Evaluations
9.3.1.
Screening Visit (Week -3)
Potential subjects will have all screening procedures as noted in the Time and Events Schedule 
completed within 1 week (Week -3). Eligible subjects must meet all of the eligibility criteria (see 
Sections 4.1, Inclusion Criteria and 4.2, Exclusion Criteria).
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
63
Approved, Date: 23 August 2018
Informed Consent must be signed at the screening visit before any study procedures are 
performed. If participating sites do not have a written policy that subjects typically are invited to 
the site in a fasting condition, an optional pre-screening visit will be necessary to obtain written 
informed consent prior to inviting subjects in a fasting state for the screening procedures.
9.3.2.
Run-in Phase (Week -2 to Day -1)
At the Week -2 run-in visit, subjects will complete a baseline assessment for IWQOL-Lite, single
item Ease of Weight Management, and the PAM; subjects should complete the PRO measures 
(whenever possible) before any training, tests, procedures (including ECG and injection-
training), discussion of AEs or the subject’s medical condition, or other consultations to prevent 
influencing subject’s perceptions (see Attachment 9, Instructions for the Completion of PRO 
Assessments). In cases where a final translated version of the assessment does not exist in the 
language spoken by the subject, the assessment should not be administered. English-speaking 
subjects in selected countries only will also complete the PROMIS SF 8b, PGIS, and be provided 
a PRO diary for them to complete the ERCQ at home. The ERCQ should be completed by the 
subject each day at the same time each day, in the same setting each day, for the 7 consecutive 
days immediately prior to the Randomization visit (eg, starting 7 days before the randomization 
visit).
An assessment of eligibility criteria will be completed (see Sections 4.1, Inclusion Criteria and 
4.2, Exclusion Criteria) and pre-study drugs will be reviewed. The investigator or designated 
study-site personnel will perform a 12-lead local ECG.
Details on specific procedures performed during this phase are described below.
9.3.2.1.
Training on Subcutaneous Drug Administration
At the Week -2 visit, subjects will receive pre-filled safety injectors containing 0.5 mL of 
placebo. Subjects will be informed that they are receiving placebo during the run-in phase and 
that the purpose of these injections is to train them on the injection technique and to assess 
compliance with dosing regimen. The investigator or designated site personnel will instruct each 
subject on how to perform self-injections. Each subject will use a pre-filled safety injector to 
perform a self-injection under the supervision of the study staff. If, after the training, the subject 
is still willing to participate in the study and perform weekly self-injections, the subject will be 
given a supply of placebo pre-filled safety injectors to take home, and instructed to administer 
injections of open-label placebo weekly at home. Subjects will also receive a study drug diary, 
and will be instructed to record the date and time of each SC self-injection.
A diagram of the injection-training procedures is provided in Figure 4.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
64
Approved, Date: 23 August 2018
Figure 4:
Injection-training Procedures
9.3.2.2.
Study Drug Diaries
Subjects will receive the study drug diary and be instructed to record the date and time of each 
self-injection throughout the run-in and treatment phase which allows an assessment of treatment 
compliance and the relationship of PK measurements and safety assessments in relation to 
dosing of study drug. The information will be entered into eCRFs by the site personnel.
9.3.2.3.
Pre-day 1 Visit (ABPM Sub-study Subjects Only)
Subjects participating in the 24-hour ABPM sub-study will return to the study site 1 or 2 days 
prior to Day 1 to receive the ABPM device and diary and obtain a 24-hour ABPM baseline 
measurement (see Section 9.2.1, 24-Hour Ambulatory Blood Pressure Monitoring [Sub-study]).
9.4.
Treatment Phase Procedures and Evaluations
Please refer to the Time and Events Schedule for the visit schedule and study procedures during 
the treatment phase.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
65
Approved, Date: 23 August 2018
9.4.1.
Day 1/ Day of Randomization
At baseline (Day 1), subjects will return any unused placebo pre-filled safety injector(s), empty 
study drug carton(s), and/or subject study drug diary to the study site. Study-site staff will count 
the unused placebo pre-filled safety injectors, empty study drug carton(s), and/or the number of 
injections recorded on the subject study drug diary to assess compliance.
Subjects who continue to express willingness to self-administer SC injections, and continue to 
meet all study entry criteria, including compliance with the open-label placebo run-in medication 
(see Sections 4.1, Inclusion Criteria and 4.2, Exclusion Criteria) will be randomly assigned to a 
treatment group using the IWRS (as described in Section 5, Treatment Allocation and Blinding).
English-speaking subjects in selected countries only will complete the PROMIS SF 8b and 
participate in an ACTT interview. All subjects should complete the PRO measure (whenever 
possible) before any training, tests, procedures, discussion of AEs or the subject’s medical 
condition, or other consultations to prevent influencing subject’s perceptions (see Attachment 9, 
Instructions for the Completion of PRO Assessments). The Run-in Phase ERCQ PRO diary
should be collected from the subset of subjects for whom it was distributed, and it should be 
checked for completeness. For subjects who participate in the 24-hour ABPM sub-study during 
the run-in phase, data will be transferred from the ABPM device and an assessment will be made 
(see Section 9.2.1).
Counseling should be done by dietitians/nutritionists on Day 1/Day of Randomization to provide 
an assessment and recommendation for a reduced-calorie diet and exercise regimen (see 
Attachment 4). At subsequent visits (Weeks 5, 10, 15, and 20), counseling and reinforcement of 
the recommended diet and exercise regimen may be conducted by a trained counselor. Subjects 
will be instructed to not start any other diet or new exercise program during the study.
Anthropometric measurements, for body weight, height, and waist circumference measurement 
procedures, are described in Attachment 3.
Subjects randomly assigned to the JNJ-64565111 or placebo treatment groups will be dispensed 
a 6-week supply of blinded study drug according to their treatment group assignment. The first 
dose of blinded study drug will be self-administered at the study site in the presence of study 
staff after all baseline procedures have been completed. Subjects will be instructed to administer 
study drug or matching placebo SC once-weekly at home (as described in Section 6.2, 
Post-Randomization Double-blind JNJ-64565111 or Matching Placebo and Open-label 
Liraglutide).
For subjects randomly assigned to the open-label liraglutide treatment group, study staff will 
train the subjects on the use of the dial-a-dose auto-injector pen. The first dose of open-label 
liraglutide will be self-administered at the study site in the presence of study staff after all 
baseline procedures have been completed. Subjects will be instructed to administer open-label 
liraglutide SC once daily at home.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
66
Approved, Date: 23 August 2018
9.4.2.
Weeks 1, 3, 4, and 24 Contact
Subjects in the open-label liraglutide treatment group will be contacted preferably by telephone 
at Weeks 1, 3, and 4 to remind them about their dosing titration (ie, to increase their dose of 
liraglutide by an 0.6 mg dose increment weekly) (see Section 6.2, Post-Randomization 
Double-blind JNJ-64565111 or Matching Placebo and Open-label Liraglutide).
Only English-speaking subjects participating with ERCQ will be contacted preferably by 
telephone at Week 24 to remind about the ERCQ diary completion.
9.4.3.
Weeks 2, 5, 10, 15, 20 Visits
Please refer to the Time and Events Schedule for the study procedures at each visit. In between 
Weeks 2, 5, 10, 15, and 20 visits, site staff is encouraged to contact subjects to reinforce the 
adherence to diet and exercise, study drug dosing reminder, assessment of subjects’ status, and 
compliance with the protocol procedures (eg, diary completion reminder).
9.4.4.
Pre-Week 26 Visit (ABPM Sub-study Subjects Only)
Those subjects participating in the 24-hour ABPM sub-study will return to the study site at 1 or 
2 days prior to the Week 26/ EOT visit to repeat the ABPM procedure. For subjects treated with 
JNJ-64565111 or matching placebo, every effort should be made to have the procedure 
performed within 7 days from the previous dose of study drug.
If the subject does not have a valid Pre-Week 26 ABPM reading due to technical issues 
(eg, breakage of device components) or the subject has unexpected illness or other circumstance 
during the day(s) of the 24-hour ABPM recording, at the discretion of the investigator, the site 
may delay subject’s Week 26/EOT visit to another week and the subject will be asked to repeat 
the procedure within 1 week prior to coming to Week 26/EOT visit. If needed, additional study 
drug may be dispensed to allow dosing 7 days prior to the repeat ABPM procedure. If the 
24-hour repeat recording is successful, this repeat recording will be used as the subject’s 
Week 26/EOT ABPM.
9.4.5.
End-of-Treatment/Early Study Drug Discontinuation
See the Time and Events Schedule for procedures to be conducted at the EOT evaluation. 
The EOT evaluations will be performed when the subject completes the 26-week treatment phase 
or prematurely discontinues study drug prior to Week 26. Every effort should be made to have 
the Week 26/ EOT visit scheduled within 7 days after the last dose of study drug.
Subjects who prematurely discontinue study drug will require an immediate EOT assessment 
(either on the day of early study drug discontinuation or as soon as possible following study drug 
discontinuation).
Site-based PRO instruments will be completed during the Week 26/EOT visit (ie, IWQOL-Lite, 
Ease of Weight Management, PAM, PROMIS SF 8b, PGIS, and PGIC). The final ERCQ diary
will be collected by the site and reviewed for completeness at Week 26. For subjects who 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
67
Approved, Date: 23 August 2018
discontinue early from study drug prior to Week 26, no ERCQ diary completion is required at 
the EOT visit. English-speaking subjects in selected countries only will be given a STEP 
Interview (see Section 9.7.3, Patient-reported Outcomes).
Subjects will be instructed that study drug will not be made available to them after they have 
completed/discontinued study drug and that they should return to their primary physician to 
determine standard of care.
9.4.6.
Management of Hyperglycemia
Throughout the 26-week treatment phase, subjects who develop hyperglycemia and have FPG 
values of 140 mg/dL (7.8 mmol/L) should receive reinforcement of diet and exercise 
recommendations followed by an FPG repeat within 14 days by the central laboratory. If the 
FPG repeat value is still 140 mg/dL (7.8 mmol/L), subjects will initiate metformin therapy at an 
initial dose and with dose titration managed by the investigator as considered clinically 
appropriate and consistent with local prescribing information. Male subjects with a serum 
creatinine 1.5 mg/dL (133 μmol/L), or female subjects with a serum creatinine 1.4 mg/dL 
(124 μmol/L), or subjects who have any other contraindication to metformin use (including 
eGFR per local prescribing information of the country of the investigational site), are not eligible 
for metformin therapy and should have their study drug discontinued and undergo an early 
withdrawal visit. 
Investigators must complete the appropriate eCRF page (documenting initiation of therapy) for 
subjects starting metformin medication. 
Double-blind study drug and open-label liraglutide must be continued after initiation of 
metformin therapy.
Once subjects have initiated metformin, they should be counseled to monitor their fasting 
self-monitored blood glucose (SMBG) at least 2 times a week (or more frequently if deemed 
necessary by the investigators) throughout the duration of the study and to contact the site if
fasting SMBG values are consistently >180 mg/dL (10.0 mmol/L). 
Subjects on metformin therapy for at least 2 weeks at the maximum tolerated dose of metformin 
(or maximum dose considered appropriate by the investigator) with FPG >180 mg/dL 
(10.0 mmol/L), must be discontinued from the study (see Section 10.2, Discontinuation of Study 
Treatment)
9.5.
Post-treatment (Follow-up) Procedures and Evaluations
Subjects who complete the 26-week treatment phase will be asked to return for the 4-week SAE
follow-up visit approximately 5 weeks after the last dose of study drug for JNJ-64565111-treated 
or placebo-treated subjects and 4 weeks after the last dose of study drug for liraglutide-treated 
subjects to collect any SAEs unless the subject has died, is lost to follow-up, or has withdrawn
consent. If the subject has died, the date and cause of death will be collected and documented.
For subjects randomly assigned to double-blind JNJ-64565111 or placebo only, blood samples 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
68
Approved, Date: 23 August 2018
will be collected at the 4-week SAE follow-up visit for PK and immunogenicity (ie, ADA) 
measurement. In addition, during this visit, subjects who received metformin therapy, regardless 
of whether randomly assigned to double-blind JNJ-64565111 or open-label liraglutide, will also 
have blood sample collected to measure FPG.
In addition, subjects who prematurely discontinue study drug for any reason prior to Week 26 
and have not withdrawn consent, were not lost to follow-up, or did not die, will continue in the 
study following the EOT visit to undergo the following off-treatment procedures based on the 
predefined visit schedule outlined in the Time and Event schedule.
These will include collection of:

SAEs

Specific AEs of interest (ie. MACE events, acute pancreatitis, and possible cases of thyroid 
neoplasm)

Vital signs (including body weight)

Concomitant medications
NOTE: If the 4-week SAE follow-up visit is expected to occur within 2 or 3 weeks from the next 
scheduled off-treatment visit, the site may combine both visits and perform all procedures of the 
combined visits. For example, assuming a subject discontinued study drug at Week 5 (EOT visit) 
and therefore 4-week SAE follow-up visit is expected to occur at Week 9, this visit can be 
combined with the off-treatment scheduled Week 10 visit. These 2 visits can be combined to 
perform the assessments/procedures from both visits as indicated on the Time and Event 
schedule (no duplicate procedures are required if they are scheduled at both visits).
If subjects that discontinued study drug early are unable to return to their site for the scheduled 
on-site study visit, an alternate contact visit should be conducted with the goal of collecting any 
SAEs, MACE events (ie, CV death, nonfatal MI and nonfatal stroke), AEs of thyroid neoplasm
and pertinent concomitant medications. Details regarding discussions via telephone, email, or 
other methods of contact must be properly documented on subject’s source record and/or 
applicable eCRFs, such as date of contact, outcome and/or responses provided by the subjects.
The site may consult subjects’ delegated contact(s) for the off-treatment follow-up if the site is 
unable to reach the subjects after multiple attempts.
9.6.
Internal Data Monitoring Committee (DMC)
An iDMC will be established to monitor safety data on an ongoing basis. The committee will 
meet periodically to review interim data. After the review, the iDMC will make 
recommendations regarding the continuation of the study. The details will be provided in a 
separate iDMC charter.
The iDMC will consist of at least 1 medical expert in the relevant therapeutic area and at least 
1 statistician. The iDMC responsibilities, authorities, and procedures will be documented in its 
charter.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
69
Approved, Date: 23 August 2018
In addition to iDMC unblinded monitoring, the study team will perform ongoing blinded 
monitoring and will alert the iDMC to any possible safety signal the blinded team notes during 
their review of the data.
9.7.
Efficacy Evaluations
9.7.1.
Primary Efficacy Endpoint
The primary measure of efficacy is percent change in body weight. The primary efficacy 
endpoint will be the percentage change in body weight from baseline to Week 26 between 
JNJ-64565111 compared to placebo.
9.7.2.
Secondary and Exploratory Efficacy Endpoints
The secondary measures of efficacy at Week 26 include proportion of subjects with 5% and 
10% weight loss from baseline, and absolute change in body weight from baseline.
Exploratory efficacy endpoints at Week 26 include change from baseline in BMI, waist 
circumference, fasting lipids (total cholesterol, LDL-C, HDL-C, and triglycerides), FPG, fasting 
insulin, fasting C-peptide, serum ß-hydroxybutyrate, SBP, DBP, pulse rate, PK exposure, and 
PROs (ie, changes in IWQOL-Lite, single item Ease of Weight Management, PAM, ERCQ 
[subset of subjects], and PROMIS SF 8b [subset of subjects]).
Additional exploratory endpoints assessed in a subset of subjects at Week 26 include qualitative 
assessments of pre-trial expectations and post-trial experiences using the ACTT pre-trial 
interviews and a modified STEP exit interview in English-speaking subjects in selected countries 
only.
The effects of JNJ-64565111 compared with liraglutide on the percentage change and absolute 
change in body weight from baseline and the proportion of subjects with 5% and 10% weight 
loss from baseline will also be assessed at Week 26.
9.7.3.
Patient-reported Outcomes
Janssen is developing a novel PRO instrument (ie, ERCQ) to assess eating-related concepts such 
as hunger, appetite, cravings and/or satiety, and to support the use of an existing PRO instrument 
assessing physical functioning. These novel measures along with previously developed 
questionnaires will be included in this study. Some questionnaires will be completed during 
scheduled site visits while others will be completed at home by the subject. It is therefore 
important for sites to be familiar with the PRO Time & Events schedule to ensure subjects 
complete the PROs at the correct setting and visit. These PROs will enable the evaluation of 
subject's experience of treatment and although the PRO endpoints are exploratory, the expected 
treatment-group differences may provide data supporting the value of the product from a 
patient's perspective.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
70
Approved, Date: 23 August 2018
All site visit-based PRO assessments (whenever possible) should be completed before any tests, 
procedures, or discussion of AEs or the subject’s medical condition (see Attachment 9, 
Instructions for the Completion of PRO Assessments). The home-based PRO assessments
(ERCQ) should be completed daily at the same time whenever possible and in the same setting 
for 7 consecutive days immediately prior to the next visit.
The Impact of Weight on Quality of Life-Lite (IWQOL-Lite)
The IWQOL-Lite (Kolotkin 2001; Kolotkin 2002) is a 31-item, self-report obesity-specific 
measure that contains 5 domains: Physical Function (11 items), Self-esteem (7 items), Sexual 
Life (4 items), Public Distress (5 items), and Work (4 items). It has been used to quantitatively 
assess an individual’s perception of how their weight affects their day-to-day life. The IWQOL-
Lite has been widely used in clinical trials and is a reliable and valid measure that has 
demonstrated good psychometric properties.
Confirmatory factor analyses provide strong support for the adequacy of the scale structure. The 
5 identified scales and the total score demonstrated excellent psychometric properties in obese 
patients (Coon 2016; Hauber 2010), and the reliability of the scales ranges from 0.90 to 0.94 and 
is 0.96 for the total score (Kolotkin 2001). A published algorithm is used to calculate domain and 
total scores, which range from 0 to 100 with higher scores indicating better well-being. 
IWQOL-Lite will be administered at Weeks -1, 15, and 26/EOT. A sample of the IWQOL-Lite 
that contains representative questions and instructions for completion are provided in the PRO 
Completion Guidelines.
IWQOL-Lite will be completed at Week -2, 15, and 26/EOT visits. 
Single Item Ease of Weight Management
A single item developed by the sponsor that inquires, “How difficult is it for you to lose 
weight?” will be completed at Weeks -2, 15, and 26/EOT visits. A sample of the single item 
assessing Ease of Weight Management is provided in the PRO Completion Guidelines.
Patient Activation Measure (PAM)
A 13-item self-report measure that identifies where individuals place within 4 different levels of 
activation. It reliably predicts future emergency room visits, hospital admissions and 
readmissions, and medication adherence (Hibbard 2005).
PAM will be completed during the Week -2, 15, and 26/EOT visits.
Eating-related Concepts Questionnaire (ERCQ)
An instrument developed by the sponsor describes the subject’s rating eating-related concepts 
such as hunger, appetite, cravings, and satiety. The ERCQ follows the FDAs Guidance for 
Industry for developing new PRO measures (FDA 2009).
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
71
Approved, Date: 23 August 2018
At Week -2 visit, English-speaking subjects in selected countries will be provided the ERCQ 
diary to complete at home. The ERCQ should be completed by the subject at the same time and 
in the same setting each day for 7 consecutive days, starting at Week -1 up to the day prior to 
Day 1 visit.
At Week 15 visit, subjects who completed ERCQ diary for 7 consecutive days prior to Day 1 
visit will be provided a new diary to complete at home. The ERCQ should be completed by the 
subjects at the same time and in the same setting each day for the following 7 consecutive days
after the Week 15 visit. The completed ERCQ diary should be returned to the site at the Week 20 
visit and another ERCQ diary will be provided to the subjects at that visit. The site should 
contact subjects at Week 24 preferably by telephone to remind the completion of this ERCQ 
diary. Subjects should begin completing this ERCQ diary for 7 consecutive days starting at 
Week 25 up to the day prior to their scheduled Week 26 visit. The completed final ERCQ diary 
should be returned by the subjects and collected by the site at the Week 26 visit. For subjects 
who discontinue early from study drug, no ERCQ diary completion is required at the EOT visit.
PROMIS Physical Function Short Form 8b
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of 
person-centered measures that evaluate physical, mental, and social health in adults and children
(HealthMeasures website). These measures can be used with the general population and with 
individuals living with chronic conditions. PROMIS Profile instruments are a collection of short 
forms containing a fixed number of items from different domains (Depression, Anxiety, Physical 
Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social 
Roles and Activities). The PROMIS Profile instruments are administered as short forms and are 
ideal when researchers prefer to ask the same question of all respondents or of the same 
respondent over time. These measures were developed and validated with state-of-the-science 
methods to be psychometrically sound (HealthMeasures website). 
In English-speaking subjects in selected countries only, PROMIS SF 8b will be administered at 
Week -2, Day 1, Week 15, and Week 26/EOT visits.
Patient Global Impression Status (PGIS) and Patient Global Impression of Change (PGIC)
Interpreting meaningful change in scores on PRO instruments is an important step in instrument 
development. The methods for interpreting meaningful change to derive responder definitions 
have evolved over time and various approaches exist. Yet, in many cases, anchor-based methods 
are preferred over distribution-based methods. Anchor-based methods link scores on the PRO to 
an external criterion that identifies subjects who have experienced an important change in their 
condition. Distribution-based approaches use the variability of PRO scores to quantify the 
magnitude of change (Coon 2016). The PGIS and the PGIC will be used as anchors, external 
criterion, to determine meaningful change in scores for the ERCQ and the PROMIS SF 8b in this 
population of non-diabetic severely obese subjects. The PGIS contains questions on how the 
subject would currently rate their ability on the concept(s) of interest. The PGIC contains 
questions on how the subject would rate their ability on the concept(s) of interest compared to 
before starting the study.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
72
Approved, Date: 23 August 2018
In English-speaking subjects in selected countries only, PGIS will be administered at Week -2, 
Week 15, and Week 26/EOT visits, and PGIC at Week 15 and Week 26/EOT visit only.
9.7.4.
Interviews
In English-speaking subjects in selected countries only, study entry (ACTT) and exit (STEP) 
structured qualitative interviews will be conducted to qualitatively describe pre-treatment goals 
and expectations and post-treatment experiences.
At Day 1 visit, English-speaking subjects in selected countries will be given an ACTT interview. 
At Week 26/EOT visit, the English-speaking subjects in selected countries will be given a STEP 
Interview. 
The principal investigator should use their discretion to determine whether the subject is 
sufficiently fluent in English to take the ACTT and STEP surveys.
Pre- and post-treatment interviews have been used in early phase clinical trials to inform 
exploratory insight into patient experiences of new medications. The data from these interviews 
will not be reconciled with the safety database of the study. These interviews are semi-structured 
and are designed to allow subjects to provide their own impressions of a study drug and not be 
restricted to items included in standard questionnaires.
9.8.
Pharmacokinetics and Immunogenicity
Serum samples will be used to evaluate the PK of JNJ-64565111, as well as immunogenicity 
based on measurement of anti-JNJ-64565111 antibodies. Serum collected for PK and 
immunogenicity analyses may additionally be used to evaluate safety or efficacy aspects that 
address concerns arising during or after the study period. Genetic analyses will not be performed 
on these serum samples. Subject confidentiality will be maintained.
9.8.1.
Pharmacokinetic Evaluations
9.8.1.1.
Sample Collection and Handling
Refer to the Time and Events Schedule for the timing and frequency of all sample collections.
Blood collections for PK assessments should be kept as close to the specified time as possible.
In all subjects randomly assigned to JNJ-64565111 or matching placebo (but not in subjects 
randomly assigned to open-label liraglutide), venous blood samples will be collected according 
to the Time and Events Schedule for determination of serum trough concentrations of 
JNJ-64565111 to assess attainment of steady-state concentrations. In addition, a post-treatment 
sample at 30 weeks will also be collected in all subjects. On the days of the trough clinic visits at 
which PK samples are to be obtained, subjects are not to inject the study drug before arriving at 
the clinic. 
The PK sampling scheme was prospectively optimized for population-based PK analyses. In 
addition to the trough samples and a post-treatment sample in all subjects, a subset of subjects 
will have 1 additional visit (Day 4 1 day sampling window) to collect a non-trough PK sample. 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
73
Approved, Date: 23 August 2018
The non-trough PK visit will occur at selected sites and will involve approximately 180 subjects 
(approximately 45 subjects each in the placebo, JNJ-64565111 5 mg, JNJ-64565111 7.4 mg, 
JNJ-64565111 10 mg groups). A sample size of 45 subjects per dose group was based on 
(1) optimal PK sampling based on Fisher Information Matrix to allow precise estimation of 
population PK parameters and (2) logistical constraints to limit the number of additional patient 
visits for PK sampling.
The exact dates and times of previous study drug injection and blood sampling for PK must be 
recorded in the eCRF or laboratory requisition form for all PK samples. 
See the laboratory manual for information regarding handling of biologic samples.
9.8.1.2.
Analytical Procedures
Serum samples will be analyzed to determine concentrations of JNJ-64565111 using a validated, 
specific, and sensitive immunoassay method by or under the supervision of the sponsor.
9.8.1.3.
Pharmacokinetic Parameters
Serum concentrations at each time point of measurement will be evaluated by descriptive 
statistics. In addition, to develop a structural PK model of JNJ-64565111 and to evaluate the 
dependence of the pharmacokinetics of JNJ-64565111 on population covariates, all PK data from 
subjects in this study will be combined with data from other clinical studies of JNJ-64565111 for 
a pooled population PK analysis. This will be performed using nonlinear mixed-effects modeling 
with the software package NONMEM. The mean (and variance) values for specific PK 
parameters (eg, clearance) will be estimated and the statistical significance of the relationships 
between covariates and PK parameters will be evaluated. This pooled analysis will be reported 
separately.
9.8.2.
Immunogenicity Assessments (Anti-JNJ-64565111 Antibodies)
The detection and characterization of anti-JNJ-64565111 antibodies will be performed using a 
validated assay method by or under the supervision of the sponsor. All samples collected for 
detection of anti-JNJ-64565111 antibodies will also be evaluated for JNJ-64565111 serum 
concentration to enable interpretation of the antibody data.
Anti-JNJ-64565111 antibodies will be evaluated in serum samples collected from all subjects 
according to the Time and Events Schedule. Additionally, serum samples should also be 
collected at the final visit from subjects who are discontinued from treatment or withdrawn from 
the study.
At visits where serum concentration of study drug and antibodies to study drug will be evaluated, 
one venous blood sample of sufficient volume should be collected. Each serum sample will be 
divided into 3 aliquots (1 each for serum concentration of study drug, antibodies to study drug, 
and a back-up).
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
74
Approved, Date: 23 August 2018
Serum samples will be screened for antibodies binding to JNJ-64565111 and the titer of 
confirmed positive samples will be reported. Other analyses may be performed to verify the 
stability of antibodies to JNJ-64565111 and/or further characterize the immunogenicity of 
JNJ-64565111.
9.9.
Archive Samples for Exploratory Research
Fasting plasma, serum, and urine samples will be collected at the time points specified in the 
Time and Events Schedule and archived for future exploratory research. The blood will be 
processed to yield plasma, which will be stored at or below -70º C. Short-term storage of 
samples for no more than 2 weeks at –20º C freezer is acceptable if the site does not have a 
freezer at –70º C or colder. Preferably, the frozen samples should be shipped to the central lab as 
soon as possible. Refer to the laboratory manual for detailed instructions for sample collection, 
processing and shipment of archive samples for exploratory research.
9.10.
Safety Evaluations
Safety evaluations will include the monitoring of AEs (including protocol-specified AEs of 
interest), vital sign measurements, clinical laboratory tests (including calcitonin, lipase, amylase, 
and sodium), and serum pregnancy testing.
Investigators will remind subjects to contact the investigational sites in the presence of 
signs/symptoms that may be consistent with acute pancreatitis (see Attachment 6), or in the 
presence of severe nausea/vomiting that limits the ability of the subject to keep adequate fluid 
intake even for a few hours, hence increasing the risk of dehydration and electrolyte imbalances. 
Based on the assessment, the investigators should use their clinical judgment to determine 
whether the subject may require immediate medical attention (eg, emergency room visit) or 
whether the subjects should be scheduled as soon as possible for an unscheduled visit to undergo 
clinical and pertinent laboratory assessments, and if deemed appropriate by the investigator, 
study drug should be interrupted until results have been reviewed. 
If a subject experiences an adverse event of vomiting assessed by the investigator as “severe” in 
intensity (see Section 12.1.3, Severity Criteria) lasting more than 24 hours and considered to be 
at least possibly related to study drug, the subject must be discontinued from study treatment (see 
Section 10.2, Discontinuation of Study Treatment).
If a subject experiences an adverse event of vomiting assessed as “moderate” in intensity lasting 
more than 48 hours, considered to be at least possibly related to study drug, and occurring within 
3 days of the next scheduled dose, further administration of study drug will be interrupted. Based 
upon the investigator’s assessment of the subject’s clinical status (which may be done via a 
telephone contact or in-clinic visit) and/or, if necessary, a review of the laboratory results (either 
obtained by central or local laboratory), the investigator will determine whether the subject can 
resume study drug (eg, no signs/symptoms of dehydration, reduction in intensity or resolution of 
adverse event, no clinically significant laboratory abnormalities), should continue to interrupt 
study drug, or be permanently discontinued from study drug (see Section 10.2, Discontinuation 
of Study Treatment).
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
75
Approved, Date: 23 August 2018
At the investigator’s discretion, an anti-emetic may be administered or prescribed if needed to 
reduce vomiting so as to avoid subsequent dehydration.
Any clinically relevant changes occurring during the study must be recorded on the Adverse 
Event section of the eCRF.
Any clinically significant abnormalities persisting at the end-of-treatment will be followed by the 
investigator until resolution or until a clinically stable endpoint is reached.
The study will include the following evaluations of safety and tolerability according to the time 
points provided in the Time and Events Schedule.
Routine safety monitoring will be conducted by the internal sponsor clinical study team and will 
be based on the review of blinded data on a regular basis.
Adverse Events
Adverse events will be reported by the subject (or, when appropriate, by a caregiver, surrogate, 
or the subject's legally acceptable representative) for the duration of the study. Adverse events 
will be followed by the investigator as specified in Section 12, Adverse Event Reporting.
Collection of Protocol-Specified Adverse Events of Interest
For any adverse event considered to be one of the following protocol-specified AEs of interest, 
and for all deaths, investigators may be asked to provide more detailed information on 
supplemental form or eCRF. 
Cardiovascular Events
Investigators will be instructed to identify the following cardiovascular events of interest:

MACE (ie, CV death, nonfatal MI and nonfatal stroke)

hypotension-related AEs
Pancreatic Events
Investigators will be instructed to identify the following pancreatic events of interest:

AEs of pancreatitis

AEs of serious or severe abdominal pain leading to suspicion of pancreatitis

confirmed lipase or amylase elevations 3× ULN.
See Attachment 7, Pancreatitis Monitoring and Withdrawal Criteria, for details of how to 
monitor and document pancreatic AEs.
Calcitonin Elevation and Thyroid Neoplasm
Investigators will be instructed to identify elevations in calcitonin and possible cases of thyroid 
hyperplasia, including but not limited to:

C-cell thyroid hyperplasia
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
76
Approved, Date: 23 August 2018

Medullary thyroid cancer

Thyroid cancer (papillary, follicular)

Thyroid nodule
See Attachment 8, Guidelines for Calcitonin Monitoring, for details of how to monitor and 
document thyroid neoplasm.
Clinical Laboratory Tests
Subjects will be monitored for safety laboratory analytes (hematology, chemistry, and urinalysis) 
as described in Attachment 5, Clinical Laboratory Tests.
Subjects with elevations in ALT (3-times ULN), in lipase/amylase (2 times ULN) or in 
calcitonin (10 pg/mL [10 ng/L]) will be monitored and managed using the algorithms
provided in Attachment 6, Algorithm for Monitoring Abnormal Liver Function Tests,
Attachment 7, Pancreatitis Monitoring and Withdrawal Criteria, and Attachment 8, Guidelines 
for Calcitonin Monitoring.
Alerts will be provided to investigators by the central laboratory identifying important laboratory 
changes or key out-of-range values, so the investigator can follow-up as necessary. For 
creatinine phosphokinase (CPK) elevations, the investigator should determine if follow-up 
evaluation is clinically appropriate to exclude a potential cardiac event.
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the Adverse Event section of the eCRF.
The actual dates and times of sample collection must be recorded in the eCRF or laboratory 
requisition form. Refer to the Time and Events Schedule for the timing and frequency of all 
sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory manual.
Resting Vital Signs (Pulse, Blood Pressure)
Vital signs will consist of pulse and blood pressure measurements and will be obtained after the 
subject has been in the sitting position for 5 minutes and before blood sample collection for 
laboratory tests. Blood pressure will be assessed manually with a mercury sphygmomanometer 
or an automated blood pressure monitor. Three consecutive blood pressure and pulse rate 
readings will be taken and recorded, at intervals of at least 1 minute apart, as specified in the 
Time and Events Schedule and in Attachment 2, Method of Blood Pressure and Pulse Rate
Measurement.
At the screening visit, blood pressure will be measured in both arms. If there is a difference 
between arms of >10 mm Hg in either systolic or diastolic pressure, the arm with the higher 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
77
Approved, Date: 23 August 2018
pressure should be used to measure blood pressure and should be used for all subsequent blood 
pressure measurements during the study. If possible, if blood pressure is measured manually, it 
should be measured by the same individual, using the same equipment, at each clinic visit to 
reduce variability.
Physical Examination
Physical examinations will include a full review of body systems (vital signs, as above, head and 
neck, eyes, chest and lungs, breast, CV, extremities and back, abdomen, foot, and neurologic 
examination). Physical examination abnormalities will be collected if considered an adverse 
event by the investigator (recorded on adverse event eCRF).
Electrocardiogram (ECG)
A standard 12-lead ECG will be conducted at the Week -2 visit. Electrocardiograms will be 
conducted and read at the investigator site or affiliated facility. Significant findings that are 
present must be documented in the source and eCRF.
During the collection of ECGs, subjects should be in a quiet setting without distractions 
(eg, television, cell phones). Subjects should rest in a supine position for at least 5 minutes 
before ECG collection and should refrain from talking or moving arms or legs. If blood sampling 
or vital sign measurement is scheduled for the same time point as ECG recording, the procedures 
should be performed in the following order: ECG(s), vital signs, blood draw.
Pregnancy Testing
Serum pregnancy testing will be conducted at screening and at the Week 26/EOT visit for all 
women of childbearing potential (ie, unless they are permanently sterilized or unless there is a 
documented history of their postmenopausal status, as defined in Section 4.1, Inclusion Criteria).
Additional serum or urine pregnancy tests may be performed, as determined necessary by the 
investigator, or required by local regulation, to establish the absence of pregnancy at any time 
during the study. Study drug should be immediately interrupted based upon a positive urine 
pregnancy test, and permanently discontinued if confirmed by a serum pregnancy test.
9.11.
Survey on Experience with Self-injection of Study Drug
A survey designed to assess subject satisfaction with the experience of self-administering 
JNJ-64565111 or matching placebo or liraglutide will be given to a subset of English-speaking 
subjects in selected countries at Week 5. The PI should use their discretion to determine whether 
the subject is sufficiently fluent in English to take the survey.
10.
SUBJECT COMPLETION/DISCONTINUATION OF STUDY TREATMENT/ 
DISCONTINUATION FROM THE STUDY
10.1.
Completion
A subject will be considered to have completed the study if he or she has completed assessments 
through Week 26 of the treatment phase.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
78
Approved, Date: 23 August 2018
The EOT evaluation should be followed by a SAE follow-up visit approximately 5 weeks after 
the last dose of JNJ-64565111-treated or placebo-treated subjects and 4 weeks after the last dose 
of study drug for liraglutide-treated subjects, as described in Section 9.5, Post-treatment Phase 
(Follow-Up) Procedures and Evaluations.
10.2.
Discontinuation of Study Treatment/ Discontinuation from the Study
Discontinuation of Study Treatment
A subject's study treatment must be discontinued if:

Subject's eGFR is <45 mL/min/1.73 m2 (provided by the central laboratory)
Note: For subjects meeting the eGFR discontinuation criterion, a repeat determination 
should be performed within 1 week and study treatment discontinued if the repeat 
determination confirms that the value still meets the criterion.

Subject has a serum sodium of <125 mEq/L (<125 mmol/L), confirmed by repeat central 
laboratory measurement.
Note: For subjects meeting the sodium discontinuation criterion, a repeat determination of 
the full chemistry panel should be performed within 1 week and study treatment 
discontinued if the repeat determination confirms that the sodium value still meets the 
criterion (unless a reversible acute cause is identified [eg, severe vomiting, dehydration] in 
which case an additional repeat determination can be performed after resolution of the 
illness). If the sodium value is improving on repeat determination, but value is still 
<130 mEq/L (<130 mmol/L), an additional repeat measurement should be performed within 
1 to 2 weeks to monitor subject’s electrolytes.

Subject experiences an episode of vomiting assessed as “severe” lasting more than 24 hours 
and considered to be at least possibly related to study drug without any other potential cause 
(eg, viral gastroenteritis, food-borne illness).

The investigator believes that for safety reasons or tolerability reasons (eg, AE) it is in the 
best interest of the subject to discontinue study treatment

Subject has episodes of tachyarrhythmia (eg, atrial flutter, atrial fibrillation, ventricular 
tachycardia) or develops persistent resting pulse rate >100 bpm for which in the opinion of 
the investigator it is in the best interest of the subject to discontinue study treatment

Liver function test abnormalities occur that meet the criteria for permanent discontinuation 
of study drug as outlined in Attachment 6, Algorithm for Monitoring Abnormal Liver 
Function Tests

Acute pancreatitis, defined by the presence of at least 2 of the following 3 circumstances: 
characteristic abdominal pain, amylase and/or lipase >3X ULN or characteristic findings on 
CT/ MRI (see Attachment 7, Pancreatitis Monitoring and Withdrawal Criteria)

Serum calcitonin value 50 pg/mL (50 ng/L) after baseline, a repeat determination should 
be performed within 2 weeks and study treatment discontinued if the repeat determination 
confirms that the value still meets the criterion
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
79
Approved, Date: 23 August 2018

The subject becomes pregnant (study drug should be immediately interrupted based upon a 
positive urinary human chorionic gonadotropin (hCG), and permanently discontinued if 
confirmed by a serum -hCG)

Subject requiring metformin is not eligible to initiate treatment with metformin based upon 
any 1 of the following criteria: 

is a male subject with a serum creatinine 1.5 mg/dL (133 mol/L), or a female subject 
with a serum creatinine 1.4 mg/dL (124 mol/L), or

has any contraindication to the use of metformin (including eGFR; per local prescribing
information of the country of the investigational site)

Subject is on metformin, and after at least 2 weeks on the maximum tolerated dose (or 
maximum dose considered appropriate by the investigator) FPG is >180 mg/dL 
(10.0 mmol/L).

Initiation and planned continued use of prohibited therapy (see Section 8, Pre-study and 
Concomitant Therapy).

For liraglutide subject who cannot tolerate the 3.0 mg dose of liraglutide by Week 6

Subject is persistently in poor compliance with study treatment or procedures

The investigator formally unblinds the subject’s treatment allocation
Subjects who prematurely discontinue study drug will require an immediate EOT assessment 
(either on the day of study drug discontinuation or as soon as possible following study drug 
discontinuation) and the 4-week SAE follow-up.
Subjects that discontinue study drug early will continue in the study (off study drug) and will be 
assessed at the subsequent visit(s) as described in the Time and Events visit schedule, starting at 
the next scheduled visit from when study drug was permanently discontinued up to the final 
Week 26 visit. These off-treatment visits will include assessment and collection of:

SAEs

Specific AEs of interest (ie, MACE events, acute pancreatitis, and possible cases of thyroid 
neoplasm)

Vital signs (including body weight)

Concomitant medications
NOTE: Subjects randomly assigned to double-blind JNJ-64565111 or placebo only, will return 
to the investigational site approximately 5 weeks after the last dose of study drug for 
JNJ64565111/placebo-treated subjects and 4 weeks after the last dose of study drug for 
liraglutide-treated subjects to collect SAEs unless the subject has died, has been lost to follow-
up, or has withdrawn consent. For subjects randomly assigned to double-blind JNJ-64565111 or 
placebo, blood samples will also be collected for PK and immunogenicity anti-drug antibody 
(ADA) measurement.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
80
Approved, Date: 23 August 2018
If subjects that discontinued study drug early are unable to return to their site for the scheduled 
on-site study visit, an alternate contact visit should be conducted with the goal of collecting any
SAEs, MACE events (ie, CV death, nonfatal MI and nonfatal stroke), and AEs of thyroid 
neoplasm. Details regarding discussions via telephone, email, or other methods of contact must 
be properly documented on subject’s source record and eCRF, including date of contact, 
outcome and responses provided by the subjects. The site may consult subjects’ delegated 
contact(s) for the off-treatment follow-up if the site is unable to reach the subjects after multiple 
attempts.
Discontinuation from the Study
A subject will be discontinued from the study for any of the following reasons:

Death

Lost to follow-up

Withdrawal of consent
When a subject is discontinued from the study, the reason for early study discontinuation is to be 
documented in the eCRF and in the source document. Study drug assigned to a subject who 
discontinued from the study may not be assigned to another subject. Subjects who discontinued 
from the study will not be replaced.
Lost to Follow-up
If a subject is lost to follow-up, every reasonable effort must be made by the study-site personnel 
to contact the subject and determine the reason for discontinuation/withdrawal. This should 
include repeated telephone calls, certified letters, email requests, etc. To ensure access to 
follow-up subjects, the sites should obtain both primary and secondary telephone contact 
numbers (eg, home, work, and mobile phone numbers), as well as other contact information 
(eg, email addresses) before randomization. In addition, the site should emphasize the 
importance of follow-up information to the subject before randomization. The measures taken to 
follow-up must be documented.
Withdrawal of Consent
Withdrawal of consent from the study by a subject should be a very unusual occurrence in a 
clinical trial. The investigator should make every effort to maintain a good relationship with 
subjects to avoid this occurrence.
Withdrawal of consent in this trial may only be logged in the eCRF after a discussion between 
the investigator and the appropriate sponsor representative.
For subjects truly requesting withdrawal of consent, it is recommended that the subject withdraw 
consent in writing; if the subject or the subject’s representative refuses or is physically 
unavailable, the site should document the reason for the subject’s failure to withdraw consent in 
writing.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
81
Approved, Date: 23 August 2018
If a subject had previously withdrawn consent from the study but decides to retract that 
withdrawal, the subject will be reconsented. The investigator will be responsible for making all 
required notifications to the Institutional Review Board (IRB) or Ethical Committee.
Withdrawal from the Use of Archive Samples in Future Research
The subject may withdraw consent for use of archive samples for future exploratory research 
(refer to Section 16.2.5, Long-Term Retention of Samples for Additional Future Research). In 
such a case, samples will be destroyed and no further testing will take place after they are no 
longer needed for the clinical study. Details of the sample retention for research are presented in 
the main ICF.
11.
STATISTICAL METHODS
Statistical analysis will be done by the sponsor or under the authority of the sponsor. A general 
description of the statistical methods to be used to analyze the efficacy and safety data is outlined 
below. Specific details will be provided in the Statistical Analysis Plan (SAP).
11.1.
Analysis Sets
The intent-to-treat (ITT) analysis set will include all subjects who are randomly assigned to a 
treatment group and have a baseline measurement of body weight. The modified intent-to-treat 
(mITT) population includes all ITT subjects who had at least 1 post-baseline measurement of 
body weight within 7 days following a dose of study drug. The completers’ analysis set will 
consist of all mITT subjects who have completed 26 weeks of double-blind treatment 
(ie, documented in the eCRF by the investigators that the subject has completed participation in 
the study through the Week 26 visit). The safety analysis set will include all randomized subjects 
who have received at least one dose of study drug.
The primary efficacy analysis, to demonstrate the superiority of JNJ-64565111 compared to 
placebo on percentage reduction in body weight from baseline to Week 26, as well as all 
secondary efficacy analyses, will be based on the mITT analysis set and will include only those 
measurements taken up to and including the last dose of study drug plus 7 days. A secondary 
analysis of the primary and secondary efficacy endpoints will be based on the ITT population. 
This analysis will include all measurements. Sensitivity analyses based on the completers’ 
analysis set will also be performed for the primary endpoint.
Efficacy data will be analyzed according to the initial randomization assignment, regardless of 
the actual treatment received. Safety data will be analyzed according to the predominant 
treatment received, in the event that a subject receives a treatment other than that to which he/she 
is randomly assigned.
11.2.
Sample Size Determination
A total of 440 subjects will be randomized into this study with 55 subjects per group allocated to 
placebo and JNJ-64565111 5.0 mg group, 110 subjects per group allocated to each of other 
3 groups: JNJ-64565111 7.4 mg, JNJ-64565111 10.0 mg, open-label liraglutide 3.0 mg. Sample
size was determined based on assessing the primary hypothesis that the treatment with 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
82
Approved, Date: 23 August 2018
JNJ-64565111 for 26 weeks leads to greater percentage reduction in body weight compared with 
placebo as well as the exploratory hypothesis that the treatment with JNJ-64565111 leads to 
greater percentage reduction in body weight compared with open-label liraglutide.
Assuming a common standard deviation (SD) of 7% with respect to percent change in body 
weight at Week 26 and a 2-sided Type 1 error rate of 0.05, it is estimated that a sample size of 
55 randomized subjects per group will have approximately 90% power to detect a treatment 
difference of 4.4%, 110 randomized subjects per group will have approximately 90% power to 
detect a treatment differences of 3.1%.
11.3.
Efficacy Analyses
All hypotheses will be tested 2-sided at a 5% significance level unless otherwise specified.
Primary Efficacy Endpoint
The primary efficacy endpoint will be the percentage change in body weight between 
JNJ-64565111 and placebo from baseline to Week 26.
The primary efficacy endpoint will be analyzed based on the mITT analysis set using a mixed 
model for repeated measures (MMRM). The analysis will use the observed data through 
Week 26 while on treatment (up to the last dose of study drug plus 7 days) and will include the 
fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the 
fixed, continuous, covariates of baseline body weight and baseline-by-visit interaction. An 
unstructured covariance will be used to model the within-patient errors. The treatment 
comparisons will be made between each of the JNJ-64565111 treatment groups and placebo at 
Week 26 based on this model.
A secondary analysis of the primary endpoint will be based on the ITT population and will 
employ pattern mixture models using multiple imputation methods. Responses for subjects who 
discontinued from the study earlier than Week 26 will be imputed based on subjects who 
discontinued treatment prematurely but subsequently provided off-treatment measurements. The 
imputation will be done within groups defined by randomized treatment. Data will be analyzed 
using the same model as in the primary analysis. The treatment comparisons between each of the 
JNJ-64565111 treatment groups and placebo will be made at Week 26. Details of this approach 
will be provided in the SAP.
Finally, the primary efficacy endpoint will be analyzed based on the completers’ analysis set.
Additional analysis using a MCP-Mod (Multiple Comparison Procedure – Modeling) approach 
will be performed to explore the dose-response relationship.
The exploratory analysis of the assessments between the JNJ-64565111 treatment groups 
(7.4 mg and 10 mg) and liraglutide on the percentage change in body weight will also be
performed. The same analysis model used for the comparisons with placebo on the primary 
efficacy endpoint will be used for these assessments.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
83
Approved, Date: 23 August 2018
Secondary Efficacy Endpoints
Secondary efficacy analyses at Week 26 will include proportion of subjects with 5% weight 
loss, proportion of subjects with 10% weight loss, and the absolute change in body weight from 
baseline.
The continuous secondary endpoints (ie, absolute change in body weight from baseline) at 
Week 26 will be analyzed with an MMRM model similar to the primary efficacy endpoint in the 
mITT analysis set.
The categorical secondary efficacy endpoint (ie, proportion of subjects with 5% weight loss, 
proportion of subjects with 10% weight loss at Week 26) will be analyzed longitudinally using 
a generalized linear mixed model. The model will include the fixed, categorical effects of 
treatment, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of 
baseline weight, and baseline-by-visit interactions. An unstructured covariance will be used to 
model the within-patient errors. The odds ratio and associated p-value for the treatment 
comparison between each of the JNJ-64565111 treatment groups versus placebo at Week 26
based on this model will be provided.
A secondary analysis of the secondary endpoints will be based on the ITT population and will 
employ pattern mixture models using multiple imputation methods based on information from 
retrieved dropouts as described above. For the categorical endpoints, response status will be
determined from the imputed continuous response based on subjects who discontinued treatment 
prematurely but subsequently provided off-treatment measurements.
The exploratory analysis of the assessments between the JNJ-64565111 treatment groups 
(7.4 mg and 10 mg) and liraglutide on 5% weight loss responders and 10% weight loss 
responders and the absolute change in body weight at Week 26 will also be performed. The same 
analysis models used for the comparisons with placebo will be used for these assessments.
Multiplicity Adjustment
The type I error will be strongly controlled at =5% for each of primary endpoint and secondary 
endpoints. The Dunnett’s method will be used to adjust the multiplicity of the comparisons of 
each of the JNJ-64565111 doses versus placebo for the primary efficacy endpoint of the 
percentage change in body weight and the secondary endpoint of the absolute change in body 
weight. The Bonferroni correction will be used to adjust the multiplicity of the comparisons for
the secondary endpoints of the proportion of subjects with weight loss 5% and 10%.  
Exploratory Endpoints
Exploratory endpoints of interest include the following to Week 26:

the change in BMI from baseline

the change in waist circumference from baseline 

the change in fasting lipids (total cholesterol, LDL-C, HDL-C, triglycerides) from baseline
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
84
Approved, Date: 23 August 2018

the change in FPG from baseline

the change in fasting insulin from baseline 

the change in fasting C-peptide from baseline

the changes in HOMA-B and HOMA-IR from baseline

the change in SBP from baseline

the change in DBP from baseline

the change in pulse rate from baseline

the change in pulse-pressure product from baseline

in a subset of subjects participating in the 24-hour ABPM assessment, the changes from 
baseline in 24-hour SBP, DBP, pulse rate, and pulse-pressure product
Change from baseline in total cholesterol, LDL-C, HDL-C, triglycerides, fasting insulin, SBP, 
DBP, and pulse-pressure rate will be analyzed using a MMRM model similar to that used to 
analyze the primary efficacy endpoint. 
The exploratory PRO endpoints will be summarized descriptively at baseline and over time. 
These endpoints include:

IWQOL-Lite total, physical function, and self-esteem, sexual life, public distress, and work 
domain scores

Ease of Weight Management total scores

PAM total scores

In English-speaking subjects in selected countries, ERCQ domain scores and PROMIS SF 
8b total scores (Note: the PGIS and PGIC will be used to calculate responder definitions for 
the new instruments only and are not exploratory objectives.)

In English-speaking subjects in selected countries, to describe pre-trial goals and 
expectations as well as post-trial experiences qualitatively using the ACTT Pre-trial 
interviews and a modified STEP exit interview  
Summary qualitative findings from pre- and post-treatment interviews (ie, ACTT and STEP 
interviews, respectively) will also be provided.
11.4.
Pharmacokinetic Analyses
Population PK analysis of serum concentration-time and exposure-response relationship data of 
JNJ-64565111 may be performed using nonlinear mixed-effects modeling. Data may be 
combined with those of other selected studies to support a relevant structural model. Available 
baseline subject characteristics (demographics, laboratory variables, genotypes, race, etc.) will be 
tested as potential covariates affecting PK parameters. Details will be given in a population PK 
analysis plan and the results of the population PK analysis will be presented in a separate report. 
A snapshot date for PK samples to be analyzed will be defined, if required. Samples collected 
before this date will be analyzed for JNJ-64565111 and included in the population PK analysis. 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
85
Approved, Date: 23 August 2018
Samples collected after the snapshot date will be analyzed at a later date, and may be included in 
a population PK re-analysis when they become available after database lock.
Data will be listed for all subjects with available serum concentrations per treatment group. 
Subjects will be excluded from the PK analysis if their data do not allow for accurate assessment 
of the PK (eg, incomplete administration of the study drug; missing information of dosing and 
sampling times; concentration data not sufficient for PK parameter calculation).
All concentrations below the lowest quantifiable concentration or missing data will be labeled as 
such in the concentration database. All subjects and samples excluded from the analysis will be 
clearly documented in the study report.
For each treatment group, descriptive statistics, including sample size (n), mean, standard 
deviation (SD), percent coefficient of variation (%CV), geometric mean, geo CV%, median, 
minimum, and maximum will be calculated for serum concentrations at each time for
JNJ-64565111.
11.5.
Immunogenicity Analyses
The incidence of anti-JNJ-64565111 antibodies will be summarized for all subjects who receive 
at least 1 dose of JNJ-64565111 and have appropriate samples for detection of antibodies to 
JNJ-64565111.
A listing of subjects who are positive for antibodies to JNJ-64565111 will be provided. The 
maximum titers of antibodies to JNJ-64565111 will be summarized for subjects who are positive 
for antibodies to JNJ-64565111.
The incidence of neutralizing antibodies (NAbs) to JNJ-64565111 will be summarized for 
subjects who are positive for antibodies to JNJ-64565111 and have samples evaluable for NAbs 
to JNJ-64565111.
Other immunogenicity analyses may be performed to further characterize the immune responses 
that are generated.
11.6.
Safety Analyses
The evaluation of safety will be based on the incidence of AEs and changes in clinical laboratory 
test results and vital sign results (blood pressure, pulse rate). Summaries of AEs, clinical 
laboratory test results, and vital sign results will be provided by treatment group. 
Adverse Events
The terms used in the eCRFs by investigators to identify AEs will be coded using the Medical 
Dictionary for Regulatory Activities (MedDRA). All reported AEs with onset during the 
treatment phase (ie, treatment-emergent adverse events [TEAEs]) will be included in the 
analysis.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
86
Approved, Date: 23 August 2018
For each AE, the percentage of subjects who experience at least 1 occurrence of the given event 
will be summarized by treatment group. The percentage of subjects with specific TEAEs will be 
summarized by severity and relationship to study drug, as classified by the investigator, by 
treatment group. The dose-response relationship of dose levels on TEAE will be assessed, 
assuming that the incidence rates of TEAE will be monotonic with respect to dose levels. A 
listing for non-TEAEs will be provided.
Further analyses, to be described in the SAP for this study which will be finalized before the 
subject is randomized, will be conducted on the prespecified AEs for which additional 
information is collected from the investigators (see Section 9.10, Safety Evaluations), and on 
other AEs.
Clinical Laboratory Tests
Laboratory data will be summarized by type of laboratory test. Normal reference ranges will be 
provided. Criteria for markedly abnormal laboratory values will be prespecified in the SAP. The 
percentage of subjects with markedly abnormal results will be summarized for each laboratory 
analyte. Descriptive statistics will be reported for each laboratory analyte at baseline and at each 
scheduled time point and for change from baseline.
Vital Signs and Physical Examination
Descriptive statistics of pulse rate and sitting blood pressure (systolic and diastolic) values and 
changes from baseline will be summarized at each scheduled time point. The percentage of 
subjects with values beyond clinically important limits will be summarized.
Physical examination findings will not be summarized except when reported as an adverse event.
11.7.
Interim Analysis
An interim analysis will be performed when approximately 90% of subjects have either 
completed or discontinued prior to approximately 10 weeks of study drug treatment. The 
objective of this interim analysis is to identify active treatment groups, if any, associated with 
safety or tolerability issues and to facilitate planning of the Phase 3 program. 
An independent statistician and a programmer (who are not associated with the JNJ-64565111 
obesity development program) responsible for providing the interim analysis results, as well as 
members of the internal DMC, will be unblinded to the individual treatment assignments during 
the conduct of the study. The unblinded individual subject data and interim analysis results will 
not be shared with investigators, subjects, or the sponsor staff who are involved in the conduct of 
the study before the final database lock. Details of the interim analysis will be provided in the 
DMC SAP. 
12.
ADVERSE EVENT REPORTING
Timely, accurate, and complete reporting and analysis of safety information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
regulatory agencies worldwide. The sponsor has established Standard Operating Procedures in 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
87
Approved, Date: 23 August 2018
conformity with regulatory requirements worldwide to ensure appropriate reporting of safety 
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
For AEs of interest, investigators may be asked to provide more detailed information on
applicable supplemental forms or eCRFs. Adverse events of interest include MACE (ie, CV 
death, nonfatal MI and nonfatal stroke), hypotension-related AEs, pancreatic events (ie, AEs of 
pancreatitis, adverse event of serious or severe abdominal pain leading to suspicion of 
pancreatitis, and confirmed lipase or amylase elevations 3× ULN), calcitonin elevation, and 
thyroid neoplasm. If AEs of interest are identified in the future, guidance concerning the 
reporting of those events may be provided to investigators via appropriately-documented study 
communications.
12.1.
Definitions
12.1.1.
Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessarily 
have a causal relationship with the treatment. An adverse event can therefore be any unfavorable 
and unintended sign (including an abnormal finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational or non-investigational) product, whether or not 
related to that medicinal (investigational or non-investigational) product (Definition per 
International Conference on Harmonisation [ICH]).
This includes any occurrence that is new in onset or aggravated in severity or frequency from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory test 
abnormalities.
Note: The sponsor collects AEs starting with the signing of the ICF (refer to Section 12.3.1, All 
Adverse Events, for time of last adverse event recording).
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any untoward medical occurrence that at any dose:

Results in death

Is life-threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically might have caused death if it were more severe)

Requires inpatient hospitalization or prolongation of existing hospitalization

Results in persistent or significant disability/incapacity

Is a congenital anomaly/birth defect
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
88
Approved, Date: 23 August 2018

Is a suspected transmission of any infectious agent via a medicinal product

Is Medically Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above. 
These should usually be considered serious.
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An AE is considered unlisted if the nature or severity is not consistent with the applicable 
product reference safety information. For JNJ-64565111, the expectedness of an AE will be 
determined by whether or not it is listed in the Investigator's Brochure. For liraglutide, the 
expectedness of an AE will be determined by whether or not it is listed in the package insert.
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very likely by the definitions listed in Section 12.1.2, Attribution Definitions.
12.1.2.
Attribution Definitions
Not Related
An AE that is not related to the use of the drug.
Doubtful
An AE for which an alternative explanation is more likely, eg, concomitant drug(s), concomitant 
disease(s), or the relationship in time suggests that a causal relationship is unlikely.
Possible
An AE that might be due to the use of the drug. An alternative explanation, eg, concomitant 
drug(s), concomitant disease(s), is inconclusive. The relationship in time is reasonable; therefore, 
the causal relationship cannot be excluded.
Probable
An AE that might be due to the use of the drug. The relationship in time is suggestive 
(eg, confirmed by dechallenge). An alternative explanation is less likely, eg, concomitant 
drug(s), concomitant disease(s).
Very Likely
An AE that is listed as a possible adverse reaction and cannot be reasonably explained by an 
alternative explanation, eg, concomitant drug(s), concomitant disease(s). The relationship in time 
is very suggestive (eg, it is confirmed by dechallenge and rechallenge).
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
89
Approved, Date: 23 August 2018
12.1.3.
Severity Criteria
An assessment of severity grade will be made using the following general categorical 
descriptors:
Mild: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with everyday activities.
Moderate: Sufficient discomfort is present to cause interference with normal activity.
Severe: Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal everyday activities.
The investigator should use clinical judgment in assessing the severity of events not directly 
experienced by the subject (eg, laboratory abnormalities).
12.2.
Special Reporting Situations
Safety events of interest on a sponsor study drug that may require expedited reporting and/or 
safety evaluation include, but are not limited to:

Overdose of a sponsor study drug

Suspected abuse/misuse of a sponsor study drug

Accidental or occupational exposure to a sponsor study drug

Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study drug, eg, name confusion)

Exposure to a sponsor study drug from breastfeeding
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a SAE should be recorded on the Serious Adverse Event page of the eCRF.
12.3.
Procedures
12.3.1.
All Adverse Events
All AEs and special reporting situations, whether serious or non-serious, will be reported from 
the time a signed and dated ICF is obtained until completion of the subject's last study-related 
procedure, which may include contact for follow-up of safety. Serious adverse events, including 
those spontaneously reported to the investigator within 5 weeks after the last dose of 
JNJ64565111/placebo or 4 weeks after the last dose of liraglutide, must be reported using the 
Serious Adverse Event Form. Anticipated events will not be recorded and reported in this study 
as to allow full reporting of AEs from these studies without any special reporting exceptions for 
individual case safety reports (ICSRs) of AEs. The sponsor will evaluate any safety information 
that is spontaneously reported by an investigator beyond the time frame specified in the protocol.
All AEs, regardless of seriousness, severity, or presumed relationship to study drug, must be 
recorded using medical terminology in the source document and the eCRF. Whenever possible, 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
90
Approved, Date: 23 August 2018
diagnoses should be given when signs and symptoms are due to a common etiology (eg, cough, 
runny nose, sneezing, sore throat, and head congestion should be reported as "upper respiratory 
infection"). Investigators must record in the eCRF their opinion concerning the relationship of 
the AE to study therapy. All measures required for AE management must be recorded in the 
source document and reported according to sponsor instructions.
The sponsor assumes responsibility for appropriate reporting of AEs to the regulatory authorities. 
The sponsor will also report to the investigator (and the head of the investigational institute 
where required) all suspected unexpected serious adverse reactions (SUSARs). The investigator 
(or sponsor where required) must report SUSARs to the appropriate Independent Ethics 
Committee (IEC) /IRB that approved the protocol unless otherwise required and documented by 
the IEC/IRB. A SUSAR will be reported to regulatory authorities unblinded. Participating 
investigators and IEC/IRB will receive a blinded SUSAR summary, unless otherwise specified.
For all studies with an outpatient phase, including open-label studies, the subject must be 
provided with a "wallet (study) card" and instructed to carry this card with them for the duration 
of the study indicating the following:

Study number

Statement, in the local language(s), that the subject is participating in a clinical study

Investigator's name and 24-hour contact telephone number

Local sponsor's name and 24-hour contact telephone number (for medical staff only)

Site number

Subject number

Any other information that is required to do an emergency breaking of the blind
12.3.2.
Serious Adverse Events
All SAEs occurring during the study must be reported to the appropriate sponsor contact person 
by study-site personnel within 24 hours of their knowledge of the event.
Information regarding SAEs will be transmitted to the sponsor using the Serious Adverse Event 
Form and Safety Report Form of the CRF, which must be completed and reviewed by a 
physician from the study site, and transmitted to the sponsor within 24 hours. The initial and 
follow-up reports of a SAE should be transmitted electronically or by facsimile (fax).
All SAEs that have not resolved by the end of the study, or that have not resolved upon 
discontinuation of the subject's participation in the study, must be followed until any of the 
following occurs:

The event resolves

The event stabilizes

The event returns to baseline, if a baseline value/status is available
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
91
Approved, Date: 23 August 2018

The event can be attributed to agents other than the study drug or to factors unrelated to 
study conduct

It becomes unlikely that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow-up after demonstration 
of due diligence with follow-up efforts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a SAE. 
Any event requiring hospitalization (or prolongation of hospitalization) that occurs during the 
course of a subject's participation in a study must be reported as a SAE, except hospitalizations 
for the following:

Hospitalizations not intended to treat an acute illness or adverse event (eg, social reasons 
such as pending placement in long-term care facility)

Surgery or procedure planned before entry into the study (must be documented in the 
eCRF).
The cause of death of a subject in a study within 4 weeks of the last dose of study drug, whether 
or not the event is expected or associated with the study drug, is considered a SAE.
12.3.3.
Pregnancy
All initial reports of pregnancy in female subjects or partners of male subjects must be reported 
to the sponsor by the study-site personnel within 24 hours of their knowledge of the event using 
the appropriate pregnancy notification form. Abnormal pregnancy outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs
and must be reported using the Serious Adverse Event Form. Any subject who becomes pregnant 
during the study must discontinue further study treatment.
Follow-up information regarding the outcome of the pregnancy and any postnatal sequelae in the 
infant will be required.
12.4.
Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safety issues or questions regarding the study are listed in the Contact Information 
page(s), which will be provided as a separate document.
13.
PRODUCT QUALITY COMPLAINT HANDLING
A product quality complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity, quality, 
durability, or reliability of a product, including its labeling or package integrity. A PQC may have 
an impact on the safety and efficacy of the product. Timely, accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor, and are mandated by regulatory agencies worldwide. The sponsor has 
established procedures in conformity with regulatory requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
92
Approved, Date: 23 August 2018
13.1.
Procedures
All initial PQCs must be reported to the sponsor by the study-site personnel within 24 hours after 
being made aware of the event.
If the defect is combined with a SAE, the study-site personnel must report the PQC to the 
sponsor according to the serious adverse event reporting timelines (refer to Section 12.3.2, 
Serious Adverse Events). Product complaints defined above for devices that are approved 
marketed devices or commercially available medical devices will be directed to the specific 
product’s manufacturer per the manufacturer’s guidelines.
If the product quality issue relates to the safety injector, the device should be retained in the 
returns sharp container (also referred to as the evidence tube) provided to the subject. The subject 
is to return the sealed returns sharp container containing the safety injector to the site and the site 
is to ship it as directed by the sponsor for investigation.
If the product quality issue relates to the solution for injection and not to the device, the safety 
injector device should be retained in the returns sharp container (also referred to as the evidence 
tube) provided to the subject. The subject is to return the sealed returns sharp container 
containing the safety injector to the site. The site should maintain the safety injector for further 
investigation if requested by the sponsor and the site is to ship it as directed by the sponsor for 
investigation.
13.2.
Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality issues are listed in the Contact Information page(s), which will be 
provided as a separate document.
14.
STUDY DRUG INFORMATION
14.1.
Physical Description of Study Drugs
JNJ-64565111 and Matching Placebo
JNJ-64565111 is a colorless solution, and is essentially free of visible particulate matter. 
JNJ-64565111 is supplied in pre-filled safety injectors containing nominal volumes of 0.25, 0.37,
or 0.5 mL of 20.0 mg/mL JNJ-64565111 solution (5.0, 7.4, and 10.0 mg, respectively). Placebo 
for JNJ-64565111 will be supplied as pre-filled safety injectors containing matching volumes 
(ie, 0.25, 0.37, or 0.5 mL) of solution for SC injection. The pre-filled safety injector is intended 
for SC administration and consists of a syringe, a needle safety device, and grip accessory. Study 
drug will be manufactured and provided under the responsibility of the sponsor. Refer to the 
Investigator's Brochure for a list of excipients.
Liraglutide
Commercially available supplies of liraglutide will be dispensed to subjects randomly assigned to 
the open-label liraglutide arm of the study. Liraglutide is formulated as a clear, colorless solution. 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
93
Approved, Date: 23 August 2018
Each 1.0 mL of liraglutide solution contains 6.0 mg of liraglutide and the following inactive 
ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14.0 mg; phenol, 5.5 mg; 
and water for injection. Each pre-filled pen contains 3.0 mL solution equivalent to 18.0 mg 
liraglutide (free-base, anhydrous).
14.2.
Packaging
JNJ-64565111 and Matching Placebo
JNJ-64565111 and matching placebo will be packaged in individual kits. Each kit will consist of 
one pre-filled safety injector consisting of a syringe, a needle safety device, and grip accessory.
Liraglutide
Commercially available supplies of liraglutide will be dispensed to subjects randomly assigned to 
the open-label liraglutide arm of the study. Liraglutide is supplied as multi-dose pens, each 
pre-filled with 18.0 mg liraglutide/ 3.0 mL solution. Liraglutide will be repackaged in individual 
kits. 
14.3.
Labeling
Study drug labels will contain information to meet the applicable regulatory requirements.
14.4.
Preparation, Handling, and Storage
All study drug must be stored at controlled temperatures ranging from 36 to 46°F (2 to 8°C) and 
protected from light and heat.
Study drug must not be utilized after the expiry date printed on the label. JNJ-64565111 or 
matching placebo does not contain preservatives; therefore, any unused portion remaining in the 
safety injector must be discarded.
Refer to the study-site investigational product and procedures manual for additional guidance on 
study drug preparation, handling, administration and storage.
Liraglutide
Store new, unused liraglutide pens in the refrigerator at 36°F to 46°F (2°C to 8°C). Store the pen in 
use for 30 days at 59ºF to 86ºF (15ºC to 30ºC) or in a refrigerator at 36°F to 46°F (2°C to 8°C).
14.5.
Drug Accountability
The investigator is responsible for ensuring that all study drug received at the site is inventoried 
and accounted for throughout the study. The dispensing of study drug to the subject, and the 
return of study drug from the subject (if applicable), must be documented on the drug 
accountability form. 
JNJ-64565111/matching placebo-treated subjects should be instructed to return the following:

unused safety injectors
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
94
Approved, Date: 23 August 2018

empty study drug cartons 

study drug diary 
Liraglutide-treated subjects should be instructed to return the following:

unused pens

used and partially used pens (without the needle)

empty study drug cartons 

study drug diary
All study drug will be stored and disposed of according to the sponsor's instructions. Study-site 
personnel must not combine contents of the study drug containers.
Study drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study site in a limited-access area or in a locked cabinet under appropriate 
environmental conditions. Unused study drug returned by the subject, must be available for 
verification by the sponsor's study-site monitor during on-site monitoring visits. The return to the 
sponsor of unused study drug for destruction, will be documented on the drug return form. When 
the study site is an authorized destruction unit and study drug supplies are destroyed on-site, this 
must also be documented on the drug return form.
Potentially hazardous materials such as used needles from liraglutide pens or used safety 
injectors containing residual liquids, should be disposed of immediately in a safe manner and 
therefore will not be retained for drug accountability purposes.
Study drug should be dispensed under the supervision of the investigator or a qualified member 
of the study-site personnel, or by a hospital/clinic pharmacist. Study drug will be supplied only 
to subjects participating in the study. Returned unused study drug must not be dispensed again, 
even to the same subject. Study drug may not be relabeled or reassigned for use by other 
subjects. The investigator agrees neither to dispense the study drug from, nor store it at, any site 
other than the study sites agreed upon with the sponsor.
15.
STUDY-SPECIFIC MATERIALS
The investigator will be provided with the following supplies:

Recruitment and retention tools

IWRS Manual and worksheets

Template ICFs

eCRF completion guidelines

Materials to promote healthy dietary and exercise habits

Study drug diaries (ie, JNJ64565111/Placebo diary, liraglutide diary)

IWQOL-Lite questionnaire
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
95
Approved, Date: 23 August 2018

single item Ease of Weight Management

PAM

7-day ERCQ diary (selected sites)

PROMIS SF 8b questionnaire (selected sites)

PGIS questionnaire (selected sites)

PGIC questionnaire (selected sites)

Survey on Subject Satisfaction with Self-injection (selected sites)

ACTT Pre-trial interviews; Modified STEP exit interviews, including training materials, 
recording devices, data collection forms for hand written notes, materials for mailing to 
vendor for qualitative analysis

Laboratory operations manual, requisition forms, sampling supplies, and equipment, if 
necessary

Computer, if the study site is assessed to require a laptop computer to enter eCRF data for 
the study

At selected sites, supplies for conducting 24-hour ABPM procedure

ABPM diary (selected sites)

PRO Completion Guideline
16.
ETHICAL ASPECTS
16.1.
Study-Specific Design Considerations
This Phase 2b dose-ranging study is being conducted to assess the safety and efficacy of 
JNJ-64565111 over a 26-week period in non-diabetic obese subjects and to provide information 
to select JNJ-64565111 dose(s) to be assessed in Phase 3 studies.
The primary ethical concerns of this study are that the safety profile of JNJ-64565111 is not fully 
established and therefore subjects may be placing themselves at an increased risk of unexpected 
events by participating in this study. Although definitive information from studies in humans is 
not yet available, safety information from the Phase 1 studies indicates that JNJ-64565111 is 
generally well tolerated and no safety concerns precluding further clinical development have 
been identified.
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study, subjects will be given any new information that may affect their decision to continue 
participation. They will be told that their consent to participate in the study is voluntary and may 
be withdrawn at any time with no reason given and without penalty or loss of benefits to which 
they would otherwise be entitled. Only subjects who are fully able to understand the risks, 
benefits, and potential AEs of the study, and provide their consent voluntarily will be enrolled. 
The investigator will be provided with detailed information about the study to ensure that the 
study research staff is fully informed.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
96
Approved, Date: 23 August 2018
Based on available data from preclinical and clinical JNJ-64565111 findings and known data 
from other GLP-1 agonists, potential adverse human effects may occur. These include increase 
in pulse rate, GI intolerability, pancreatitis, and elevation in calcitonin. Also, occasional 
increases in FPG and decrease in plasma sodium levels have been observed in subjects with 
T2DM treated with JNJ-64565111. In addition to the routine assessment of AEs, the following 
safety measures are included to monitor and address these potential effects: subjects with 
personal or family histories of MTC or MEN2A, active or chronic pancreatitis, and hepatic 
disease will be excluded from participating in the study, and those enrolled will undergo periodic
monitoring of calcitonin, lipase/amylase, and liver enzymes. Specific monitoring algorithms are 
provided in case of elevations that warrant further follow-up and investigations in subjects 
experiencing prespecified elevation of these parameters.
In subjects with T2DM treated with metformin, the addition of JNJ-64565111 led to inconsistent 
changes in glycemic endpoints after 4-weeks of treatment, with some subjects experiencing 
increase in FPG and 24-hour mean glucose. While glucagon and GLP-1 agonism have 
counteracting effects on glucose control, dual agonism of GLP-1 and GCGR generally leads to 
improved glucose control in subjects with T2DM as the effects of GLP-1 to increase insulin
secretion appear to overcome the effects of glucagon agonism to increase endogenous glucose 
production. However, it is possible that some subjects may be more sensitive to the glucagon 
agonism induced by JNJ-64565111 than to the GLP-1 agonism, and these subjects may have 
plasma glucose concentrations increased by treatment with JNJ-64565111. As subjects with 
severe obesity, such as those enrolled in this study, are at risk to develop prediabetes and 
diabetes over time, the glycemic status of all subjects enrolled will be monitored throughout the 
duration of study, and subjects with persistent glycemic elevation will be required to initiate 
treatment with metformin. Furthermore, in Study 64565111EDI1002 two subjects were reported 
to have AEs of hyponatremia in the context of dehydration or following episodes of vomiting. 
Few other subjects had mild reduction in plasma sodium levels not considered to be clinical 
meaningful by the reporting investigators. It is not known whether changes in plasma sodium are 
related to concomitant GI AEs (such as vomiting) or to other mechanisms. In the present study, 
electrolytes will be monitored frequently, and subjects with low sodium levels will not be 
allowed to participate in the study. In addition, those who develop persistent reductions in 
sodium levels will be permanently discontinued from study drug. 
This study design includes the use of a placebo group, which is of key importance in helping to 
characterize both the safety and efficacy of JNJ-64565111. A study without a placebo arm 
cannot properly determine the weight-lowering efficacy of a weight-management medication. 
Similarly, given background occurrence of AEs in this population in which comorbidities are 
common, without a placebo, it is not possible to precisely define the safety and tolerability 
profile of a new treatment for obesity. Given the continuing need for new medications to 
improve the care of patients with obesity, providing a thorough evaluation of a medication such 
as JNJ-64565111 that may provide good efficacy and other useful benefits, is important. In 
considering the balance of risk to subjects allocated to the placebo group it is important to note 
that while obesity is associated with cardiovascular morbidity and mortality it is commonly not 
treated pharmacologically. Liraglutide (Saxenda®) is included as an active comparator as it is the 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
97
Approved, Date: 23 August 2018
only GLP-1 receptor agonist approved for the treatment of obesity. As JNJ-64565111 and 
liraglutide both act on the GLP-1 receptor but JNJ-64565111 also acts on the GCGR the 
comparison of the efficacy, tolerability and safety is an important assessment in this study. The 
liraglutide arm of the study is open-label because the product is purchased commercially and has
a characteristic injection device that would not allow masking. As described above, all subjects 
including those on placebo will receive diet and exercise counseling from a trained counselor.
Women of childbearing potential enrolled in the study and who are sexually active must agree to 
use a highly effective birth control method (failure rate of <1% per year when used consistently 
and correctly) throughout the study. Serum pregnancy testing will be performed on all women of 
childbearing potential at screening and EOT, in addition to selected time points during the study 
at the discretion of the investigator. Women must also agree not to donate eggs (ova, oocytes) for 
the purposes of assisted reproduction during the study or for a period of at least 4 weeks after the 
last dose of study drug.
Clinical and laboratory evaluations will be performed throughout the study (according to the 
Time and Events Schedule) to monitor the safety of subjects. Subjects who discontinue early 
from the study will have a post-study visit, to allow collection of information on SAEs, and 
support a complete assessment of key safety events in the intact randomized study population.
The approximate maximum blood volume that would be collected if a subject were to complete 
the 4-week follow-up visit after the Week 26 /EOT visit will be approximately 176.0 mL in 
subjects randomly assigned to JNJ-64565111 or matching placebo, and approximately 137.5 mL
in subjects randomly assigned to the open-label liraglutide treatment arm. The total blood volume 
to be collected is considered to be an acceptable amount of blood to be collected over this time 
period from the population in this study; it is less than the amount of blood in a standard blood 
donation (ie, <500 mL over 60 days) (American Red Cross).
16.2.
Regulatory Ethics Compliance
16.2.1.
Investigator Responsibilities
The investigator is responsible for ensuring that the study is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory and 
country-specific requirements.
Good Clinical Practice is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety, and well-being of 
study subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and that the study data are credible.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
98
Approved, Date: 23 August 2018
16.2.2.
Independent Ethics Committee or Institutional Review Board
Before the start of the study, the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copies of the following documents (as required by local 
regulations):

Final protocol and, if applicable, amendments

Sponsor-approved ICF (and any other written materials to be provided to the subjects)

Investigator's Brochure (or equivalent information) and amendments/addenda

Sponsor-approved subject recruiting materials

Information on compensation for study-related injuries or payment to subjects for 
participation in the study, if applicable

Investigator's curriculum vitae or equivalent information (unless not required, as 
documented by the IEC/IRB)

Information regarding funding, name of the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for subjects

Any other documents that the IEC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/IRB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct, unless required locally), the ICF, applicable 
recruiting materials, and subject compensation programs, and the sponsor has received a copy of 
this approval. This approval letter must be dated and must clearly identify the IEC/IRB and the 
documents being approved.
Approval for the collection of optional samples for research and for the corresponding ICF must 
be obtained from the IEC/IRB. Approval for the protocol can be obtained independent of this 
optional research component.
During the study, the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:

Protocol amendments (excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct)

Revision(s) to ICF and any other written materials to be provided to subjects

If applicable, new or revised subject recruiting materials approved by the sponsor

Revisions to compensation for study-related injuries or payment to subjects for participation 
in the study, if applicable

New edition(s) of the Investigator's Brochure and amendments/addenda

Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annually)

Reports of AEs that are serious, unlisted/unexpected, and associated with the study drug
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
99
Approved, Date: 23 August 2018

New information that may adversely affect the safety of the subjects or the conduct of the 
study

Deviations from or changes to the protocol to eliminate immediate hazards to the subjects

Report of deaths of subjects under the investigator's care

Notification if a new investigator is responsible for the study at the site

Development Safety Update Report and Line Listings, where applicable

Any other requirements of the IEC/IRB
For all protocol amendments (excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct), the amendment and applicable ICF revisions 
must be submitted promptly to the IEC/IRB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/IRB will be asked to review and reapprove this study, where 
required.
At the end of the study, the investigator (or sponsor where required) will notify the IEC/IRB 
about the study completion (if applicable, the notification will be submitted through the head of 
investigational institution).
16.2.3.
Informed Consent
Each subject must give written consent according to local requirements after the nature of the 
study has been fully explained. The ICF(s) must be signed before performance of any study-
related activity. The ICF(s) that is/are used must be approved by both the sponsor and by the 
reviewing IEC/IRB and be in a language that the subject can read and understand. The informed 
consent should be in accordance with principles that originated in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicable regulatory requirements, and sponsor policy.
Before enrollment in the study, the investigator or an authorized member of the study-site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study, and any discomfort participation in the study may entail. 
Subjects will be informed that their participation is voluntary and that they may withdraw 
consent to participate at any time. They will be informed that choosing not to participate will not 
affect the care the subject will receive for the treatment of his or her disease. Finally, they will be 
told that the investigator will maintain a subject identification register for the purposes of long-
term follow-up if needed and that their records may be accessed by health authorities and 
authorized sponsor personnel without violating the confidentiality of the subject, to the extent 
permitted by the applicable law(s) or regulations. By signing the ICF the subject is authorizing 
such access and agrees to allow his or her study physician to recontact the subject for the purpose 
of obtaining consent for additional safety evaluations, if needed.
The subject will be given sufficient time to read the ICF and the opportunity to ask questions. 
After this explanation and before entry into the study, consent should be appropriately recorded 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
100
Approved, Date: 23 August 2018
by means of the subject's personally dated signature. After having obtained the consent, a copy of 
the ICF must be given to the subject.
If the subject is unable to read or write, an impartial witness should be present for the entire 
informed consent process (which includes reading and explaining all written information) and 
should personally date and sign the ICF after the oral consent of the subject is obtained.
16.2.4.
Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary to fulfill the objectives of the study.
These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identity of subjects confidential.
The informed consent obtained from the subject (or his or her legally acceptable representative) 
includes explicit consent for the processing of personal data and for the investigator/institution to 
allow direct access to his or her original medical records (source data/documents) for study-
related monitoring, audit, IEC/IRB review, and regulatory inspection. This consent also 
addresses the transfer of the data to other entities and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study, and the applicable laws and regulations.
Exploratory DNA, biomarker, PK, and immunogenicity research is not conducted under 
standards appropriate for the return of data to subjects. In addition, the sponsor cannot make 
decisions as to the significance of any findings resulting from exploratory research. Therefore, 
exploratory research data will not be returned to subjects or investigators, unless required by law
or local regulations. Privacy and confidentiality of data generated in the future on stored samples 
will be protected by the same standards applicable to all other clinical data.
16.2.5.
Long-Term Retention of Samples for Additional Future Research
Samples collected in this study for archive samples for future exploratory research may be stored 
for up to 15 years (or according to local regulations) for additional research. Samples will only 
be used to understand JNJ-64565111, to understand obesity, to understand differential drug 
responders, and to develop tests/assays related JNJ-64565111 and obesity. The research may 
begin at any time during the study or the post-study storage period.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
101
Approved, Date: 23 August 2018
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research.
16.2.6.
Country Selection
This study will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access to the developed product if the need for the product persists, unless explicitly 
addressed as a specific
ethical consideration in Section 16.1, Study-Specific Design 
Considerations.
17.
ADMINISTRATIVE REQUIREMENTS
17.1.
Protocol Amendments
Neither the investigator nor the sponsor will modify this protocol without a formal amendment 
by the sponsor. All protocol amendments must be issued by the sponsor, and signed and dated by 
the investigator. Protocol amendments must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly submitted to the IEC/IRB and relevant competent authority. 
Documentation of amendment approval by the investigator and IEC/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study, the 
IEC/IRB (where required) only needs to be notified.
During the course of the study, in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representative listed in the Contact Information page(s), which will be provided as a separate
document. Except in emergency situations, this contact should be made before implementing any 
departure from the protocol. In all cases, contact with the sponsor must be made as soon as 
possible to discuss the situation and agree on an appropriate course of action. The data recorded 
in the eCRF and source documents will reflect any departure from the protocol, and the source 
documents will describe this departure and the circumstances requiring it.
17.2.
Regulatory Documentation
17.2.1.
Regulatory Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory authorities 
in each respective country, if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2.
Required Pre-study Documentation
The following documents must be provided to the sponsor before shipment of study drug to the 
study site:

Protocol and amendment(s), if any, signed and dated by the PI 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
102
Approved, Date: 23 August 2018

A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly identify the specific 
protocol by title and number and must be signed (or sealed, where appropriate per local 
regulations) by the chairman or authorized designee

Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, 
from the IEC/IRB, a general statement may be substituted for this list. If an investigator or a 
member of the study-site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opinion of the study

Regulatory authority approval or notification, if applicable

Signed and dated statement of investigator (eg, Form FDA 1572), if applicable

Documentation of investigator qualifications (eg, curriculum vitae)

Completed investigator financial disclosure form from the PI, where required

Signed and dated Clinical Trial Agreement, which includes the financial agreement

Any other documentation required by local regulations
The following documents must be provided to the sponsor before enrollment of the first subject:

Completed investigator financial disclosure forms from all subinvestigators

Documentation of subinvestigator qualifications (eg, curriculum vitae)

Name and address of any local laboratory conducting tests for the study, and a dated copy of 
current laboratory normal ranges for these tests, if applicable

Local 
laboratory 
documentation 
demonstrating 
competence 
and 
test 
reliability 
(eg, accreditation/license), if applicable
17.3.
Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study. This document will be reviewed by the 
sponsor study-site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study file. To ensure subject confidentiality, no copy will be made. All 
reports and communications relating to the study will identify subjects by subject identification
and date of birth. In cases where the subject is not randomized into the study, the date seen and 
date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility for inclusion in the study.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
103
Approved, Date: 23 August 2018
17.4.
Source Documentation
At a minimum, source documents consistent in the type and level of detail with that commonly 
recorded at the study site as a basis for standard medical care must be available for the following: 
subject identification, eligibility, and study identification; study discussion and date of signed 
informed consent; dates of visits; results of safety and efficacy parameters as required by the 
protocol; record of all AEs
and follow-up of AEs; concomitant medication; drug 
receipt/dispensing/return records; study drug administration information; and date of study 
completion and reason for early discontinuation of study drug or withdrawal from the study, if 
applicable.
The author of an entry in the source documents should be identifiable.
Specific details required as source data for the study and source data collection methods will be 
reviewed with the investigator before the study and will be described in the monitoring 
guidelines (or other equivalent document).
An electronic source system may be utilized, which contains data traditionally maintained in a 
hospital or clinic record to document medical care (eg, electronic source documents) as well as 
the clinical study-specific data fields as determined by the protocol. This data is electronically 
extracted for use by the sponsor. If the electronic source system is utilized, references made to 
the CRF in the protocol include the electronic source system but information collected through 
the electronic source system may not be limited to that found in the CRF. Data in this system 
may be considered source documentation.
17.5.
Case Report Form Completion
Case report forms are prepared and provided by the sponsor for each subject in electronic format.
All data relating to the study must be recorded in eCRF. All eCRF entries, corrections, and 
alterations must be made by the investigator or authorized study-site personnel. The investigator 
must verify that all data entries in the eCRF are accurate and correct.
The study data will be transcribed by study-site personnel from the source documents onto an 
eCRF, if applicable. Study-specific data will be transmitted in a secure manner to the sponsor.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject's source documents. Data must be entered into
eCRF in English. The eCRF must be completed as soon as possible after a subject visit and the 
forms should be available for review at the next scheduled monitoring visit.
If necessary, queries will be generated in the electronic data capture (eDC) tool. If corrections to 
an eCRF are needed after the initial entry into the eCRF, this can be done in either of the 
following ways:

Investigator and study-site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto-query (generated by the eDC tool).
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
104
Approved, Date: 23 August 2018

Sponsor or sponsor delegate can generate a query for resolution by the investigator and 
study-site personnel.
17.6.
Data Quality Assurance/Quality Control
Steps to be taken to ensure the accuracy and reliability of data include the selection of qualified 
investigators and appropriate study sites, review of protocol procedures with the investigator and 
study-site personnel before the study, and periodic monitoring visits by the sponsor, and direct 
transmission of clinical laboratory data from a central laboratory into the sponsor's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples.
Guidelines for eCRF completion will be provided and reviewed with study-site personnel before 
the start of the study.
The sponsor will review eCRF for accuracy and completeness during on-site monitoring visits 
and after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study database they will be verified for 
accuracy and consistency with the data sources.
17.7.
Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF 
and all source documents that support the data collected from each subject, as well as all study 
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study documents as specified by the applicable regulatory requirement(s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2 years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by the applicable regulatory requirements or by an 
agreement with the sponsor. It is the responsibility of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will 
accept the responsibility. The sponsor must be notified in writing of the name and address of the 
new custodian. Under no circumstance shall the investigator relocate or dispose of any study 
documents before having obtained written approval from the sponsor.
If it becomes necessary for the sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the investigator/institution must permit access to such 
reports.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
105
Approved, Date: 23 August 2018
17.8.
Monitoring
The sponsor will use a combination of monitoring techniques (central, remote, or on-site 
monitoring) to monitor this study.
The sponsor will perform on-site monitoring visits as frequently as necessary. The monitor will 
record dates of the visits in a study-site visit log that will be kept at the study-site. The first 
post-initiation visit will be made as soon as possible after enrollment has begun. At these visits, 
the monitor will compare data entered into the
eCRF with the source documents
(eg, hospital/clinic/physician’s office medical records); a sample may be reviewed. The nature 
and location of all source documents will be identified to ensure that all sources of original data 
required to complete the eCRF are known to the sponsor and study-site personnel and are 
accessible for verification by the sponsor study-site contact. If electronic records are maintained 
at the study site, the method of verification must be discussed with the study-site personnel.
Direct access to source documents (medical records) must be allowed for the purpose of 
verifying that the recorded data are consistent with the original source data. Findings from this 
review will be discussed with the study-site personnel. The sponsor expects that, during 
monitoring visits, the relevant study-site personnel will be available, the source documents will 
be accessible, and a suitable environment will be provided for review of study-related 
documents. The monitor will meet with the investigator on a regular basis during the study to 
provide feedback on the study conduct.
17.9.
Study Completion/Termination
17.9.1.
Study Completion/End of Study
The study is considered completed with the last visit/contact for the last subject participating in 
the study. The final data from the study site will be sent to the sponsor (or designee) after 
completion of the final subject visit/contact at that study site, 3 days after the subject’s 
visit/contact (query generation and resolution excluded), or in the time frame specified in the 
Clinical Trial Agreement.
17.9.2.
Study Termination
The sponsor reserves the right to close the study site or terminate the study at any time for any 
reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A
study site is considered closed when all required documents and study supplies have been 
collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to:

Failure of the investigator to comply with the protocol, the requirements of the IEC/IRB or 
local health authorities, the sponsor's procedures, or GCP guidelines
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
106
Approved, Date: 23 August 2018

Inadequate recruitment of subjects by the investigator

Discontinuation of further study drug development
17.10. On-Site Audits
Representatives of the sponsor's clinical quality assurance department may visit the study site at 
any time during or after completion of the study to conduct an audit of the study in compliance 
with regulatory guidelines and company policy. These audits will require access to all study 
records, including source documents, for inspection. Subject privacy must, however, be 
respected. The investigator and study-site personnel are responsible for being present and 
available for consultation during routinely scheduled study-site audit visits conducted by the 
sponsor or its designees.
Similar auditing procedures may also be conducted by agents of any regulatory body, either as 
part of a national GCP compliance program or to review the results of this study in support of a 
regulatory submission. The investigator should immediately notify the sponsor if he or she has
been contacted by a regulatory agency concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding JNJ-64565111 or the 
sponsor's operations (eg, patent application, formulas, manufacturing processes, basic scientific 
data, prior clinical data, formulation information) supplied by the sponsor to the investigator and 
not previously published, and any data, including pharmacogenomic or exploratory biomarker
research data, generated as a result of this study, are considered confidential and remain the sole 
property of the sponsor. The investigator agrees to maintain this information in confidence and 
use this information only to accomplish this study, and will not use it for other purposes without 
the sponsor's prior written consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of JNJ-64565111, and thus may be 
disclosed as required to other clinical investigators or regulatory agencies. To permit the 
information derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor with all data obtained in the study.
The results of the study will be reported in a Clinical Study Report generated by the sponsor and 
will contain data from all study sites that participated in the study as per protocol. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study will be used to determine a coordinating investigator. Study subject identifiers will not be 
used in publication of results. Any work created in connection with performance of the study and 
contained in the data that can benefit from copyright protection (except any publication by the 
investigator as provided for below) shall be the property of the sponsor as author and owner of 
copyright in such work.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
107
Approved, Date: 23 August 2018
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study-site-specific data after the primary data are published. If an investigator wishes to publish 
information from the study, a copy of the manuscript must be provided to the sponsor for review 
at least 60 days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in 
writing, the investigator will withhold such publication for up to an additional 60 days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity or 
regulatory compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. For multicenter study designs and sub-study approaches, secondary results 
generally should not be published before the primary endpoints of a study have been published. 
Similarly, investigators will recognize the integrity of a multicenter study by not submitting for 
publication data derived from the individual study site until the combined results from the 
completed study have been submitted for publication, within 12 months of the availability of the 
final data (tables, listings, graphs), or the sponsor confirms there will be no multicenter study 
publication. Authorship of publications resulting from this study will be based on the guidelines 
on authorship, such as those described in the Uniform Requirements for Manuscripts Submitted 
to Biomedical Journals, which state that the named authors must have made a significant 
contribution to the design of the study or analysis and interpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as 
required by law.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
108
Approved, Date: 23 August 2018
REFERENCES
1.
Adipex-P® [package insert] Horsham, PA. Teva Select Brands, 2014.
2.
American Red Cross. Blood Facts and Statistics. http://www.redcrossblood.org/learn-about-blood/blood-facts-
and-statistics Last accessed on 6 June 2016.
3.
Belviq® [package insert] Zofingen, Switzerland. Arena Pharmaceuticals GmbH, 2012.
4.
Chandarana K, Batterham RL. Shedding pounds after going under the knife: metabolic insights from cutting 
the gut. Nat Med. 2012;18(5):668-669.
5.
Clinical Study Protocol 64565111EDI1002. A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose 
Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in 
Men and Women with Type 2 Diabetes Mellitus. Janssen Research & Development (12 May 2017).
6.
Cohen MA, Ellis SM, Le Roux CW, et. al. Oxyntomodulin suppresses appetite and reduces food intake in 
humans. J Clin Endocrinol Metab. 2003;88(10):4696-4701.
7.
Contrave® [package insert]; Deerfield, IL; Takeda Pharmaceuticals America, Inc. 2014
8.
Coon CD, Cappeller, JC. Interpreting change in scores on patient-reported outcome instruments. Therapeutic 
innovation & regulatory Science. 2016;50(1):22-29. 
9.
Day, JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. 
Nat Chem Biol. 2009;5:749-757.
10.
Field, BC, Wren AM, Peters V, et al. PYY3-36 and oxyntomodulin can be additive in their effect on food 
intake in overweight and obese humans. Diabetes. 2010;59:1635-1639.
11.
FDA. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to 
Support Labeling Claims. December 2009. Available at: 
https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf. Accessed 18 December 2017.
12.
Gomez-Arbelaez D, Crujeiras AB, Castro AI, et al. Acid-base safety during the course of a very low-calorie-
ketogenic diet. Endocrine. 2017;58(1):81-90.
13.
Guidance for Industry Developing Products for Weight Management. U.S. Department of Health and Human 
Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). February 2007.
14.
Guideline on clinical investigation of medicinal products used in weight management. 
EMA/CHMP/311805/2014. 23 June 2016.
15.
Hales CM (2017), Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity Among Adults and Youth: United 
States, 2015-2016. https://www.cdc.gov/nchs/data/databriefs/db288.pdf. Accessed 06 Dec 2017.
16.
Hauber AB, Mohamed AF, Johnson FR, Oyelowo O, Curtis BH, Coon C. Estimating importance weights for 
the IWQOL-Lite using conjoint analysis. Qual Life Res. 2010;19(5):701-709.
17.
Hibbard JH, Mahoney, ER, Stockard J, and Tusler M. Development and testing of a short form of the patient 
activation measure. Health Services Research. 2005;40:1918–1930.
18.
HealthMeasures website. Available at: http://www.healthmeasures.net/explore-measurement-systems/promis. 
Accessed: 26 January 2018.
19.
Investigator’s Brochure. JNJ-64565111, Edition 4. Janssen Research and Development (December 2017).
20.
Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life 
in obesity Obes Res. 2001;9(2):102-111.
21.
Kolotkin RL, Crosby RD. Psychometric evaluation of the impact of weight on quality of life-lite questionnaire 
(IWQOL-Lite) in a community sample. Quality of Life Research. 2002;11:157-171.
22.
Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review 
of the literature. BMJ. 2017;356:477.
23.
Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. 
Diabetes Metab Res Rev. 1999;6:412-426.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
109
Approved, Date: 23 August 2018
24.
le Roux CW Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-
en-Y gastric bypass. Ann Surg. 2007;246(5):780-785.
25.
Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). 
Ann Intern Med. 2009;150(9):604-612.
26.
National Institutes of Health (NIH). The practical guide: identification, evaluation, and treatment of overweight 
and obesity in adults. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, 
and North American Association for the Study of Obesity, 2000. NIH Publication Number 00-4084.
27.
Nichols GA, Horberg M, Koebnick C, et al. Cardiometabolic risk factors among 1.3 million adults with 
overweight or obesity, but not diabetes, in 10 geographically diverse regions of the United States, 2012-2013. 
Prev Chronic Dis. 2017;14:E22.
28.
Padwal R, Li SK, Lau, DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and 
meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003;27:1437-1446.
29.
Pickering TG, Hall JE, Appel LJ. Recommendations for blood pressure measurement in humans and 
experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the 
Subcommittee of Professional and Public Education of the American Heart Association. Circulation. 
2005;111:697-716.
30.
Qsymia® [package insert] Mountain View, CA; VIVUS, Inc. 2014.
31.
Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in 
the prediction of first atherothrombotic events. Circulation. 2004;109:Suppl 1:IV6-IV19.
32.
Saxenda® [package insert], Bagsvaerd, Denmark. Novo Nordisk A/S, 2017.
33.
WHO 2017. World Health Organization. World Health Factsheet, Fact sheet N°311 Updated October 2017: 
http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed November 2017.
34.
Wolfe BM (2017), Kvach E, Eckel RH. Treatment of Obesity: Weight Loss and Bariatric Surgery. Circ Res 
2017;118(11):1844-1855. 
35.
Wynne K, Park AJ, Small CJ, et al., Subcutaneous oxyntomodulin reduces body weight in overweight and 
obese subjects: a double-blind, randomized, controlled trial. Diabetes. 2005;54(8):2390-2395.
36.
Xenical [package insert] South San Francisco, CA. Genentech USA, Inc., 2015.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
110
Approved, Date: 23 August 2018
Attachment 1: New York Heart Association Classification of Cardiac Disease
The following table represents the NYHA classification of cardiac disease:
Functional Capacity 
Objective Assessment 
Class I. Patients with cardiac disease but without resulting limitation of physical 
activity. Ordinary physical activity does not cause undue fatigue, palpitation, 
dyspnea, or anginal pain.
A. No objective evidence of 
cardiovascular disease.
Class II. Patients with cardiac disease resulting in slight limitation of physical 
activity. They are comfortable at rest. Ordinary physical activity results in fatigue, 
palpitation, dyspnea, or anginal pain.
B. Objective evidence of 
minimal cardiovascular 
disease.
Class III. Patients with cardiac disease resulting in marked limitation of physical 
activity. They are comfortable at rest. Less than ordinary activity causes fatigue, 
palpitation, dyspnea, or anginal pain.
C. Objective evidence of 
moderately severe 
cardiovascular disease.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical 
activity without discomfort. Symptoms of heart failure or the anginal syndrome may 
be present even at rest. If any physical activity is undertaken, discomfort is 
increased.
D. Objective evidence of 
severe cardiovascular disease.
Source: The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of 
Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994:253-256.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
111
Approved, Date: 23 August 2018
Attachment 2: Method of Blood Pressure and Pulse Rate Measurement
Subject Preparation
The subject should remove all clothing that covers the location of cuff placement. (The sleeve should not be rolled 
up so that it has a tourniquet effect.)
The subject should be comfortably seated with legs uncrossed, and back and arm supported, so that the upper 
arm is at the level of the right atrium (midpoint of the sternum).
The subject should be instructed to relax and not talk; approximately 5 minutes should pass before the first 
reading is taken.
Blood Pressure Measurement Device
Blood pressure readings should be taken manually with a mercury sphygmomanometer or an automated blood 
pressure monitor. If an automated blood pressure monitor is used, the pulse rate reading provided by the device can 
be used as the subject’s pulse rate measurement.
Cuff Size
A cuff should be chosen that is appropriate for the individual, based upon the upper arm circumference in 
centimeters. The bladder of the cuff should encircle at least 80% of the arm circumference.
Arm Circumference (cm)
Size
22-26
Small Adult
27-34
Adult
35-44
Large Adult
45-52
Adult Thigh
For the subject with an arm circumference over 50 cm when a thigh cuff cannot be fitted over the arm, an 
appropriately-sized cuff should be placed on the subject’s forearm, the forearm should be supported at heart level, 
and the radial pulse at the wrist should be used.
Cuff Placement
Palpate the brachial artery in the antecubital fossa.
Place the midline of the bladder of the cuff so that it is over the arterial pulse on the subject’s bare upper arm. The 
lower end of the cuff should be 2 to 3 cm above the antecubital fossa to allow space for the stethoscope.
Pull the cuff snugly around the bare upper arm. Neither the observer nor the subject should talk.
Inflation/Deflation
Inflate the cuff to at least 30 mmHg above the point at which the radial pulse disappears. Deflate the mercury 
column at 2 to 3 mmHg per second.
The first and last audible sounds should be taken as systolic and diastolic pressure.
Number of Measurements
Three readings should be taken at intervals of at least 1 minute apart, and the results recorded.
Blood pressure should be measured at the screening visit in both arms. If there is an inter-arm difference of more 
than 10 mmHg in either the systolic or diastolic pressure, the arm with the higher pressure should be used for all 
subsequent blood pressure measurement during the study.
If possible, if the blood pressure is measured manually, it should be taken by the same individual, using the same 
equipment, at each visit so as to reduce inter-observer variability (Pickering 2005).
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
112
Approved, Date: 23 August 2018
Attachment 3: Anthropometric Measurements
Height will be measured using a wall-mounted stadiometer or one mounted on a balance beam scale, 
whichever is most appropriate for the individual subject. Subjects should be wearing socks or barefoot 
and should not be wearing shoes.
Body weight will be measured using a calibrated scale. Subjects should be weighed wearing underwear 
and a gown; they will be instructed to take off their shoes and to empty their bladders before being 
weighed. The scale should be calibrated according to the manufacturers specifications and at the 
frequency recommended by the manufacturer before the first subject is weighed. Calibration must be 
documented in the calibration log.
Waist circumference will be measured with the subject standing, wearing underwear, with or without a 
gown. The measurement will be performed at a level midway between the superior aspect of the iliac 
crests and the lower lateral margin of the ribs (refer to diagram below). The measurement need not be at 
the level of the umbilicus. The measuring tape will be kept horizontal.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
113
Approved, Date: 23 August 2018
Attachment 4: Standardized Nonpharmacologic Weight Reduction Therapy
At randomization (ie, Day 1), trained counselors will utilize standard educational materials to deliver a 
counseling session. This session will assist the counselors in providing subjects with a variety of diet and 
physical activity tools to help subjects incorporate healthy practices into their daily lives. Subjects will be 
provided with user-friendly and interactive subject support materials. Subject support materials contain 
educational insight into the topic area, specific action steps to improve lifestyle habits, and interactive 
exercises that make it easy for each subject to think through and apply. 
General patient education materials will be supplied to support diet counseling. Study sites are 
encouraged to provide diet and physical activity information (eg, pamphlets or brochures or other such 
material) relevant to the local country or region.
a.
Weight Loss Diet
The energy level of the prescribed diet will be 600 kcal (2,083 kilo Joules [kJ]) less than the individual 
subject’s calculated total energy expenditure, and should have:

<10% of calories per day derived from added sugars

<10% of calories per day derived from saturated fat

<2.3 g of sodium per day
Basal metabolic rate (BMR) is estimated as kilocalories per day by means of the Harris-Benedict 
equation.

For men: 66.473 + (5.003 x height [cm]) + (13.752 x weight [kg]) – (6.755 x age)

For women: 655.096 + (1.850 x height [cm]) + (9.563 x weight [kg]) – (4.676 x age)

Total energy expenditure is estimated as: BMR*1.3 (correction factor for mild to 
moderate activity)
                                                

Harris JA, Benedict FG. A biometric study of basal metabolism in man. Washington, DC: Carnegie Institute of 
Washington; 1919:Publication 279.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
114
Approved, Date: 23 August 2018
Attachment 5: Clinical Laboratory Tests
Blood samples for serum chemistry and hematology, and urine samples for urinalysis will be collected
at timepoints specified in the Time and Events Schedule. The investigator must review the laboratory
report, document this review, and record any clinically relevant changes occurring during the study in the
Adverse Event section of the eCRF and take appropriate action (eg, repeating abnormal laboratory result
or further evaluation as considered clinically appropriate). The following tests will be performed by the 
central laboratory.

Hematology Panel
-hemoglobin
-platelet count
-hematocrit
-red blood cell (RBC) count
-white blood cell count with differential

Serum Chemistry Panel
-sodium
-alkaline phosphatase
-potassium
-creatine phosphokinase
-magnesium
-lactic acid dehydrogenase
-chloride
-amylase
-bicarbonate
-lipase
-uric acid
-calcium
- blood urea nitrogen
-phosphate
-creatinine
-albumin
-aspartate aminotransferase
-total protein
-alanine aminotransferase
-gamma-glutamyltransferase
-total bilirubin

Serum ß-hydroxybutyrate

Serum calcitonin

Fasting insulin*

Follicle-stimulating hormone only for women >45 years of age with amenorrhea for at least 
6 months and <18 months prior to screening

Fasting serum lipid profile (triglycerides, LDL-C, HDL-C, total cholesterol) *

HbA1c

Fasting plasma glucose*

Urinalysis
Dipstick done at central laboratory
-specific gravity
-pH
-protein
-blood
-ketones
-bilirubin
-urobilinogen
-nitrite
-leukocyte esterase
If dipstick result is abnormal, microscopic examination will be performed.

Serum (β-human chorionic gonadotropin [β-hCG] pregnancy testing will be conducted for all women 
of childbearing potential (ie, unless they are permanently sterilized or unless there is a documented 
history of their postmenopausal status) at the screening and Week 26/EOT visits. Additional serum 
or urine pregnancy tests may be performed throughout the study in sufficient number, as determined 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
115
Approved, Date: 23 August 2018
necessary by the investigator, or required by local regulation, to establish the absence of pregnancy 
during the study. 
* Subjects must be fasting for at least 8 hours before blood sample collections.
Estimated Glomerular Filtration Rate (eGFR)

The estimated glomerular filtration rate (eGFR) will be reported according to the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation** at study visits when serum 
creatinine is measured. The CKD-EPI equation based on serum creatinine, age, sex, and race for 
adults age 18 years expressed as a single equation is:
CKD-EPI Formula (for Scr expressed in mg/dL)
eGFR = 141 × min (Scr /, 1)× max(Scr /, 1)-1.209 × 0.993Age × 1.018 [if female] ×
1.159 [if black]
= 0.7 for females
= 0.9 for males
= -0.329 for females
= -0.411 for males
min = the minimum of Scr/or 1 max = the maximum of Scr/or 1
CKD-EPI Formula (for Scr expressed in mol/L)
eGFR = 141 × min (Scr /, 1)× max(Scr /, 1)-1.209 × 0.993Age × 1.018 [if female] ×
1.159 [if black]
= 61.9 for females
= 79.6 for males
= -0.329 for females
= -0.411 for males
min = the minimum of Scr/or 1 max = the maximum of Scr/or 1
**Levey AS, Stevens LA, Schmid CH, et.al. CKD-EPI (Chronic Kidney Disease Epidemiology 
Collaboration). Ann Intern Med. 2009;150(9):604-12.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
116
Approved, Date: 23 August 2018
Attachment 6: Algorithm for Monitoring Abnormal Liver Function Tests
If the investigator feels that the subject cannot safely continue administration of study drug regardless of 
the algorithm, the subject should discontinue study drug and continue to the EOT visit.
Key: ALT=alanine aminotransferase; EOT=End-of-Treatment; LFT=liver function test; Tbili=total bilirubin; 
ULN=upper limit of normal
*  LFT (ie, ALT, AST, total bilirubin, alkaline phosphatase, GGT) within 2 to 3 days of investigator receipt of 
report, with earlier testing (ie, within 1 day of receipt of laboratory report) for more substantial elevations in 
ALT (≥5xULN) or total bilirubin (≥2xULN) levels
** Focused medical history (including review of prior history of liver or biliary disorders, concurrent symptoms, 
review of all concomitant medications [eg, acetaminophen-containing medications, over-the-counter or herbal 
medications, nutritional supplements] including any changes in medications, detailed review of alcohol use; 
liver ultrasound and follow-up imaging as appropriate; hepatitis serology (anti-HAV, HBsAg, anti-HBs, anti-
HB core, anti- HCV, HCV RNA, EBV and CMV screen) and autoantibodies (eg, ANA, anti-smooth muscle 
antibody) should be obtained as appropriate, with additional evaluation as clinically indicated. The extent of the 
evaluations should be made in consultation with the sponsor.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
117
Approved, Date: 23 August 2018
Attachment 7: Pancreatitis Monitoring and Withdrawal Criteria
All subjects will be carefully monitored for pancreatitis during the study. Investigators will urge subjects 
to make an appointment for an unscheduled visit if the subject experiences persistent nausea and/or 
vomiting for 3 days, with or without abdominal pain.
Blood samples for analysis of serum amylase and lipase by a central laboratory should be obtained at the 
visit, and other additional investigations should be performed in order to establish diagnosis, per 
investigator’s discretion.
Study drug should be interrupted immediately if any of the following circumstances occur at any time 
during treatment:

If pancreatitis is suspected, or

Serum amylase 2x ULN, or

Serum lipase 2x ULN.
The pancreatic enzyme tests should be repeated within 7 days after the first sample (with both samples 
analyzed by the central laboratory), and appropriate imaging tests should be performed to establish 
diagnosis. The results of these tests should be recorded in the source documents.
All subjects with elevated pancreatic enzymes should be followed-up with multiple serum amylase and 
lipase tests until resolution.
Study drug should be discontinued if acute pancreatitis is confirmed, based on at least 2 of the following 
3 signs or symptoms: 

characteristic abdominal pain,

amylase and/or lipase >3x ULN, or

characteristic findings on CT/MRI.
In any of the circumstances described above occur during the study, the investigator must complete the 
AE/SAE eCRF page and a Pancreatitis Adverse Event of Special Interest Form. If the event meets the 
SAE criteria, the information will be transmitted to the sponsor using the Serious Adverse Event Form
within 24 hours of the repeat laboratory test.
If a subject discontinues study drug according to the Pancreatitis Monitoring and Withdrawal Criteria 
then, the event should be recorded as an AE and the reason for withdrawal should be documented as an 
AE. The subject should be followed to a satisfactory conclusion (ie, until the adverse event resolves, the 
laboratory value returns to baseline, or the condition becomes stable).
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
118
Approved, Date: 23 August 2018
Attachment 8: Guidelines for Calcitonin Monitoring
Calcitonin 10 ng/L and <20 ng/L
Confounders that can affect calcitonin measurements should be taken into consideration before aggressive 
diagnostic procedures are undertaken for subjects with CT 10 to < 20 ng/L at the screening visit. Specific history 
should be elicited to identify these confounders. Confounders (ie, drugs [H2 blockers, proton pump inhibitors 
(PPIs)] other causes of hypergastrinemia [eg, pernicious anemia], smoking, autoimmune thyroiditis, presence of 
heterophilic antibodies) should be factored into the interpretation of the values on a case-by-case basis. If drugs can 
be discontinued safely, the screening calcitonin can be repeated after a wash-out period. Calcitonin levels return to 
the normal range by 10 days after stopping PPIs.
Calcitonin 20 ng/L
All calcitonin values 20 ng/L will be flagged on the laboratory reports from the central laboratory and will be 
submitted to the sponsor and study site. Subjects will have to undergo a repeat measurement. The timing of the 
repeat measurement will depend on when the calcitonin value 20 ng/L was first observed. In particular:

calcitonin 20 ng/L on Day 1/Randomization visit: a repeat measurement of calcitonin should be performed 
preferably within 7 days.

calcitonin 20 ng/L at any time after Day 1/Randomization: a repeat measurement of calcitonin should be 
performed preferably within 2 weeks. 
If the repeat calcitonin is confirmed to be 20 ng/L, the event “elevated calcitonin” should be reported as an AE of 
interest.
Depending on the degree of the confirmed calcitonin elevation, additional clinical management or diagnostic 
procedures should be performed. In particular:
Calcitonin 20 ng/L and <50 ng/L
Subjects with calcitonin levels in this range at baseline Day 1 or subsequent visits should have the measurement 
repeated for confirmation per the suggested window period outlined above. This cohort will provide valuable 
insights into any potential effect that JNJ-64565111 may have on calcitonin levels in subjects with values above the 
normal range at baseline. If the repeat value or if any subsequent value measured during the trial is 50 ng/L then 
the subject moves into the evaluation category listed above for values 50 ng/L.
Calcitonin 50* ng/L and <100 ng/L
If subjects develop a calcitonin value within this specified range post-randomization, specific medical evaluation 
will be indicated including a thyroid ultrasound and a pentagastrin stimulation test if available and if not 
contraindicated (Note: pentagastrin is contraindicated in subjects with known coronary artery disease). Those 
subjects with positive pentagastrin stimulation tests will be considered to undergo surgery. In the US, where 
pentagastrin is not available, thyroid ultrasound and fine needle aspiration biopsy may add important clinical 
information informing the need for surgery.
A repeat determination should be performed within 2 weeks if serum calcitonin value 50 pg/mL (50 ng/L) after 
baseline and the study drug treatment should be permanently discontinued if the repeat determination confirms that 
the serum calcitonin value remains 50 pg/mL (50 ng/L).
Calcitonin 100* ng/L
For any value of 100 ng/L, the subject should be assumed to have significant C-cell disease and a high likelihood 
of having medullary carcinoma of the thyroid. Diagnostic evaluation should consist of thyroid ultrasound, fine 
needle aspiration of any nodules >1 cm and potentially surgery with neck dissection. Family history of MTC or 
MEN2 should be evoked and a rearranged during transfection (RET) proto-oncogene analysis should be undertaken.
* A repeat determination should be performed within 2 weeks if serum calcitonin value 50 pg/mL (50 ng/L) after 
baseline and the study drug treatment should be permanently discontinued if the repeat determination confirms that 
the serum calcitonin value remains 50 pg/mL (50 ng/L).
NOTE: pg/mL is the conventional unit and ng/L is the SI unit. 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
119
Approved, Date: 23 August 2018
Attachment 9: Instructions for the Completion of PRO Assessments 
The following instructions are intended to assist investigators, study coordinators, and those with 
monitoring responsibilities with the accurate completion of all the PRO questionnaires. For some sites, 
PRO questionnaires will be completed during scheduled site visits while other PRO questionnaires will be 
completed at home by the subject. It is therefore important for sites to be familiar with the PRO Time & 
Events schedule to ensure subjects complete the PROs at the correct setting and visit. Please refer to the 
PRO Completion Guideline for further information.
Site Responsibilities (General)
For this study, we expect that it will take approximately 20 minutes for the subjects to be trained and 
complete the PROs that are intended to be completed during site visits. For those PROs that are intended 
to be completed at home, it will take subjects less than 5 minutes a day to complete. 
General:

Never copy PROs from other sources (eg, websites); use only the PRO diaries provided. 
Site visit-based assessments, sites must:

Ensure subject completes the PROs before any clinical assessments are done or results are provided.

Please have the subject complete the PROs in the same order each time. 
Home-based assessments, sites must:

Ensure subject understands what is expected of them when they return home. 

Distribute the PRO home diaries and have the subject review to see if they have questions.

Have the subject complete the PROs in the order that they appear in the diary.

Remind the subject to return the PRO home diary at their next scheduled visit. 
Preparing the Subject
General:

Instruct subjects to complete all PRO questionnaires using a blue or black ballpoint pen.  

Explain that all the information on the PROs is confidential, and that someone from the study staff 
will only check for completeness and not share the results with other clinical staff.

Explain to subjects the reasons why they are being asked to complete the PROs, ie, they are part of 
the overall medical assessment and are designed to find out more information about how having their 
disease has affected their life. 

Allow as much time as the subject needs to orient themselves and complete all PROs.

Instruct the subjects to: 

Read the instructions for each questionnaire carefully.

Note the recall period for each questionnaire.

Complete all PROs; Instruct the subject not to skip any questions/or questionnaires.

Subjects must interpret questions and complete the PROs without input from anyone. If asked for 
help interpreting or completing the PROs by the subject, please simply reply that there are no right or 
wrong answers and he/she should use his/her best judgment to complete each question (based on 
what the subject thinks the question is asking). 
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
120
Approved, Date: 23 August 2018

Do not attempt to interpret or explain the instructions, questions, or response options.

If the subject has difficulty choosing between 2 response options, simply state “choose the answer 
that most closely matches your experience.”
Site visit-based assessments:

Provide a quiet, private or semi-private location for the subject to complete the PROs.

Ensure subjects have access to study staff for questions.
Home-based assessments:

Instruct the subject to complete each daily assessment at the same time each day, in the same setting 
each day, for the following 7 consecutive days.

These questionnaires are administered at home because of the concepts being measured and the 
period of recall.   
Quality Control

Complete the subject number, visit date and time on every PRO questionnaire.
Site visit-based assessments:

Before the subject leaves:

Check for any questions that might have been skipped/left blank.

If an item has been skipped, point this out to the subject and ask them to complete.

If an item has more than one response, ask the subject to reconsider the question and try to 
choose the answer that most closely matches their experience.
Home-based assessments:

Before the subject leaves the appropriately scheduled site visit, distribute the PRO home diary, 
provide instructions for completion, and remind subject to return the booklet at the next scheduled 
site visit.

Questionnaires in the diary should be completed by the subject daily for the next 7 consecutive days.

Upon the subject’s return for their next scheduled site visit, collect the PRO home diary from the 
subject and check for completeness.
Special Issues

Subjects should be instructed to complete the PROs without input from anyone. However, if a 
subject cannot read the PROs or complete it/them independently (eg, due to visual impairment, 
limited literacy, or difficulty with pens), then a designated person can read the items and response 
choices aloud and mark the appropriate response choices as verbally stated by the subject. 

The designated person should read each question in its entirety in a neutral voice, avoiding any cues, 
even if interrupted by the subject with an answer. The designated person should repeat each of the 
subject’s answers, eg, “A little bit.” The subject should not be prompted by the designated person in 
any other way. No help should be offered to the subject in interpreting the questionnaire.

If a person is designated to assist the subject with the PROs, this person should remain consistent 
across assessment questionnaires and across assessment periods.

If a designated person assists the subject with the PROs, this should be noted in the Footer section on 
the first page of each PRO assessment instrument.
NCT03486392


JNJ-64565111 (efinopegdutide)
Clinical Protocol 64565111OBE2001– Amendment 1
121
Approved, Date: 23 August 2018
INVESTIGATOR AGREEMENT
NCT03486392

SAP_001.pdf: 
1
Approved, Date: 26 March 2019
Janssen Research & Development 
Statistical Analysis Plan
A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, 
Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of 
JNJ-64565111 in Non-diabetic Severely Obese Subjects
Protocol 64565111OBE2001; Phase 2b
Amendment 1
JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Status:
Approved
Date:
26 March 2019
Prepared by:
Janssen Research & Development, LLC
Document No.: EDMS-ERI-159995420, 3.0
Compliance: The study described in this report was performed according to the principles of Good Clinical Practice (GCP). 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and 
may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed
by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as 
privileged or confidential.
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
2
Approved, Date: 26 March 2019
TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
AMENDMENT HISTORY.............................................................................................................................. 4
ABBREVIATIONS ........................................................................................................................................ 5
INTRODUCTION.................................................................................................................................. 7
1.
1.1.
Trial Objectives ................................................................................................................................ 7
1.2.
Trial Design...................................................................................................................................... 8
1.3.
Statistical Hypotheses for Trial Objectives..................................................................................... 10
1.4.
Sample Size Justification ............................................................................................................... 10
1.5.
Randomization and Blinding .......................................................................................................... 11
GENERAL ANALYSIS DEFINITIONS ..............................................................................................12
2.
2.1.
Visit Windows................................................................................................................................. 12
2.2.
Pooling Algorithm for Analysis Centers..........................................................................................12
2.3.
Analysis Sets.................................................................................................................................. 13
2.3.1.
All Randomized Analysis Set...................................................................................................... 13
2.3.2.
Efficacy Analysis Sets................................................................................................................. 13
2.3.3.
Safety Analysis Set..................................................................................................................... 13
2.3.4.
Pharmacokinetics Analysis Set .................................................................................................. 13
2.3.5.
Pharmacodynamics Analysis Set ...............................................................................................13
2.3.6.
Immunogenicity Analysis Set...................................................................................................... 14
2.4.
Definition of Subgroups.................................................................................................................. 14
2.5.
Study Day and Relative Day.......................................................................................................... 14
2.6.
Baseline ......................................................................................................................................... 15
INTERIM ANALYSIS AND DATA MONITORING COMMITTEE REVIEW....................................... 15
3.
SUBJECT INFORMATION................................................................................................................ 15
4.
4.1.
Demographics and Baseline Characteristics................................................................................. 15
4.2.
Disposition Information................................................................................................................... 16
4.3.
Treatment Compliance................................................................................................................... 17
4.4.
Extent of Exposure.........................................................................................................................17
4.5.
Protocol Deviations ........................................................................................................................18
4.6.
Prior and Concomitant Medications...............................................................................................18
EFFICACY ......................................................................................................................................... 18
5.
5.1.
Analysis Specifications................................................................................................................... 18
5.1.1.
Level of Significance................................................................................................................... 18
5.1.2.
Data Handling Rules................................................................................................................... 19
5.2.
Primary Efficacy Endpoint.............................................................................................................. 20
5.2.1.
Definition..................................................................................................................................... 20
5.2.2.
Estimand..................................................................................................................................... 20
5.2.3.
Analysis Methods........................................................................................................................20
5.3.
Major Secondary Endpoints........................................................................................................... 21
5.3.1.
Definition..................................................................................................................................... 21
5.3.2.
Analysis Methods........................................................................................................................22
5.4.
Exploratory Efficacy Variable(s)..................................................................................................... 22
5.4.1.
Definition..................................................................................................................................... 22
5.4.2.
Analysis Methods........................................................................................................................23
SAFETY............................................................................................................................................. 24
6.
6.1.
Adverse Events..............................................................................................................................24
6.2.
Clinical Laboratory Tests................................................................................................................ 26
6.3.
Vital Signs and Physical Examination Findings............................................................................. 26
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
3
Approved, Date: 26 March 2019
6.4.
Electrocardiogram..........................................................................................................................27
PHARMACOKINETICS/IMMUNOGENICITY/PHARMACODYNAMICS .......................................... 27
7.
7.1.
Pharmacokinetics...........................................................................................................................27
7.2.
Immunogenicity..............................................................................................................................29
7.3.
Pharmacokinetic/Pharmacodynamic Relationships....................................................................... 30
REFERENCES............................................................................................................................................ 31
ATTACHMENTS......................................................................................................................................... 32
ATTACHMENT 1 CLINICAL LABORATORY TESTS ............................................................................... 32
ATTACHMENT 2 PRE-DEFINED LIMIT OF CHANGE (PDLC) CRITERIA FOR LABORATORY 
TESTS................................................................................................................................................ 34
ATTACHMENT 3 ADVERSE EVENTS OF INTEREST ............................................................................. 36
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
4
Approved, Date: 26 March 2019
AMENDMENT HISTORY
SECTION(S)
CHANGE and RATIONALE
Global 
Change
“Pulse Pressure Product” and “Rate Pressure Product” were used interchangeably; the term “Rate 
Pressure Product” will be used going forward.
1.1, 1.3, 5.4.1
Reworded the objectives and hypotheses to enhance clarity of phrasing (eg, “absolute change from 
baseline in body weight” from “absolute change in body weight from baseline” 
2.1
Visit windows now include post-Week 26 to account for subjects brought back for visits after 
Week 26 to reduce subjects who were lost to follow-up.  
2.3.2
Refined mITT Analysis Set definition to include subjects taking at least one dose of study 
medication
2.3.2
Clarify that the Completers’ Analysis Set is defined by the Treatment Disposition eCRF status
2.3.2
Added ABPM analysis set
4.1
Demographics tables will be generated for 5 analysis sets: ITT, mITT, Safety, PK, and Completers.  
Within each analysis set, the number of subjects stratified within the ABPM/non-ABPM groups 
will be provided.
4.2
Screen failures will not be summarized.  Protocol deviations will be listed that may include 
deviations related to medication dispensed.
4.3
Treatment compliance formula was refined to only account for period of time between first and last 
dose; non-compliance is not counted after the last dose.
4.4
For the purpose of summarizing exposure, Treatment Duration does not take drug interruptions into 
account.  Steps for imputing missing treatment end dates were refined.
4.5
Protocol deviations, as identified by the Study Team, will be listed but not summarized.
5.0, 5.2.3
“Data collected after the last dose plus 7 days” changed to “Data collected after the last dose plus 2 
days for liraglutide subjects and 14 days for JNJ64565111 and placebo subjects will be excluded 
from the mITT analysis.”  This changed is based on what is known about PK.
5.1
Expanded details related to multiple testing procedures to include the comparison of liraglutide and 
placebo. 
5.1.2, 5.4.2
SBP/pulse and DBP/pulse are not considered endpoints as part of the ABPM analysis
5.2.3
Subgroup and lower-level terms included in model evaluating treatment*subgroup interaction.
5.2.3, 5.4.2
For endpoints with only one post-baseline visit, an ANCOVA model will be used with treatment as 
a fixed factor and baseline as a covariate.
5.2.3
Change “Sensitivity Analysis” to “Supportive Analysis”
5.2.3, 5.3.2
Allow for copy control method to be used if there are not enough retrieved drop-outs to impute 
missing data as originally intended.
5.3.2
Clarify that nominal p-values will be provided.
5.3.2
The analysis of categorical endpoints will be performed using logistic regression given the 
challenges of running a longitudinal categorical analysis in which few subjects at the early time 
points are considered responders.
5.4.2
Add shift table for obesity class
5.4.2
The endpoint for ABPM is last on-treatment measurement, even if it is not within the Week 26 
window.
6
Reference to Section 2.3.4 should be 2.3.3.
6.1
Mild and Moderate AEs will not be pooled for the purpose of summarizing AEs by severity.
6.2, 6.3
References to Attachments 4 and 5 correctly renumbered Attachments 1 and 2, respectively.
6.2
Shift tables for laboratory values will not be generated.
6.2
“Markedly abnormal” laboratory values are not defined.
6.3
Physical examination data will not be listed.
7.1
The details under which measurements should be excluded from the PK analysis are provided.
ATCH 2
Added PDLCs for calcitonin, amylase and lipase
ATCH 2
Beta-Hydroxybutyrate above 208.22 mg/L will be flagged as PDLC.  
ATCH 3
Refer to excel files; reference in ERIS.
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
5
Approved, Date: 26 March 2019
ABBREVIATIONS
-hCG
Serum -human chorionic gonadotropin
ABPM
Ambulatory blood pressure monitoring
ACTT
Anticipations of Clinical Trial Treatment
ADA
anti-drug antibody
AE(s)
Adverse event(s)
BMI
Body mass index
bpm
Beats per minute
CI
Confidence interval
CKD-Epi
Chronic Kidney Disease Epidemiology Collaboration
CPK
Creatinine phosphokinase
CT
computed tomography
DBP
Diastolic blood pressure
DMC
Data Monitoring Committee
eCRF(s)
Electronic case report form(s) 
eGFR
Estimated glomerular filtration rate
EOT
End-of-treatment
ERCQ 
Eating-related Concept Questionnaire
EW
Early withdrawal
FDA
US Food and Drug Administration
FPG
Fasting plasma glucose
GCP
Good Clinical Practice
GI
Gastrointestinal
GLP-1
Glucagon-like peptide-1
GLP-1R
GLP-1 receptor
HbA1c
Hemoglobin A1c
HDL-C
High-density lipoprotein cholesterol
HOMA-B
Homeostasis Model Assessment for B cell function
HOMA-IR
Homeostasis Model Assessment of insulin resistance
IA
Interim analysis
ITT
Intent-to-treat
IWQOL-Lite
Impact of Weight on Quality of Life-Lite
IWRS
Interactive web response system
LDL-C
Low-density lipoprotein cholesterol
MACE
Major adverse cardiovascular events
MedDRA
Medical Dictionary for Regulatory Activities
mITT
Modified intent-to-treat
mmHg
Millimeters mercury
MMRM
Mixed model for repeated measures
PAM
Patient Activation Measure
PDLC
Pre-defined limits of change
PGIC
Patient Global Impression of Change
PGIS 
PGIS Patient Global Impression Status
PK
Pharmacokinetics
PRO
Patient-reported outcome(s) (paper or electronic as appropriate for this study)
PROMIS SF 8b
PROMIS physical function Short Form 8b
RPP
Rate pressure product
SAE(s)
Serious adverse event(s)
SAP
Statistical analysis plan
SBP
Systolic blood pressure
SC
Subcutaneous, subcutaneously
SD
Standard deviation
SI
International System of Units
SMQ
Standardised MedDRA Query
STEP
Safety, Tolerability, and Efficacy Preview
TEAE(s)
Treatment-emergent adverse event(s)
ULN
Upper limit of normal
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
6
Approved, Date: 26 March 2019
US
United States
WBC
White blood cell
WHO
World Health Organization
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
7
Approved, Date: 26 March 2019
INTRODUCTION
1.
This statistical analysis plan (SAP) contains the definitions of analysis sets, key derived 
variables, and statistical methods for the analyses of efficacy and safety data from study 
JNJ-64565111OBE2001. This SAP is based on Clinical Protocol JNJ-64565111OBE2001 dated 
23 August 2018. Titles, mock-ups and programming instructions for all statistical outputs (tables, 
figures and listings) are provided in a separate document entitled Data Presentation 
Specifications (DPS). A separate Data Monitoring Committee (DMC) SAP will describe the 
statistical methods used for the Interim Analysis (IA).  
This SAP includes the analyses of the self-administered patient-reported outcome (PRO) 
measures presented in the clinical study report. A separate SAP contains the statistical methods 
for the Anticipations of Clinical Trial Treatment (ACTT) and Safety, Tolerability, and Efficacy 
Preview (STEP) interviews collected in this study.
1.1.
Trial Objectives
Primary Objectives
In non-diabetic severely obese subjects, to assess the effects of JNJ-64565111 compared with 
placebo after 26 weeks of treatment on: 

the percentage change from baseline in body weight 

safety and tolerability
Secondary Objectives
In non-diabetic severely obese subjects, to assess the effects of JNJ-64565111 compared with 
placebo after 26 weeks of treatment on:

the proportion of subjects with 5% weight loss from baseline

the proportion of subjects with ≥10% weight loss from baseline

the absolute change from baseline in body weight
Exploratory Objectives
In non-diabetic severely obese subjects, to assess the effects of JNJ-64565111 compared with 
placebo after 26 weeks of treatment on:

the change from baseline in body mass index (BMI) 

the change from baseline in waist circumference 

the change from baseline in fasting lipids (total cholesterol, LDL-C, HDL-C, triglycerides) 

the change from baseline in fasting plasma glucose (FPG) 

the change from baseline in fasting insulin from baseline 

the change from baseline in fasting C-peptide from baseline
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
8
Approved, Date: 26 March 2019

the changes from baseline in Homeostasis Model Assessment for B cell function (HOMA-
B) and HOMA-insulin resistance (IR) 

the change from baseline in systolic blood pressure (SBP)

the change from baseline in diastolic blood pressure (DBP)

the change from baseline in pulse rate 

the change from baseline in pulse-pressure product

in a subset of subjects participating in the 24-hour ABPM assessment, the changes from 
baseline in 24-hour SBP, DBP, pulse rate, and pulse-pressure product 

Pharmacokinetic (PK) exposure

the change from baseline in scores on the Impact of Weight on Quality of Life-Lite
(IWQOL-Lite),2,3 single item Ease of Weight Management, and the Patient Activation 
Measure (PAM)  

in English-speaking subjects in selected countries only, the change from baseline in scores 
on the eating-related concept question (ERCQ) and the PROMIS physical function short
form 8b (PROMIS SF 8b) (Note: the Patient Global Impression Status [PGIS] and Patient 
Global Impression of Change [PGIC] will be used to calculate responder definitions for 
these new instruments only and are not exploratory objectives). 

in English-speaking subjects in selected countries only, describe pre-trial goals and 
expectations as well as post-trial experiences qualitatively using the Anticipations of 
Clinical Trial Treatment (ACTT) Pre-trial interviews and a modified Safety, Tolerability, 
and Efficacy Preview (STEP) exit interview 
In non-diabetic severely obese subjects, to assess the effects of JNJ-64565111 compared with 
liraglutide after 26 weeks of treatment on:

the absolute change and percentage change from baseline in body weight

the proportion of subjects with 5% weight loss from baseline

the proportion of subjects with ≥10% weight loss from baseline 
1.2.
Trial Design
This is a randomized, double-blind placebo-controlled and open-label active-controlled, parallel-
group, 5-arm, multicenter study. Non-diabetic, severely obese subjects who are ≥18 and 
≤70 years of age and have a BMI ≥35 to ≤50 kg/m2 will be assessed.
Subjects meeting all eligibility criteria will enter a 2-week run-in phase, which is to occur 
approximately 1 week after the screening visit and is designed to train the subject on SC 
self-injection and to establish the subject’s ability to comply with the protocol-specified 
requirements. On Day 1, approximately 440 subjects who continue to meet eligibility criteria 
will be randomly assigned in a 1:1:2:2:2 ratio to blinded treatment with placebo, JNJ-64565111 
(5.0, 7.4, or 10.0 mg) or open-label liraglutide, stratified by ABPM sub-study participation (yes 
or no), and then will enter a 26-week treatment phase. Post-randomization visits will be 
conducted at Weeks 5, 10, 15, 20, 26/end-of-treatment (EOT) visit and 4-week SAE follow-up 
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
9
Approved, Date: 26 March 2019
after Week 26/EOT visit. A subset of subjects in the ABPM sub-study will have 2 additional 
visits (ie, Pre-Day 1 and Pre-Week 26). A subset of subjects will have 1 additional visit (Day 4 
1 day sampling window) to collect a non-trough PK sample. All subjects will be contacted 
preferably by telephone to reinforce the adherence to diet and exercise, study drug dosing 
reminder, assessment of subjects’ status, and compliance with the protocol procedures (eg, diary 
completion reminder) at Week 2. Study-site staff is encouraged to contact subjects (preferably by 
telephone) to do the same at some time in between Week 5, 10, 15, 20, and 26 visits. Subjects in 
the open-label liraglutide treatment group will also be contacted preferably by telephone at 
Weeks 1, 3, and 4 to remind about the dosing titration (ie, to increase their dose of liraglutide by 
an 0.6 mg dose increment weekly). 
Subjects who withdraw from the study will not be replaced.
The overall study duration is approximately 33 weeks and comprises of 3 phases:

Pre-treatment phase

Screening phase: 1 week

Run-in (injection-training) phase: 2 weeks

Treatment phase (double-blind and open-label arms)

Placebo- and active-controlled treatment phase: 26 weeks

Post-treatment phase (SAE follow-up visit): 4 weeks
A diagram of the study design is provided in Figure 1.2.1.
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
10
Approved, Date: 26 March 2019
Figure 1.2.1:
Schematic Overview of the Study
1.3.
Statistical Hypotheses for Trial Objectives
In non-diabetic severely obese subjects, treatment for 26 weeks with JNJ-64565111 compared 
with placebo leads to a greater:
Primary: 

percentage reduction from baseline in body weight
Secondary: 

proportion of subjects with 5% weight loss from baseline

proportion of subjects with ≥10% weight loss from baseline

absolute reduction from baseline in body weight 
1.4.
Sample Size Justification
A total of approximately 440 subjects will be randomized into this study with approximately 
55 subjects per group allocated to placebo and JNJ-64565111 5.0 mg group, and approximately 
110 subjects per group allocated to each of the other three groups: JNJ-64565111 7.4 mg, 
JNJ-64565111 10.0 mg, open-label liraglutide 3.0 mg. Sample size was determined based on 
assessing the primary hypothesis that the treatment with JNJ-64565111 for 26 weeks leads to 
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
11
Approved, Date: 26 March 2019
greater percentage reduction in body weight compared with placebo as well as the exploratory 
hypothesis that the treatment with JNJ-64565111 leads to greater percentage reduction in body 
weight compared with open-label liraglutide. 
Assuming a common standard deviation (SD) of 7% with respect to percent change in body 
weight at Week 26 and a 2-sided Type 1 error rate of 0.05, it is estimated that a sample size of 
55 randomized subjects per group will have approximately 90% power to detect a treatment 
difference of 4.4%, 110 randomized subjects per group will have approximately 90% power to 
detect a treatment differences of 3.1%.
1.5.
Randomization and Blinding
On Day 1, subjects will be randomly assigned to 1 of 5 treatment groups based on a computer-
generated randomization schedule prepared before the study by or under the supervision of the 
sponsor. The randomization will use randomly permuted blocks. In addition, to assure 
maintenance of the randomization ratio in the ABPM sub-study, subjects will be stratified in the 
interactive web response system (IWRS) by participation in the 24-hour ABPM sub-study (yes 
or no). Subject enrollment into the ABPM sub-study at selected study sites will be tracked and 
capped as necessary. If the overall study target enrollment has been achieved, subject recruitment 
may be closed even if the target enrollment numbers for the ABPM sub-study have not been 
reached. 
At baseline (Day 1), the treatment code, which is linked to the randomization schedule, will be 
assigned after logging on to the IWRS designated by the sponsor. The requestor must use his or 
her own user identification and personal identification number when contacting the IWRS, and 
will then give the relevant subject details to uniquely identify the subject. Based on this 
information, the IWRS will assign a unique treatment code, which will dictate the treatment 
assignment and matching study drug kit for the subject. As subjects are randomly assigned to 
treatment, the IWRS will assign a study drug kit to be dispensed at that visit. New study drug kits 
will be assigned each time the IWRS is accessed for dispensing additional study drug.
Blinding
Liraglutide will be administered in an open-label fashion in this study. 
JNJ-64565111 and placebo will be given in a double-blind fashion, as described below. To 
maintain blinding, subjects randomized to placebo will be subsequently randomized to receive 
the corresponding volumes of placebo matching the 5.0, 7.4, and 10.0 mg JNJ-64565111 doses. 
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality to allow the investigator to break the blind for an 
individual subject.
Under normal circumstances, the blind should not be broken until all subjects have completed 
the study and the database is locked. Otherwise, the blind should be broken only if specific 
emergency treatment/course of action would be dictated by knowing the treatment status of the 
subject. 
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
12
Approved, Date: 26 March 2019
GENERAL ANALYSIS DEFINITIONS
2.
2.1.
Visit Windows
As subjects do not always adhere to the protocol visit schedule, the following rules are applied to 
assign actual visits to analysis visits. Listed below are the visit windows and the target days for 
each visit. The reference day is Study Day 1 (date of first dose). If a subject has 2 or more actual 
visits in one visit window, the visit closest to the target day will be used as the protocol visit for 
that visit window. The other additional visit(s) will not be used in the summaries or analyses but 
they can be used for determination of clinically important endpoints. If 2 actual visits are 
equidistant from the target day within a visit window, the later visit is used.
All assignments will be made in chronological order. Once a visit date is assigned to a visit 
window, it will no longer be used for a later time point except for the endpoint. Listed below 
(Table 2.1.1) are the visit windows and the target days for each visit defined in the protocol. A 
Post-Week 26 window was created to account for subjects who returned at a time that would no 
longer be considered consistent with a Week 26 measurement.
Table 2.1.1: Visit Windows
Parameter
Scheduled Visit 
Number
Time Interval
(label on output)
Time Interval
(Day)a
Target Time Point 
(Day)
Serum Chemistry 
and Trough PK
2
Baseline
1b
1
3
Week 2
2–25
15
4
Week 5
26-53
36
5
Week 10
54-88
71
6
Week 15
89-123
106
7
Week 20
124-162
141
8
Week 26
163- 203
183
9
Post-Week 26
>203
All other 
parameters
2
Baseline
≤1b
1
4
Week 5
2-53
36
5
Week 10
54-88
71
6
Week 15
89-123
106
7
Week 20
124-162
141
8
Week 26
163-203
183
9
Post-Week 26
>203
a
Relative to the day of the first dose of double-blind study medication.
b
Up to the first dose of double-blind study medication.
2.2.
Pooling Algorithm for Analysis Centers
All centers will be pooled. In other words, center will not be included in any statistical model. If 
the analyses should involve geographical region, the Regions will be defined by country as 
follows:

Europe: UK, Belgium, Sweden, Poland

North America: Canada, US
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
13
Approved, Date: 26 March 2019
2.3.
Analysis Sets
2.3.1.
All Randomized Analysis Set
The all randomized analysis set is not used in the study.
2.3.2.
Efficacy Analysis Sets

The intent-to-treat (ITT) analysis set will include all subjects who are randomly assigned to 
a treatment group and have a baseline body weight measurement. 

The modified intent-to-treat (mITT) population includes all ITT subjects who have taken at 
least one dose of study medication and have at least 1 post-baseline body weight 
measurement; for subjects randomized to liraglutide, only those who titrate to 3.0 mg will be 
included in the mITT population.  

The completers’ analysis set will consist of all mITT subjects who have completed 26 weeks 
of treatment (ie, documented in the Treatment Disposition eCRF by the investigators that 
the subject has completed treatment through the Week 26 visit window). 

The ABPM analysis set will consist of all mITT subjects who have valid baseline and valid 
post-baseline ABPM readings.  If the post-baseline reading was collected after the last dose 
plus 2 days for liraglutide subjects and 14 days for JNJ64565111 and placebo subjects, the 
subject will be excluded from the ABPM analysis set. 
The primary efficacy analysis, to demonstrate the superiority of JNJ-64565111 compared to 
placebo on percentage reduction in body weight from baseline to Week 26, as well as all 
secondary efficacy analyses, will be based on the mITT analysis set.
A secondary analysis of the primary and secondary efficacy endpoints will be based on the ITT 
population (including data after the on-treatment period). This analysis will include all 
measurements through the Week 26 visit window. Supportive analyses based on the completers’ 
analysis set will also be performed for the primary endpoint. 
2.3.3.
Safety Analysis Set
The safety analysis set will include all randomized subjects who have received at least one dose 
of study drug.
2.3.4.
Pharmacokinetics Analysis Set
The PK evaluable (PK) analysis set includes treated subjects (received at least one dose of 
JNJ-64565111) who have at least one post-baseline PK sample for analysis.  
Pharmacokinetics analyses will be performed using the PK analysis set. Analysis will be based 
on the actual treatment received.
2.3.5.
Pharmacodynamics Analysis Set
Pharmacodynamics analyses will use the mITT analysis set. Analysis will be based on the actual 
treatment received.
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
14
Approved, Date: 26 March 2019
2.3.6.
Immunogenicity Analysis Set
The immunogenicity evaluable (IE) analysis set includes treated subjects (received at least one
dose of JNJ-64565111) who have a sample at baseline and at least 1 post-baseline sample for 
analysis. Immunogenicity analyses will use this analysis set. Analysis will be based on the actual 
treatment received.  
2.4.
Definition of Subgroups
Subgroup analyses may be performed based on the subgroups defined below. 
Subgroup
Definition
Sex
female
male
Age
18-59 years
60-70 years
Race
White
Black or African American
Asian
Other
Ethnicity
Hispanic or Latino
Not Hispanic or Latino
Unknown
Not reported
Region
North America
Europe
Baseline BMI
<40 kg/m2
≥40 kg/m2
Baseline eGFR
<90 mL/min/1.73m2
≥90 mL/min/1.73m2
Randomization strata
ABPM sub-study participation: Yes
ABPM sub-study participation: No
For subjects who participate in the ABPM sub-study, the subgroup analysis may be performed 
based on the history of hypertension (yes/no).
2.5.
Study Day and Relative Day
Study Day 1 or Day 1 refers to the day of the first study agent administration on or after the 
randomization date. All efficacy and safety assessments at all visits will be assigned a day 
relative to this date.
Study day or relative day for a visit is defined as:

Visit date - (date of Study Day 1) +1, if visit date is ≥date of Day 1

Visit date - Date of Day 1, if visit date <date of Day 1
There is no 'Day 0'
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
15
Approved, Date: 26 March 2019
2.6.
Baseline 
Baseline is defined as the last observation prior to the first study agent administration on or after 
the randomization date.
INTERIM ANALYSIS AND DATA MONITORING COMMITTEE REVIEW
3.
A pre-planned interim analysis (IA) will be performed when approximately 90% of subjects have 
either completed or discontinued prior to 10 weeks of study treatment. This IA will require 
support from an internal Data Monitoring Committee (DMC) and the analysis will be described 
in a separate DMC SAP.  
The objective of this interim analysis is to identify active treatment groups, if any, associated 
with safety or tolerability issues and to facilitate planning of the Phase 3 program. There will be 
no alpha adjustment for unblinded review(s). Additionally, based on ongoing blinded safety 
reviews by the study team, the study team may ask the DMC to evaluate specific safety data in 
an unblinded manner.
SUBJECT INFORMATION
4.
The number of subjects in each analysis set will be summarized and listed by treatment group,
combined JNJ-64565111 treatment group, and overall. In addition, the distribution of subjects by
region, country, and site ID will be presented unless otherwise noted.
4.1.
Demographics and Baseline Characteristics
Table 4.1.1 presents a list of the demographic variables that will be summarized by treatment 
group, combined JNJ-64565111 treatment group, and overall for the ITT analysis set, mITT 
analysis set, safety analysis set, completers’ analysis set, and PK analysis set.
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
16
Approved, Date: 26 March 2019
Table 4.1.1: 
Demographic Variables
Continuous Variables
Summary Type
Age (years)
Descriptive statistics 
(N, mean, standard 
deviation [SD], 
median and range 
[minimum and 
maximum]).
Weight (kg)
Height (cm)
Body Mass Index (BMI) (kg/m2)
Waist circumference (cm)
Pulse rate (bpm)
Systolic Blood Pressure (mmHg)
Diastolic Blood Pressure (mmHg)
Rate pressure product (bpm*mmHg)
eGFR (mL/min/1.73m2)
HbA1c
FPG (mmol/L)
Fasting insulin (pmol/L)
Fasting C-peptide (nmol/L)
Fasting serum lipids: total cholesterol, triglycerides, high-density-lipoprotein cholesterol 
(HDL-C), low-density-lipoprotein cholesterol (LDL-C)
IWQOL-Lite physical function domain score
Beta-hydroxybutyrate (mmol/L)
Categorical Variables
Summary Type
Age (18-30 years, 31-50 years, 51-64 years, and >65 years)
Frequency 
distribution with the 
number and 
percentage of 
subjects in each 
category.
Age for analysis (18-59 years and ≥60 years)
Sex (male, female)
Racea (White, Black or African American, Asian, American Indian or Alaska Native, Native 
Hawaiian or other Pacific Islander, Multiple, Other)
Race for analysis (White, Black or African American, Asian, and Other)
Ethnicity (Hispanic or Latino, Not Hispanic or Latino, Unknown, Not reported)
Region (North America, Europe)
Baseline BMI (<40, ≥40 kg/m2)
Randomization strata (ABPM sub-study participation: Yes/No)
Baseline eGFR (<90, ≥90 mL/min/1.73m2)
Baseline SBP (<140 mmHg, ≥ 140 mmHg)
a
If multiple race categories are indicated, the Race is recorded as 'Multiple'
4.2.
Disposition Information
The number of subjects in the following disposition categories will be summarized by treatment 
group and overall:

Subjects randomized;

Subjects in the ITT analysis set;

Subjects in the mITT analysis set;

Subjects in the completers’ analysis set;

Subjects in the mITT analysis set who discontinue from treatment before the Week 26 visit 
(ie, investigator indicates on the eCRF [treatment disposition page] that the subject 
discontinued from treatment);

Subjects in the mITT analysis set who discontinue from study before the Week 26 visit 
(ie, investigator indicates on the eCRF [trial disposition page] that the subject discontinued 
from study);
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
17
Approved, Date: 26 March 2019

Subjects in the safety analysis set;

Reasons for discontinuation of study.
For subjects who discontinue from the study after randomization, the corresponding reasons for 
(1) discontinuation from the treatment, and (2) discontinuation from the study during the 
26-week treatment phase will be summarized.
The distribution of the time to study discontinuation for the 26-week treatment phase will be 
displayed with Kaplan-Meier curves. Subjects who terminate study participation prematurely at 
any time will be considered an ‘Event’ and their date of study discontinuation will be used in the 
time to event calculation. Subjects who complete the study will be censored on their date of 
study completion. Descriptive analyses for the time to early discontinuation will be provided.
Listings of subjects will be provided for the following categories:

Subjects who discontinued study agent;

Subjects who terminated study prematurely;

Subjects who were unblinded during the study period;

Subjects who were randomized yet did not receive study agent.
4.3.
Treatment Compliance
Treatment compliance will be derived based on the information from the study drug 
administration eCRF page.
Compliance with study medication will be calculated as follows:

Study agent compliance (%) = 100 x [number of doses taken/total treatment duration in 
weeks rounded up to nearest integer]

Open-label Liraglutide compliance (%) = 100 x [number of doses taken/total treatment 
duration in days].
4.4.
Extent of Exposure
Treatment duration will be calculated (in days) based on the dosing schedule as follows:
Study agent: Date of last dose – date of first dose + 8 days
Liraglutide: Date of last dose – date of first dose + 1 day
If the end date of the study medication intake is not known (eg, subject is lost to follow-up), it 
will be imputed as the earlier of the date of death, disposition date (ie, End of study date, End of 
Treatment) and 28 days from the date that the last medication kit was dispensed.  
Descriptive statistics for treatment duration (N, mean, standard deviation, median, and range) 
will be presented by treatment group for the safety analysis set. The number and percentage of 
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
18
Approved, Date: 26 March 2019
subjects who receive study agent will also be summarized by treatment group with the duration 
in each of the following categories:

For double-blind treatment phase, <2 weeks, 2 to <6 weeks, 6 to <12 weeks, 12 to 
<18 weeks, 18 to <24 weeks, and ≥24 weeks
4.5.
Protocol Deviations
Subjects with major protocol deviations will be identified prior to database lock and the subjects 
with major protocol deviations will be listed.
4.6.
Prior and Concomitant Medications
Prior and Concomitant medications will be coded using the World Health Organization Drug 
Dictionary (WHO-DD). Prior medications are defined as any therapy used before the day of first 
dose (partial or complete) of study agent. Concomitant medications are defined as any therapy 
used on or after the same day as the first dose of study agent, including those that started before 
and continue on after the first dose of study agent.
Summaries of concomitant medications will be presented by ATC term and treatment group. The 
proportion of subjects who receive each concomitant medication will be summarized as well as 
the proportion of subjects who receive at least one concomitant medication. In addition, 
concomitant medications of interest will be presented.  
Prior medications will be summarized by treatment group/dose level and ATC term.
EFFICACY
5.
The primary analysis of the primary, secondary and exploratory efficacy endpoints of the main 
study will be based on the mITT analysis set and will include only those post-baseline 
measurements taken within the 26-week double-blind phase while on treatment. Data collected 
after the last dose plus 2 days for liraglutide subjects, and after the last dose plus 14 days for 
JNJ64565111 and placebo subjects will be excluded from the mITT analysis. A secondary 
analysis of the primary and secondary efficacy endpoints will be based on the ITT analysis set. 
This analysis will include post-baseline measurements taken within the 26-week double-blind 
phase regardless of whether on-treatment or off-treatment. Sensitivity analyses for the primary 
efficacy endpoint using the completers’ analysis set will also be performed.  
Regardless of the actual treatments the subjects received, efficacy data will be analyzed 
according to the initial randomization assignment for the treatment (26-week) phase.
5.1.
Analysis Specifications
5.1.1.
Level of Significance
Unless otherwise specified, all statistical tests will be interpreted at a 2-sided significance level 
of 5% and all confidence intervals at a 2-sided confidence level of 95%. 
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
19
Approved, Date: 26 March 2019
The type I error rate will be strongly controlled at two-sided α=5% for each of the primary 
endpoint and secondary endpoints. Dunnett’s method will be used to adjust for the multiplicity of 
the comparisons of each of the JNJ-64565111 doses and liraglutide versus placebo for the
primary efficacy endpoint of the percentage change in body weight and separately for the 
secondary endpoint of the absolute change in body weight. Similarly, the Bonferroni correction 
will be used to adjust the multiplicity for the comparisons of each JNJ-64565111 dose and 
liraglutide to placebo for the secondary endpoints of the proportion of subjects with weight loss 
> 5% and >10%.
5.1.2.
Data Handling Rules
Unlike other assessments which are scheduled to be collected once at each visit, three 
consecutive readings of the SBP, DBP and pulse rate will be measured (at intervals of at least 
1 minute apart) and recorded. The average of the multiple measurements will be computed at 
each visit for all subjects and this averaged value will be used in all the analyses and summaries 
of blood pressure and pulse rate. 
Ambulatory Blood Pressure Monitoring (ABPM) Sub-study
The 24-hour ABPM sub-study will be performed in a subset of approximately 120 subjects at 
selected sites. The ABPM blood pressure and pulse rate readings will be collected over a 24-hour 
period at each of these 2 time points: 1 or 2 days prior to the Day1/Randomization visit and 1 or 
2 days prior to the Week 26/ EOT.
The ABPM devices are calibrated to record the blood pressure (SBP and DBP) and pulse rate 
measurements every 20 minutes during daytime hours and every 30 minutes during nighttime 
hours. These blood pressure measurements will be used to determine: 

mean 24-hour SBP, mean daytime SBP, mean nighttime SBP

mean 24-hour DBP, mean daytime DBP, mean nighttime DBP

mean 24-hour pulse rate, mean daytime pulse rate, mean nighttime pulse rate

mean 24-hour rate pressure product, mean daytime rate pressure product, mean nighttime 
rate pressure product
To derive the above means, the following steps will be taken:

Hourly means will be averaged to derive the 24-hour means

Hourly means that account for data collected from 8:00 am to 10:59 pm will be averaged to 
derive daytime mean 

Hourly means that account for data collected from 11:00 pm to 7:59 am will be averaged to 
derive the nighttime mean. 
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
20
Approved, Date: 26 March 2019
The 24-hour ABPM recording will be considered ‘valid’ if two rules are met:
1.
There are at least 42 valid scheduled readings within the 22 hours of recording time.
2.
There are no more than 2 consecutive hours of missing data (readings) within the 22 hours 
of recording time.
Only valid readings will be included in the ABPM analysis. Subjects without valid reading post-
baseline will be excluded from the analysis.
Details regarding the handling of missing and partial dates, the derivation of PRO measures will 
be contained in the data presentation specifications (DPS).
5.2.
Primary Efficacy Endpoint
5.2.1.
Definition
The primary efficacy endpoint will be the percentage change in body weight from baseline to 
Week 26.
5.2.2.
Estimand
Population: non-diabetic, obese subjects in the mITT analysis set who are ≥18 and ≤70 years of 
age and have a BMI ≥35 to ≤50 kg/m2
Variable: percentage change in body weight from baseline to Week 26
Population-level summary: mean percentage change in body weight from baseline to Week 26
5.2.3.
Analysis Methods
Primary Analysis
The primary analysis of the primary endpoint will be based on the mITT population and will use 
a mixed model for repeated measures (MMRM). The analysis will use the observed data through 
Week 26 while on treatment and will include the fixed, categorical effects of treatment, visit, and 
treatment-by-visit interaction, as well as the fixed, continuous, covariates of baseline body 
weight and baseline-by-visit interaction. Data collected after the last dose plus 14 days for 
5111/placebo subjects (2 days for liraglutide subjects) will be excluded from the mITT analysis.
An unstructured covariance will be used to model the within-patient errors. The treatment 
comparisons will be made between each of the JNJ-64565111 treatment groups and placebo at 
Week 26.  
Secondary Analysis
A secondary analysis of the primary endpoint will be based on the ITT population using all 
observed data (on or off-treatment) and will employ pattern mixture models using multiple 
imputation methods. Responses for subjects who discontinued from the study earlier than 
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
21
Approved, Date: 26 March 2019
Week 26 will be imputed based on subjects who discontinued treatment prematurely but 
subsequently provided off-treatment measurements. The imputation will be done within groups 
defined by randomized treatment. A MMRM analysis will be used with fixed, categorical effects 
of treatment, visit, and treatment-by-visit interaction, as well as the fixed, continuous, covariates 
of baseline body weight and baseline-by-visit interaction. The treatment comparisons between 
each of the JNJ-64565111 treatment groups and placebo will be made at Week 26. Copy control 
imputation may be used as an alternative to a retrieved dropout approach.
Supportive Analyses
Sensitivity analyses for the primary efficacy endpoint will be performed based on the 
completers’ analysis set using the same mixed model for repeated measures as in the primary 
analysis.
The primary analysis will also be repeated with the addition of strata (ABPM substudy 
participation) as a fixed effect to determine if there is a difference in the point estimates after 
adjustment for strata in the model.
Subgroup Analyses
Additional analyses of the primary efficacy endpoint in the mITT analysis set will be performed 
to assess consistency of treatment effect on percent weight loss for the subgroups defined in 
Section 2.4 (if there are at least 100 subjects in the subgroup). The interaction of treatment with 
each of the subgroups will be analyzed based on the MMRM model for the primary efficacy 
analysis with the addition of the subgroup and the appropriate corresponding interaction terms. If 
an interaction is observed (2-sided significance level of 0.10), then further evaluations will be 
performed to assess and explain the nature of the interaction [quantitative or qualitative 
interaction]. The percent change from baseline and the 95% CI for differences between each 
dose of JNJ-64565111 and liraglutide compared to placebo will be presented for the subgroups.
Exploratory Analyses
Additional analysis using an MCP-Mod (Multiple Comparison Procedure – Modelling) approach 
will be performed to explore the dose response relationship. 
The exploratory analysis of the assessments between the JNJ-64565111 treatment groups and 
liraglutide on the percentage change in body weight at Week 26 will also be performed. The 
same analysis models used for the comparisons with placebo on the primary efficacy endpoint 
will be used for these assessments. For subjects on liraglutide, the observed data through 
Week 26 while on treatment will be used.  Nominal p-values will be provided.
5.3.
Major Secondary Endpoints
5.3.1.
Definition
Secondary efficacy analyses at Week 26 will include proportion of subjects with 5% weight 
loss, proportion of subjects with 10% weight loss, and the absolute change in body weight from 
baseline.
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
22
Approved, Date: 26 March 2019
5.3.2.
Analysis Methods
Primary Analysis
The continuous secondary endpoints (i.e., absolute change in body weight from baseline) at 
Week 26 will be analyzed with an MMRM model similar to the primary efficacy endpoint in the 
mITT analysis set.
The categorical secondary efficacy endpoint (i.e., proportion of subjects with 5% weight loss, 
proportion of subjects with 10% weight loss at Week 26) will be analyzed using the mITT 
analysis set such that only subjects with observed Week 26 on-treatment weight measurements 
are eligible to be considered responders (either 5% weight loss or 10% weight loss) and 
subjects without Week 26 on-treatment weight measurements will be considered non-responders. 
A logistic regression model will include the fixed, categorical effect of treatment and the 
continuous covariate of baseline weight. The odds ratio and associated adjusted p-value for the 
treatment comparison between each of the JNJ-64565111 treatment groups versus placebo at 
Week 26 based on this model will be provided.
Secondary Analysis
A secondary analysis of the secondary endpoints will be based on the ITT population using all 
observed data (on or off-treatment) and will employ pattern mixture models using multiple 
imputation methods based on information from retrieved dropouts as described above. For the 
categorical endpoints, response status will be determined from the imputed continuous response 
based on subjects who discontinued treatment prematurely but subsequently provided off-
treatment measurements. Copy control imputation may be used as an alternative to a retrieved 
dropout approach. 
Exploratory Analyses
The exploratory analysis of the assessments between the JNJ-64565111 treatment groups and 
liraglutide on 5% weight loss responders and 10% weight loss responders and the absolute 
change in body weight at Week 26 will also be performed. The same analysis models used for 
the comparisons with placebo will be used for these assessments.
5.4.
Exploratory Efficacy Variable(s)
5.4.1.
Definition
Exploratory Endpoints

the change from baseline in BMI 

the change from baseline in waist circumference 

the change from baseline in fasting lipids (total cholesterol, LDL-C, HDL-C, triglycerides) 

the change from baseline in FPG

the change from baseline in fasting insulin 
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
23
Approved, Date: 26 March 2019

the change from baseline in fasting C-peptide 

the changes from baseline in HOMA-B and HOMA-IR

the change from baseline in SBP 

the change from baseline in DBP 

the change from baseline in pulse rate 

the change from baseline in pulse-pressure product

in a subset of subjects participating in the 24-hour ABPM assessment, the changes from 
baseline in 24-hour SBP, DBP, pulse rate and pulse-pressure product

the change from baseline in scores on the IWQOL-Lite,2,3 single item Ease of Weight 
Management, and PAM  

the change from baseline in scores on the ERCQ and the PROMIS physical function short 
form 8b (PROMIS SF 8b). (Note: the Patient Global Impression Status [PGIS] and Patient 
Global Impression of Change [PGIC] will be used to calculate responder definitions for 
these new instruments only and are not exploratory objectives).
5.4.2.
Analysis Methods
The continuous exploratory efficacy endpoints (Change from baseline in BMI, waist 
circumference, total cholesterol, LDL-C, HDL-C, triglycerides, FPG, fasting insulin, C-peptide, 
SBP, DBP, pulse rate, pulse rate product) will be analyzed using a MMRM model similar to that 
used to analyze the primary efficacy endpoint. An ANCOVA model will be used for endpoints 
with only one planned post-baseline timepoint.
Shift tables will be used to summarize obesity class (Class I = 30 kg/m2 – 34.9 kg/m2; Class II = 
35 kg/m2 – 39.9 kg/m2; Class III = ≥ 40 kg/m2) at baseline vs. end of treatment. Descriptive 
statistics (N, mean, standard deviation, median, and range) for the actual values and the changes 
from baseline will be presented by treatment group and visit for all exploratory endpoints 
including ‘mean 24-hour SBP’, ‘mean 24-hour DBP’, ‘mean daytime SBP’, ‘mean daytime 
DBP’, ‘mean nighttime SBP’, and the ‘mean nighttime DBP ’, ‘mean 24-hour pulse rate’, ‘mean 
daytime pulse rate’, ‘mean nighttime pulse rate’, ‘and mean 24-hour RPP. RPP is defined as the 
product of heart rate and systolic blood pressure. Changes from baseline for each endpoint at the 
last on-treatment measurement will be analyzed using an ANCOVA model in the mITT analysis 
set. The analysis will be based on observed data and will include the fixed, categorical effects of 
treatment as well as the fixed, continuous covariate of baseline value. The treatment comparisons 
for the JNJ-64565111 versus placebo will be made at the last on-treatment measurement.
For ABPM sub-study participants, baseline body weight, percentage change and absolute change 
from baseline in body weight will be summarized by treatment and visit. 
A MMRM model similar to that used to analyze the primary efficacy endpoint will be used to 
analyze the exploratory PRO endpoints for endpoints with more than one planned post-baseline 
timepoint.  
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
24
Approved, Date: 26 March 2019
The other PRO assessments will be described in a separate SAP for PROs.
SAFETY
6.
All safety analyses and summaries will be based on the safety analysis set (Section 2.3.3). Safety 
data will be analyzed according to the predominant treatment received, in the event that a subject 
received a treatment other than that to which they were randomly assigned to receive. The 
predominant treatment is defined as the treatment to which the subject was exposed for the 
greatest duration during the core treatment phase.
The evaluation of safety will be based on the incidence of AEs and changes in clinical laboratory 
test results and vital sign results (blood pressure, pulse rate). There will be no imputation of 
missing values for clinical laboratory test results and vital sign measurements in the safety 
analyses and there will be no hypothesis testing for results from safety analyses. Summaries of 
AEs, clinical laboratory test results, and vital sign results will be provided by treatment group
and for the combined JNJ-64565111 treatment group.
6.1.
Adverse Events
The verbatim terms used in the CRF by investigators to identify adverse events will be coded 
using the Medical Dictionary for Regulatory Activities (MedDRA). A treatment-emergent AE 
(TEAE) is defined as an adverse event with an onset after the initiation study medication and 
before the last study medication date of the double-blind (26-week) treatment phase for plus 
28 days for liraglutide subjects, and plus 35 days for JNJ64565111 and placebo subjects. AEs 
with a start date prior to initiation of double-blind study medication which are subsequently 
reported to have either an increase in intensity or change in attribution in relationship to study 
medication (ie, no attribution to possible, probably, very likely) after the initiation of double-
blind study medication will also be considered as TEAEs.
If the event occurs on the day of the initial administration of study agent, and either event time or 
time of administration are missing, then the event will be assumed to be treatment emergent. If 
the event date is recorded as partial or completely missing, then the event will be considered to 
be treatment emergent unless it is known to be prior to the first administration of study agent 
based on partial onset date or resolution date. All reported treatment-emergent adverse events 
will be included in the analysis. For each adverse event, the number and percentage of subjects 
who experience at least 1 occurrence of the given event will be provided by preferred term, 
grouped by system organ class (SOC), and presented by treatment group.
In addition, 
comparisons between treatment groups may be provided as needed.
Summary tables will be provided for:

AEs

AEs leading to discontinuation 

Drug-related AEs

Drug-related AEs leading to discontinuation
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
25
Approved, Date: 26 March 2019

Serious AEs (SAEs)

Serious AEs leading to discontinuation

Serious drug-related AEs leading to discontinuation and deaths

AEs by system organ class

AEs by severity

AEs by relationship to study agent: related (which includes possibly related, probably 
related and very likely related, as reported by the investigator) and not related (which 
includes not related and doubtfully related, as reported by the investigator)

AEs by the action taken regarding the study medication

AEs by the outcome
In addition to the summary tables, listings will be provided for subjects who had:

SAEs

AEs leading to discontinuation
Incidence of other treatment-emergent adverse events of special interest will be summarized.
Deaths will be displayed by actual treatment received. Frequencies for the following parameters 
will be included in the summary table:

Number of subjects who died

Cause of death

Relationship to study agent (yes/no)
A listing of subjects who died will be provided.
As a screening tool, the 95% CIs for percentage difference between JNJ-64565111 and placebo 
will be provided for the AEs which are reported in at least four or more subjects in any treatment 
group during the treatment phase. Four (rule-of-4) is chosen based on the recommendation from 
the Safety, Planning, Evaluation, and Report (SPERT).1 No multiplicity adjustment will be 
applied. The exclusion of “0” in the 95% CI around the difference in incidence (JNJ-64565111
compared to placebo) for a particular AE does not necessarily imply that the higher incidence is 
related to drug. The intent of providing the 95% CIs is as a filter to identify AEs that require 
additional assessment.
Adverse events that are identified by the above screening procedure will be subject to further 
evaluation. The additional assessment may include some or all of the following, comparing 
JNJ-64565111 and placebo
1.
Investigator assessed relationship of AE to study drug, investigator assessed intensity of AE
2.
Time to AE relative to start of double-blind study medication, duration of AE, action taken 
on study drug/occurrence of AEs leading to discontinuation
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
26
Approved, Date: 26 March 2019
3.
Other relevant safety information such as observations in other trials
Adverse Events of Interest
Protocol prespecified AEs of interest included MACE, hypotension-related AEs, pancreatic 
events, calcitonin elevation, and thyroid neoplasm. Prior to study unblinding, additional AEs of 
interest were identified including nausea, vomiting, diarrhea, and AEs of injection site reaction. 
Since investigators may have reported the same clinical condition using different AE terms, prior 
to study unblinding a list of reported terms that are suggestive of the AEs of nausea, vomiting, 
diarrhea, injection site reactions, and pancreatic-related AEs was generated. These preferred 
terms were used to generate combined analyses for each of these specific AEs of interest.
6.2.
Clinical Laboratory Tests
All clinical laboratory tests will be displayed for the subjects included in the safety analysis set.
Laboratory data will be summarized for each type of laboratory test listed in Attachment 1. 
Normal reference ranges for each test will also be provided.
Descriptive statistics will be presented for all chemistry, hematology, and urinalysis (pH and 
specific gravity) laboratory tests at scheduled time points. Descriptive statistics will be presented 
based on measurements on study medication, including up to a maximum of 2 days after the last 
dose of study medication for liraglutide subjects and 14 days for JNJ64565111 and placebo 
subjects, as well as all measurements regardless of the time of the last dose of double-blind study 
drug for subjects who discontinue from treatment before Week 26. Summaries based on both 
standard units (SI) and conventional units will be provided.
Change from baseline to scheduled time point as well as the 95% CI will be summarized for 
chemistry, hematology, and urinalysis (pH, and specific gravity) tests and displayed by visit and 
treatment group.
Number and percentage of subjects with post-baseline clinically important laboratory values will 
be presented by treatment group.
The percentage of subjects with specific treatment-emergent laboratory values meeting pre-
defined limit of change (PDLC) criteria will be summarized for these laboratory analytes. The 
95% CI for the percentage difference between the treatment groups will be provided for each 
treatment and combined JNJ64565111 treatment group for the PDLC criterion which have at 
least 4 or more subjects in any treatment group; a corresponding listing will also be provided. 
The criteria for PDLC values are listed in Attachment 2.
6.3.
Vital Signs and Physical Examination Findings
Continuous vital sign parameters including pulse, blood pressure (systolic and diastolic) will be
summarized at each assessment time point. Changes from Baseline will be summarized for the
26-week treatment phase. Descriptive statistics (mean, standard deviation, median, interquartile 
range [IQR], minimum and maximum) will be presented at each scheduled time point, including 
the 95% CI for the change from baseline for the 26-week core treatment phase. The descriptive 
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
27
Approved, Date: 26 March 2019
statistics will be presented based on measurements on study medication, including up to a 
maximum of 2 days after the last dose of study medication for liraglutide subjects and 14 days 
for JNJ64565111 and placebo subjects, as well as all measurements regardless of the time of the 
last dose for subjects who discontinue from treatment before Week 26. The pulse and blood 
pressure measurements will be based on the average of the consecutive sitting pulse and blood 
pressure readings that were to be collected at each visit.  
The percentage of subjects with specific treatment-emergent vital sign values meeting PDLC
criteria (Attachment 2) will be summarized for these vital sign parameters. The 95% CI for the 
percentage difference between the treatment groups will be provided for each treatment and 
combined JNJ64565111 treatment group for the PDLC criterion which have at least 4 or more 
subjects in any treatment group; a corresponding listing will also be provided.  
Physical examination findings will not be summarized except when reported as an adverse event.
6.4.
Electrocardiogram
A 12-lead ECG will be performed during screening. No summary is planned. 
PHARMACOKINETICS/IMMUNOGENICITY/PHARMACODYNAMICS
7.
7.1.
Pharmacokinetics
Pharmacokinetics (PK) samples for measuring serum JNJ-64565111 concentrations will be 
collected from all subjects at the specified visits as shown in the schedule of events of the 
protocol. In all subjects randomly assigned to JNJ-64565111 or matching placebo (but not in 
subjects randomly assigned to open-label liraglutide), venous blood samples will be collected 
according to the Time and Events Schedule for determination of serum trough concentrations of 
JNJ-64565111 to assess attainment of steady state concentrations. In addition, a sample at the 
4-week safety follow-up visit will also be collected in all subjects. On the days of the trough 
clinic visits at which PK samples are to be obtained, subjects are not to inject the study drug 
before arriving at the clinic. In addition to the trough samples and a post-treatment sample in all 
subjects, a subset of subjects will have 1 additional visit (Day 4 ± 1 day sampling window) to 
collect a non-trough PK sample. The non-trough PK visit will occur at selected sites and will 
involve approximately 180 subjects (approximately 45 subjects each in the placebo, 
JNJ-64565111 5 mg, JNJ-64565111 7.4 mg, JNJ-64565111 10 mg groups). All PK evaluations 
will be based on the PK analysis set. No imputation for missing concentration data will be 
performed. 
The data analysis of trough and non-trough serum JNJ-64565111 concentrations includes the 
following:

Tabular summary of serum JNJ-64565111 concentrations at each PK visit by treatment 
group.

Tabular summary of serum JNJ-64565111 concentrations at each visit by treatment group 
and body weight tertiles at baseline.
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
28
Approved, Date: 26 March 2019

Proportion of subjects without detectable serum JNJ-64565111 concentration at each visit 
by treatment group.

Median trough, non-trough, and week 30 temporal serum JNJ-64565111 concentrations 
plotted over time by treatment group.

Median trough serum JNJ-64565111 concentrations plotted over time by treatment group to 
assess attainment of steady-state.
In addition, the relationship between serum JNJ-64565111 concentrations, and antibody to 
JNJ-64565111 status, safety and efficacy may be explored using graphical displays. The 
proportion of 5% and 10% weight loss response rates and % weight loss at Week 26 will be 
presented in a bar graph by the corresponding serum JNJ-64565111 concentration quartiles at 
Week 26 for subjects treated with JNJ-64565111.
For summary statistics of serum JNJ-64565111 concentrations, concentration values below the 
lower limit of quantification will be treated as zero. Once a subject meets one of the following 
dosing deviation criteria, the subject’s data will be excluded from the by-visit data analyses from 
that point onwards.
Dosing deviation criteria:

Discontinue SC study agent administrations.

Skipped an SC administration.

Received an incomplete/ incorrect SC dose.

Received an incorrect SC study agent.

Received an additional SC dose.
In addition, if a subject has an administration more than 4 days earlier or later than the scheduled 
dosing date, the concentration data collected between such a dosing visit and the subsequent 
dosing visit will be excluded from the by-visit data analyses. For the Week 26 visit, if the PK 
sampling time deviates more than 4 days earlier or later than the scheduled date, the PK 
concentration at this visit will be excluded from the by-visit data analyses.  
The conditions under which to exclude measurements from PK analysis:

If date/time of Baseline sample is after date/time of first dose, then exclude the Baseline 
sample

If Day 4 sample is >8 days after 1st dose, then exclude the Day 4 sample

If date of Week 2 sample – date of previous dose before date of Week 2 sample is < 3 days 
or > 11 days, then exclude Week 2 sample

If date of Week 5 sample – date of previous dose before date of Week 5 sample is < 3 days 
or > 11 days, then exclude Week 5 sample

If date of Week 10 sample – date of last dose before date of Week 10 sample is < 3 days or 
> 11 days, then exclude Week 10 sample
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
29
Approved, Date: 26 March 2019

If date of Week 15 sample – date of last dose before date of Week 15 sample is < 3 days or 
> 11 days, then exclude Week 15 sample 

If date of Week 20 sample – date of last dose before date of Week 20 sample is < 3 days or 
> 11 days, then exclude Week 20 sample

If relative Study Day of Week 26 sample is < Day 178 or >Day 186 then exclude Week 26 
sample

If relative Study Day of Week 30 sample is < Day 206 or >Day 214 then exclude Week 30 
sample

If subject discontinues treatment early, then exclude the “Week 30” or “4 Week Follow-up” 
PK sample.  
Population PK analyses will be performed to characterize the population PK parameters based on 
the available JNJ-64565111 concentration data obtained through the Week 30 visit. Sparse PK 
data from the current study may be pooled with previous Phase 1 data with rich PK profiles to 
allow estimation of structural PK parameters. The population pharmacokinetic approach will also 
be used to identify and quantify any significant covariates such as demographic characteristics 
(including but not limited to body weight, ethnic origin, sex, and age) and concomitant 
medications that have substantial impact on the population pharmacokinetics of JNJ-64565111 in 
subjects with severe obesity. A detailed analysis plan for population PK analysis will be 
developed separately, and a stand-alone technical report will be written to summarize the results 
of the population PK analysis.
7.2.
Immunogenicity
Blood samples will be collected to examine the formation of antibodies to JNJ-64565111 at the 
specified visits (Day 1, Weeks 5, 10, 15, 26, and 30) as shown in the schedule of events of the 
protocol. For subjects who discontinue SC study agent administrations, samples will be collected 
at their 4-week safety follow-up visit.
The data analysis of antibodies to JNJ-64565111 will be summarized if sufficient numbers of 
subjects are positive for antibodies and will include the following:

The antibody status (positive, negative) of subjects will be summarized by JNJ-64565111 
treatment groups. For subjects who discontinue SC study agent administrations and 
complete 4-week safety follow-up, a listing of their antibody status will be presented.

The relationship between antibody to JNJ-64565111 status and efficacy and safety may be 
assessed at Week 26. 

5% and 10% weight loss response rates and % weight loss at Week 26 by antibody to 
JNJ-64565111 status and treatment group

Injection site reaction by antibody to JNJ-64565111 status and treatment group.

The relationship between antibody to JNJ-64565111 status at Week 10 and antibody to 
JNJ-64565111 status at Week 26 will be explored.

The onset and duration of antibody to JNJ-64565111
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
30
Approved, Date: 26 March 2019

Figure of median serum JNJ-64565111 concentrations by antibody to JNJ-64565111 status.
Other analyses may be performed to verify the stability of antibodies to JNJ-64565111 and/or 
further characterize the immunogenicity of JNJ-64565111.
7.3.
Pharmacokinetic/Pharmacodynamic Relationships
The relationship between serum JNJ-64565111 concentrations and % weight loss may be 
explored and results will be reported in an independent technical report.
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
31
Approved, Date: 26 March 2019
REFERENCES
1.
Crowe, B.J. et al., 2009, Recommendations for safety planning, data collection, evaluation and reporting 
during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. 
Clin Trials 6, 430-40. 
2.
Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life 
in obesity Obes Res 2001; 9(2):102-111.
3.
Kolotkin RL, Crosby RD. Psychometric evaluation of the impact of weight on quality of life-lite questionnaire 
(IWQOL-Lite) in a community sample. Quality of Life Research 2002; 11: 157-171.
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
32
Approved, Date: 26 March 2019
ATTACHMENTS
ATTACHMENT 1 CLINICAL LABORATORY TESTS
Blood samples for serum chemistry and hematology, and urine samples for urinalysis will be collected 
at timepoints specified in the Time and Events Schedule. The investigator must review the laboratory
report, document this review, and record any clinically relevant changes occurring during the study in the
Adverse Event section of the eCRF and take appropriate action (eg, repeating abnormal laboratory result
or further evaluation as considered clinically appropriate). The following tests will be performed by the 
central laboratory.

Hematology Panel
-hemoglobin
-platelet count
-hematocrit
-red blood cell (RBC) count
-white blood cell count with differential

Serum Chemistry Panel
-sodium
-alkaline phosphatase
-potassium
-creatine phosphokinase
-magnesium
-lactic acid dehydrogenase
-chloride
-amylase
-bicarbonate
-lipase
-uric acid
-calcium
- blood urea nitrogen
-phosphate
-creatinine
-albumin
-aspartate aminotransferase
-total protein
-alanine aminotransferase
-gamma-glutamyltransferase
-total bilirubin

Serum ß-hydroxybutyrate

Serum calcitonin

Fasting insulin*

Follicle-stimulating hormone only for women >45 years of age with amenorrhea for at least 
6 months and <18 months prior to screening

Fasting serum lipid profile (triglycerides, LDL-C, HDL-C, total cholesterol) *

HbA1c

Fasting plasma glucose*

Urinalysis
Dipstick done at central laboratory
-specific gravity
-pH
-protein
-blood
-ketones
-bilirubin
-urobilinogen
-nitrite
-leukocyte esterase
If dipstick result is abnormal, microscopic examination will be performed.
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
33
Approved, Date: 26 March 2019

Serum (β-human chorionic gonadotropin [β-hCG] pregnancy testing will be conducted for all women 
of childbearing potential (ie, unless they are permanently sterilized or unless there is a documented 
history of their postmenopausal status) at the screening and Week 26/EOT visits. Additional serum 
or urine pregnancy tests may be performed throughout the study in sufficient number, as determined 
necessary by the investigator, or required by local regulation, to establish the absence of pregnancy 
during the study. 
* Subjects must be fasting for at least 8 hours before blood sample collections.
Estimated Glomerular Filtration Rate (eGFR)

The estimated glomerular filtration rate (eGFR) will be reported according to the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation** at study visits when serum 
creatinine is measured. The CKD-EPI equation based on serum creatinine, age, sex, and race for 
adults age 18 years expressed as a single equation is:
CKD-EPI Formula (for Scr expressed in mg/dL)
eGFR = 141 × min (Scr /, 1)× max(Scr /, 1)-1.209 × 0.993Age × 1.018 [if female] ×
1.159 [if black]
= 0.7 for females
= 0.9 for males
= -0.329 for females
= -0.411 for males
min = the minimum of Scr/or 1 max = the maximum of Scr/or 1
CKD-EPI Formula (for Scr expressed in mol/L)
eGFR = 141 × min (Scr /, 1)× max(Scr /, 1)-1.209 × 0.993Age × 1.018 [if female] ×
1.159 [if black]
= 61.9 for females
= 79.6 for males
= -0.329 for females
= -0.411 for males
min = the minimum of Scr/or 1 max = the maximum of Scr/or 1
**Levey AS, Stevens LA, Schmid CH, et.al. CKD-EPI (Chronic Kidney Disease Epidemiology 
Collaboration). Ann Intern Med. 2009;150(9):604-12.
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
34
Approved, Date: 26 March 2019
ATTACHMENT 2 PRE-DEFINED LIMIT OF CHANGE (PDLC) CRITERIA FOR 
LABORATORY TESTS
Laboratory Test
Parameter for ANY value and LAST value
CHEMISTRY
Albumin
Composite: <LLN and >25% decrease from BL
ALT
Absolute Value: >3X ULN
Absolute Value: >5X ULN
Absolute Value: >8X ULN
AST
Absolute Value: >3X ULN
Absolute Value: >5X ULN
Absolute Value: >8X ULN
ALT >3X ULN and Tbili >2X ULN
Composite: ALT >3X ULN and Tbili >2X ULN [with the Tbili elevation >2 X ULN 
within 30 days of the ALT elevation >3x ULN]
AST >3X ULN and Tbili >2X ULN
Composite:  AST >3X ULN and Tbili >2X ULN [with the Tbili elevation >2 X ULN 
within 30 days of the AST elevation >3x ULN]
Amylase
Absolute Value: >2X ULN
Absolute Value: >3X ULN
Absolute Value: >5X ULN
Beta-Hydroxybutyrate
Absolute value> 20.822 mg/dL (>2.0 mmol/L)
Bilirubin
Composite:  >ULN and > 25% increase from BL
Absolute Value: >2XULN
Bicarbonate
Absolute Value: <16 mEq/L
Calcitonin
Absolute Value: >20 ng/L (>5.85 pmol/L)
Absolute Value: >50 ng/L (>14.63 pmol/L)
Absolute Value: >100 ng/L (>29.26 pmol/L)
Calcium
Composite: >ULN and >10 % increase from BL
Creatinine Kinase
Absolute Value: >1000 U/L
eGFR
Composite: < 80 and decrease>30% from BL
Change:  decrease>50% from BL
Lipase
Absolute Value: >2X ULN
Absolute Value: >3X ULN
Absolute Value: >5X ULN
Magnesium
Composite: <LLN and >25% decrease from BL
Composite: >ULN and >25% increase from BL
Phosphorus
Composite: <LLN and >25% decrease from BL
Composite: >ULN and >25% increase from BL
Potassium
Composite: <LLN and >15% decrease from BL
Composite: >ULN and >15% increase from BL
Sodium
Composite: <LLN and decrease >5 mEq/L or more from BL
Composite: >ULN and increase >5 mEq/L or more from BL
Absolute Value: <125 mEq/L
Uric Acid
Composite: <LLN and >25% decrease from BL
HEMATOLOGY
Hemoglobin
Change: ≥2 g/dl decrease from BL
Change: ≥2 g/dL increase from BL
Platelets
Composite: >ULN and increase >25% from BL
White Blood Count
Composite: < LLN and >25% decrease from BL
Composite: > ULN and >50 % increase from BL
VITAL SIGNS
Pulse Rate
Absolute Value: ≤50 beats per minute
Absolute Value: ≥90, ≥100 beats per minute
Changes from baseline >30 bpm, >50 bpm
Absolute value ≥120 bpm and >30 bpm increase from baseline
Absolute value ≤50 bpm and >20 bpm decrease from baseline
Decreases from baseline >5, >10, >15, >20 bpm at consecutive visits
Increases from baseline >5, >10, >15, >20 bpm at consecutive visits
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
35
Approved, Date: 26 March 2019
Laboratory Test
Parameter for ANY value and LAST value
Systolic Blood Pressure
Composite: ≥20 mm Hg decrease from BL and ≤90 mm Hg
Composite: ≥20 mm Hg increase from BL and ≥160 mm Hg
Composite: ≥30 mm Hg decrease from BL and ≤90 mm Hg
Composite: ≥30 mm Hg increase from BL and ≥160 mm Hg
Decreases from baseline >5, >10, >15, >20, >25, >30 mmHg at consecutive visits
Increases from baseline >5, >10, >15, >20, >25, >30 mmHg at consecutive visits
Diastolic Blood Pressure
Composite: ≥15 mm Hg decrease from BL and ≤50 mm HG
Composite: ≥15 mm Hg increase from BL and ≥100 mm Hg
Composite: ≥20 mm Hg decrease from BL and ≤50 mm HG
Composite: ≥20 mm Hg increase from BL and ≥100 mm Hg
Decreases from baseline >5, >10, >15, >20, >25, >30 mmHg at consecutive visits
Increases from baseline >5, >10, >15, >20, >25, >30 mmHg at consecutive visits
NCT03486392


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
                                                                                           Statistical Analysis Plan Amendment 1 64565111OBE2001
36
Approved, Date: 26 March 2019
ATTACHMENT 3 ADVERSE EVENTS OF INTEREST
In order to support the additional assessment of particular categories of adverse events of interest, a list of 
selected preferred or high level terms have been created. A blinded review prior to database lock was to 
be performed to assure that no reported term suggestive of the AE of interest was omitted. AEs of interest 
include:
•
Vomiting 
•
Diarrhea
•
Nausea
•
Pancreatic events
•
Injection site reactions
The list of preferred and high-level terms for the pre-specified adverse events is provided in
EDMS-ERI-181673715.  
NCT03486392